
<html lang="en"     class="pb-page"  data-request-id="7c082fa1-2855-462e-94dd-05dc5c0742bb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm501532z"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection" /></meta><meta name="dc.Creator" content="Pierre L.  Beaulieu" /></meta><meta name="dc.Creator" content="Paul C.  Anderson" /></meta><meta name="dc.Creator" content="Richard  Bethell" /></meta><meta name="dc.Creator" content="Michael  Bös" /></meta><meta name="dc.Creator" content="Yves  Bousquet" /></meta><meta name="dc.Creator" content="Christian  Brochu" /></meta><meta name="dc.Creator" content="Michael G.  Cordingley" /></meta><meta name="dc.Creator" content="Gulrez  Fazal" /></meta><meta name="dc.Creator" content="Michel  Garneau" /></meta><meta name="dc.Creator" content="James R.  Gillard" /></meta><meta name="dc.Creator" content="Stephen  Kawai" /></meta><meta name="dc.Creator" content="Martin  Marquis" /></meta><meta name="dc.Creator" content="Ginette  McKercher" /></meta><meta name="dc.Creator" content="Marc-André  Poupart" /></meta><meta name="dc.Creator" content="Timothy  Stammers" /></meta><meta name="dc.Creator" content="Bounkham  Thavonekham" /></meta><meta name="dc.Creator" content="Dominik  Wernic" /></meta><meta name="dc.Creator" content="Jianmin  Duan" /></meta><meta name="dc.Creator" content="George  Kukolj" /></meta><meta name="dc.Description" content="The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, bett..." /></meta><meta name="Description" content="The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, bett..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 25, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501532z" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501532z" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501532z" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501532z" /></link>
        
    
    

<title>Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501532z" /></meta><meta property="og:title" content="Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0018.jpeg" /></meta><meta property="og:description" content="The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, better tolerability, and reduced risk for emergence of drug-resistant virus. We have pursued non-nucleoside NS5B polymerase allosteric inhibitors as combination partners with other direct acting antivirals (DAAs) having a complementary mechanism of action. Herein, we describe the discovery of a potent follow-up compound (BI 207524, 27) to the first thumb pocket 1 NS5B inhibitor to demonstrate antiviral activity in genotype 1 HCV infected patients, BILB 1941 (1). Cell-based replicon potency was significantly improved through electronic modulation of the pKa of the carboxylic acid function of the lead molecule. Subsequent ADME-PK optimization lead to 27, a predicted low clearance compound in man. The preclinical profile of inhibitor 27 is discussed, as well as the identification of a genotoxic metabolite that led to the discontinuation of the development of this compound." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501532z"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501532z">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501532z&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501532z&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501532z&amp;href=/doi/10.1021/jm501532z" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10130-10143</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm5015132" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm501552x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pierre+L.++Beaulieu">Pierre L. Beaulieu</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+C.++Anderson">Paul C. Anderson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Bethell">Richard Bethell</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++B%C3%B6s">Michael Bös</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yves++Bousquet">Yves Bousquet</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Brochu">Christian Brochu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+G.++Cordingley">Michael G. Cordingley</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gulrez++Fazal">Gulrez Fazal</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michel++Garneau">Michel Garneau</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Gillard">James R. Gillard</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Kawai">Stephen Kawai</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Marquis">Martin Marquis</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ginette++McKercher">Ginette McKercher</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marc-Andr%C3%A9++Poupart">Marc-André Poupart</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy++Stammers">Timothy Stammers</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bounkham++Thavonekham">Bounkham Thavonekham</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dominik++Wernic">Dominik Wernic</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianmin++Duan">Jianmin Duan</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George++Kukolj">George Kukolj</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Boehringer Ingelheim (Canada) Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#fa889f899d9f949f889b96d4969b8cba98959f928893949d9f88d793949d9f96929f9397d4999597"><span class="__cf_email__" data-cfemail="097b6c7a6e6c676c7b68652765687f496b666c617b60676e6c7b2460676e6c65616c6064276a6664">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501532z&amp;href=/doi/10.1021%2Fjm501532z" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10130–10143</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 13, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 October 2014</li><li><span class="item_label"><b>Published</b> online</span>25 November 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 December 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501532z" title="DOI URL">https://doi.org/10.1021/jm501532z</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10130%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPierre%2BL.%2BBeaulieu%252C%2BPaul%2BC.%2BAnderson%252C%2BRichard%2BBethell%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D23%26contentID%3Djm501532z%26title%3DDiscovery%2Bof%2BBI%2B207524%252C%2Ban%2BIndole%2BDiamide%2BNS5B%2BThumb%2BPocket%2B1%2BInhibitor%2Bwith%2BImproved%2BPotency%2Bfor%2Bthe%2BPotential%2BTreatment%2Bof%2BChronic%2BHepatitis%2BC%2BVirus%2BInfection%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10143%26publicationDate%3DDecember%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501532z"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1282</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501532z" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;L. Beaulieu&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;C. Anderson&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Bethell&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Bös&quot;},{&quot;first_name&quot;:&quot;Yves&quot;,&quot;last_name&quot;:&quot;Bousquet&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Brochu&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;G. Cordingley&quot;},{&quot;first_name&quot;:&quot;Gulrez&quot;,&quot;last_name&quot;:&quot;Fazal&quot;},{&quot;first_name&quot;:&quot;Michel&quot;,&quot;last_name&quot;:&quot;Garneau&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Gillard&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Kawai&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Marquis&quot;},{&quot;first_name&quot;:&quot;Ginette&quot;,&quot;last_name&quot;:&quot;McKercher&quot;},{&quot;first_name&quot;:&quot;Marc-André&quot;,&quot;last_name&quot;:&quot;Poupart&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;Stammers&quot;},{&quot;first_name&quot;:&quot;Bounkham&quot;,&quot;last_name&quot;:&quot;Thavonekham&quot;},{&quot;first_name&quot;:&quot;Dominik&quot;,&quot;last_name&quot;:&quot;Wernic&quot;},{&quot;first_name&quot;:&quot;Jianmin&quot;,&quot;last_name&quot;:&quot;Duan&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Kukolj&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;10130-10143&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501532z&quot;},&quot;abstract&quot;:&quot;The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, better tolerability, and reduced risk for emergence of drug-resistant virus. We have pursued non-nucleoside NS5B polymerase allosteric inhibitors as combination partners with other direct acting antivirals (DAAs) having a complementary mechanism of action. Herein, we describe the discovery of a potent follow-up compound (BI 207524, 27) to the first thumb pocket 1 NS5B inhibitor to demonstrate antiviral activity in genotype 1 HCV infected patients, BILB 1941 (1). Cell-based replicon potency was significantly improved through electronic modulation of the pKa of the carboxylic acid function of the lead molecule. Subsequent ADME-PK optimization lead to 27, a predicted low clearance compound in man. The preclinical profile of inhibitor 27 is discussed, as well as the identification of a genotoxic metabolite that led to the d&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501532z&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501532z" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501532z&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501532z" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501532z&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501532z" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501532z&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501532z&amp;href=/doi/10.1021/jm501532z" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501532z" /></input><a href="/doi/pdf/10.1021/jm501532z" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (981 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501532z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501532z%26sid%3Dliteratum%253Aachs%26pmid%3D25393851%26genre%3Darticle%26aulast%3DBeaulieu%26date%3D2014%26atitle%3DDiscovery%2Bof%2BBI%2B207524%252C%2Ban%2BIndole%2BDiamide%2BNS5B%2BThumb%2BPocket%2B1%2BInhibitor%2Bwith%2BImproved%2BPotency%2Bfor%2Bthe%2BPotential%2BTreatment%2Bof%2BChronic%2BHepatitis%2BC%2BVirus%2BInfection%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D23%26spage%3D10130%26epage%3D10143%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jmcmar.2014.57.issue-23/20141211/jmcmar.2014.57.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The development of interferon-free regimens for the treatment of chronic HCV infection constitutes a preferred option that is expected in the future to provide patients with improved efficacy, better tolerability, and reduced risk for emergence of drug-resistant virus. We have pursued non-nucleoside NS5B polymerase allosteric inhibitors as combination partners with other direct acting antivirals (DAAs) having a complementary mechanism of action. Herein, we describe the discovery of a potent follow-up compound (BI 207524, <b>27</b>) to the first thumb pocket 1 NS5B inhibitor to demonstrate antiviral activity in genotype 1 HCV infected patients, BILB 1941 (<b>1</b>). Cell-based replicon potency was significantly improved through electronic modulation of the p<i>K</i><sub>a</sub> of the carboxylic acid function of the lead molecule. Subsequent ADME-PK optimization lead to <b>27</b>, a predicted low clearance compound in man. The preclinical profile of inhibitor <b>27</b> is discussed, as well as the identification of a genotoxic metabolite that led to the discontinuation of the development of this compound.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HCV is a blood-borne pathogen that causes serious and often fatal liver damage and is the leading cause of liver transplantation in industrialized nations. An estimated 130–170 million people are infected worldwide, and conditions associated with HCV infection represent a significant economic burden on health care systems.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The viral functions encoded by the HCV genome have been the focus of intense drug discovery efforts since the isolation and characterization of the virus 25 years ago.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> The recent approval in 2011 of the first HCV direct acting antivirals (DAAs) has provided improved treatment options for patients suffering from chronic hepatitis C virus infection. First generation NS3/4A protease inhibitors (boceprevir (Victrelis) from Merck and telaprevir (Incivek) from Vertex Pharmaceuticals) have resulted in improved efficacy for the treatment of genotype-1 (gt1) HCV infection when complementing the previous standard of care (SoC) consisting of pegylated interferon-α (PegIFN) and ribavirin (RBV), a broad-spectrum antiviral agent.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> However, despite improved overall outcomes, these treatments suffer from the combined side effects of the SoC and the new drugs themselves, resulting in significant discontinuations of therapy. Furthermore, the treatment remains ineffective in up to 20–30% of treatment naive gt1 patients, which predominate in North America, Europe, and Japan. The lack of efficacy in some patient populations is caused in part by rapid emergence of virus that is resistant to the new agents.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Second-generation protease inhibitors with improved efficacy, lower dosing requirements, and increased tolerability such as faldaprevir (Boehringer Ingelheim, Phase 3) and recently approved simeprevir (Olysio; Medivir/Tibotec), as well as the nucleotide NS5B inhibitor sofosbuvir (Solvadi; Gilead) have provided patients with improved outcomes (80% to >90% cure rates in gt1) but still require combination with SoC to reduce emergence of resistant virus in this difficult to treat population.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The development of interferon-free regimens would represent a preferred option and relies on combination of potent DAAs with complementary modes of action, which through a concerted assault on virus-essential functions, are expected to inhibit HCV replication while minimizing selection of resistant variants. Such regimens would provide improved tolerability by eliminating the necessity for interferon-based immune cotherapy. Examples of DAA combinations in late stage clinical investigation include permutations of NS3/4A protease, nucleoside/nucleotide and non-nucleoside NS5B polymerase, and NS5A function inhibitors.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">We have been actively pursuing non-nucleoside NS5B allosteric inhibitors as potential combination partners with other DAAs.<a onclick="showRef(event, 'cit7a cit7b'); return false;" href="javascript:void(0);" class="ref cit7a cit7b">(7a, 7b)</a> The HCV-encoded NS5B RNA-dependent RNA polymerase is a key component of the replication machinery of the virus and has provided fertile grounds for the discovery of antiviral agents.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> In addition to nucleoside and nucleotide substrate-based inhibitors, this enzyme, which catalyzes the replication of viral RNA, has proven susceptible to inhibition by agents that interfere with conformational changes that are important in the early steps of viral RNA synthesis. Molecules that bind to one of five distinct allosteric sites (denoted thumb sites 1 and 2 and palm sites 1, 2, and 3) have been identified, and the mechanisms through which they inhibit enzymatic activity have been validated both in cell-based replicon assays that reproduce replication of subgenomic HCV RNA<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and subsequently in the clinic for all but Palm site 3.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> We recently described the discovery of <b>1</b> (BILB 1941, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), the first thumb pocket 1 NS5B inhibitor to demonstrate antiviral activity in patients infected with gt1 HCV. Compound <b>1</b> is an indole-based cinnamic acid derivative that displays moderate antiviral activity in gt1a/1b replicon assays (EC<sub>50</sub> = 153 and 84 nM, respectively) and favorable pharmacokinetics in preclinical animal species.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In a 5-day multiple rising dose monotherapy trial in gt1-HCV infected patients, <b>1</b> produced significant antiviral activity (up to 2.5 log<sub>10</sub> reduction in viremia) when dosed at 450 mg q8h.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Unfortunately, GI intolerance precluded testing of the compound at higher doses, but this proof-of-concept trial suggested that more potent analogs may improve antiviral response. We describe herein the discovery of a follow-up candidate from this class, which displayed improved potency compared with <b>1</b> in both gt1a/1b replicons while maintaining a similarly favorable PK profile.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of the first thumb pocket 1 NS5B inhibitor with antiviral activity in man.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As mentioned above, a follow-up candidate to <b>1</b> requires potency improvement while maintaining a similar or better PK profile (e.g., longer human <i>t</i><sub>1/2</sub>). Since the preclinical toxicological profile of <b>1</b> in animals was not predictive of the GI intolerance side effects that were observed at doses required to provide a uniform response across HCV gt1a and gt1b infected subjects, we postulated that further structural optimization leading to increased potency could translate into improved response, increased tolerability, or reduced dosing requirements. SAR that led to the discovery of compound <b>1</b> provided the foundation for an optimization strategy of this lead. For example, the cyclopentyl ring at the 3-position of the indole scaffold was maintained even though replacement by a cyclohexyl ring was known to provide 2–3-fold potency improvements, but at the expense of metabolic stability due to CYP450-mediated oxidative metabolism of that substituent.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Likewise, no advantage was anticipated from expanding further from the indole nitrogen methyl substituent.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> On the other hand, the indole C-2 heterocyclic substituent, the central amino acid linker, and the right-hand-side cinnamic acid moiety were shown to be determinants and modulators of potency and ADME-PK profiles.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Since the presence of the cinnamic acid moiety was beneficial for potency and solubility (compound <b>1</b> apparent p<i>K</i><sub>a</sub> = 4.5 as derived from a pH-titration profile) and did not compromise Caco-2 permeability, cellular activity, or oral absorption, we investigated the effect of adding substituents on the cinnamic acid aromatic ring in an attempt to improve the profile of <b>1</b>. Both the steric and electronic impact of substituents on this part of the molecule (e.g., conformational rigidification, p<i>K</i><sub>a</sub> of carboxylic acid group) were investigated, and initial outcomes are reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Exploration of Substituted Right-Hand-Side Cinnamic Acid Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Values are an average of at least two determinations.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Full length NS5B enzymatic assay.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a></p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Luc reporter assay.<a onclick="showRef(event, 'cit14c cit14d'); return false;" href="javascript:void(0);" class="ref cit14c cit14d">(14c, 14d)</a></p></div></div><div></div></div><div class="NLM_p">As can be seen in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, substitution in the ortho-position relative to the nitrogen atom (compounds <b>2</b>–<b>7</b>) reduced potency compared with unsubstituted analog <b>1</b>, particularly in the case of bulky substituents (e.g., CF<sub>3</sub>, <b>5</b>) suggesting that substitutions affecting coplanarity of the amide linkage relative to the phenyl ring were detrimental to interactions with NS5B.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> On the other hand, introduction of substituents in the ortho-position relative to the acrylic acid moiety (compounds <b>8</b>–<b>14</b>) were well tolerated, even for bulky groups such as CF<sub>3</sub> that remained within 3-fold potency (compound <b>11</b>) of <b>1</b>. The introduction of electron donating alkoxy groups ortho relative to the acrylic acid function provided the most benefit. For example, a methoxy substituent produced a 2.5-fold improvement in replicon potency (compound <b>13</b>). Furthermore, an additive effect was observed upon methoxylation of both ortho-positions (compound <b>14</b>), which led to an analog that exhibited close to a 10-fold improvement in potency (EC<sub>50</sub> = 8 nM) relative to our previous clinical candidate <b>1</b>. The improved antiviral potency of alkoxy-cinnamic acid derivatives such as <b>13</b> and <b>14</b> cannot be rationalized on the basis of their intrinsic potency as measured in our biochemical assays or lipophilicity (calculated log <i>P</i> = 5.4 and 5.3 for <b>1</b> and <b>13</b>, respectively). On the other hand, the electronic impact of electron-donating alkoxy substituents on the ionizability (i.e., p<i>K</i><sub>a</sub> as derived from pH titration curves) of the cinnamic acid is significant (measured p<i>K</i><sub>a</sub> = 4.5 and 6.5 for <b>1</b> and <b>15</b>, respectively) and may account for the increased ability of alkoxy-derivatives to permeate hepatocyte membranes and inhibit replication of subgenomic RNA in cell-based replicon assays. This hypothesis is corroborated by cell permeability measurements in a Caco-2 assay where apparent apical → basolateral permeability values of 11.2 × 10<sup>–6</sup> cm/s and 19.0 × 10<sup>–6</sup> cm/s were observed for <b>1</b> and <b>15</b>, respectively.</div><div class="NLM_p">Although compound <b>14</b> had reasonable stability in the presence of human and rat liver microsomes (HLM/RLM <i>T</i><sub>1/2</sub> = 121/42 min) and good permeability as measured in a Caco-2 cell assay (apical → basolateral =17.6 × 10<sup>–6</sup> cm/s), <b>14</b> was poorly absorbed when administered orally to rats in a cassette screen (mixture of four compounds; see <a class="ref internalNav" href="#sec5" aria-label="experimental section">experimental section</a> for details) at 4 mg/kg, with plasma inhibitor concentrations reaching 0.4 and 0.3 μM at 1 and 2 h time points, respectively. Monosubstituted methoxy analog <b>13</b>, with EC<sub>50</sub> = 32 nM and <i>C</i><sub>1h/2h</sub> = 1.1/0.5 μM in a 4 mg/kg rat cassette screen, became a prototype for further investigation of alkoxycinnamic acid derivatives as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Alkoxy Cinnamic Acid SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Values are an average of at least two determinations.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Full length NS5B enzymatic assay.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a></p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Luc reporter assay.<a onclick="showRef(event, 'cit14c cit14d'); return false;" href="javascript:void(0);" class="ref cit14c cit14d">(14c, 14d)</a></p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Human liver microsome stability.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">JChem 5.0.0 (<a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>).</p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">Following oral administration to rats as mixtures of four compounds at a dose of 4 mg/kg each.</p></div></div><div></div></div><div class="NLM_p">Variations in intrinsic potency of compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) in the enzymatic NS5B assay apparently were not reflected in the cell-based replicon assay since all compounds had comparable potency (EC<sub>50</sub> = 24–65 nM). Thus, increasing the size of the alkoxy substituent (e.g., <b>16</b>–<b>20</b>) did not provide advantages over smaller groups such as methoxy and ethoxy (compounds <b>13</b> and <b>15</b>). In addition to simple alkyl ethers, functionalized ethers were also examined. For example, methoxyethoxy analog <b>21</b> had reduced lipophilicity and a comparable profile to <b>13</b> and <b>15</b>. Ether side chains containing basic substituents such as ethylamino, picolinyl, and ethylmorpholino were also investigated but did not provide any potency advantage and, in some cases, compromised other key parameters such as Caco-2 permeability when zwitterionic species were generated (results not shown). As cell-based potency improved, the optimization strategy shifted some focus to identifying analogs that also displayed favorable ADME and PK properties, thus advancing their overall profile toward eventual selection of a follow-up compound to <b>1</b>.</div><div class="NLM_p">The metabolic stability of the analogs presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> ranged from satisfactory to excellent when incubated with human liver microsomes (<i>t</i><sub>1/2</sub> = 50 to >300 min), and inhibitors <b>15</b>–<b>17</b> had excellent Caco-2 permeability (Caco-2<sub>A→B</sub> = (19–23) × 10<sup>–6</sup> cm/s). A cassette of four compounds (<b>13</b>, <b>15</b>–<b>17</b>) was administered orally to rats at a dose of 4 mg/kg each, and compound plasma exposures were measured at 1 and 2 h time points. Consistent with the Caco-2 permeability data, alkoxycinnamic acid derivatives displayed promising oral absorption in rats (plasma <i>C</i><sub>1h</sub> = 0.9–1.3 μM), except for <i>n</i>Pr analog <b>17</b>, which showed reduced exposure and was eliminated from further consideration. While both methoxy and ethoxy cinnamic acid derivatives were subsequently pursued in parallel for some time, analogs bearing an ethoxy substituent often displayed improved properties over corresponding methoxy analogs, and efforts were eventually focused on further optimization of <b>15</b>.</div><div class="NLM_p">Studies that lead to the discovery of <b>1</b> had revealed the ability of indole C-2 substituents to modulate the physicochemical properties and ADME-PK profile of this class of inhibitors.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> This position thus became the next focus of exploration in our attempts to identify potent analogs that maintain an overall PK profile minimally comparable to <b>1</b>. Approximately 30 variations were examined, much of the selection building on SAR previously established in the unsubstituted cinnamic acid series.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These included alkyl, aryl, and five- and six-membered heterocycles and a selection of those analogs is presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Although a variety of C-2 heterocycles provided compounds with good antiviral potency in the gt1b luciferase replicon assay (EC<sub>50</sub> < 30 nM), only a limited set of analogs were identified that combined good cell-based potency with a satisfactory <i>in vitro</i> ADME profile and maintained lipophilicity in a satisfactory range. In particular, halo-pyridine and halo-pyrimidine derivatives (e.g., <b>24</b>, <b>27</b>, and <b>28</b>) displayed good to excellent metabolic stability upon incubation with human or rat liver microsomes (HLM <i>t</i><sub>1/2</sub> = 273 to >300 min; RLM <i>t</i><sub>1/2</sub> = 104 to >300 min) and excellent Caco-2 permeability (A → B > 13 × 10<sup>–6</sup> cm/s). The <i>in vitro</i> ADME profiles translated into good oral plasma exposure at the 1 h time point when compounds were screened in rats as a mixture of four compounds, each dosed at 4 mg/kg. In particular, halo-pyrimidine analogs <b>27</b> and <b>28</b>, as well as fluoropyridine <b>23</b>, displayed high exposures (<i>C</i><sub>1h</sub> = 3.4 and 1.8 μM for pyrimidines <b>27</b> and <b>28</b> and 1.3 μM for fluoropyridine <b>23</b>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. C-2 Optimization of 2-Ethoxycinnamic Acid Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Values are an average of at least two determinations.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Full length NS5B enzymatic assay.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a></p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Luc reporter assay.<a onclick="showRef(event, 'cit14c cit14d'); return false;" href="javascript:void(0);" class="ref cit14c cit14d">(14c, 14d)</a></p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Human liver microsome stability.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">JChem 5.0.0 (<a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>).</p></div><div class="footnote" id="t3fn6"><sup>Table f</sup><p class="last">Apical to basolateral direction.</p></div><div class="footnote" id="t3fn7"><sup>Table g</sup><p class="last">Following oral administration to rats as mixtures of four compounds at a dose of 4 mg/kg each.</p></div></div><div></div></div><div class="NLM_p">Previous studies performed in the unsubstituted cinnamic acid series had shown that a cyclobutane 2-aminocarboxylic acid linker in the central portion of the molecule provided superior PK profiles (e.g., compound <b>1</b>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Once again in this series, while <i>gem</i>-dimethyl linkers had excellent cell-based potency (e.g., <b>31</b> and <b>33</b>), these analogs displayed significantly reduced oral exposure in rat cassettes when compared with the corresponding cyclobutane derivatives (<b>27</b> and <b>34</b>). Similarly, cyclopropane derivatives (e.g., <b>32</b>) exhibited reduced potency as a result of slightly altered dihedral angles (as determined by NMR studies) in the central portion of the unbound molecule compared with the NS5B-bound conformation of inhibitors.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, inhibitor <b>34</b> had an overall well-balanced profile encompassing potency, <i>in vitro</i> ADME properties, and <i>in vivo</i> rat exposure.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Central Amino Acid Linker Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0015.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0016.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Values are an average of at least two determinations.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Full length NS5B enzymatic assay.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a></p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Luc reporter assay.<a onclick="showRef(event, 'cit14c cit14d'); return false;" href="javascript:void(0);" class="ref cit14c cit14d">(14c, 14d)</a></p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Human liver microsome stability.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">JChem 5.0.0 (<a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>).</p></div><div class="footnote" id="t4fn6"><sup>Table f</sup><p class="last">Apical to basolateral direction.</p></div><div class="footnote" id="t4fn7"><sup>Table g</sup><p class="last">Following oral administration to rats as mixtures of four compounds at a dose of 4 mg/kg each.</p></div></div><div></div></div><div class="NLM_p">As depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, additional structural modifications to the right-hand-side alkoxycinnamic acid moiety were explored, including substitution of the cinnamic acid double bond with methyl, ethyl, or fluorine groups (<b>35</b>) in an attempt to explore steric shielding of the acrylic acid moiety and electronic effects, as well as conformational rigidification (<b>36</b>). While these modifications were relatively well tolerated, none provided an advantage over the original alkoxycinnamic acid moiety (results not shown).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cinnamic acid double bond substitution and rigidification.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Three analogs that had improved replicon potency compared with <b>1</b> and also showed promising preliminary ADME-PK characteristics were selected for advanced profiling. Individual rat PK profiles for compounds <b>23</b>, <b>27</b>, and <b>34</b> are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> and compared with that of clinical candidate <b>1</b>. Compound <b>27</b> displayed comparable exposure in rat to compound <b>1</b> albeit with lower bioavailability, but clearance was reduced and half-life was increased from 1.5 to 2.4 h in this rodent species. Characteristic of carboxylic acid containing molecules, the volume of distribution remained low but comparable to <b>1</b>. In rats, compound <b>27</b> showed favorable distribution from plasma to the liver target organ with liver/plasma ratio ∼5 at 6 h post-dosing.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Single Compound Rat PK Parameters</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">oral parameters (10 mg/kg)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IV parameters (2 mg/kg)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (μM·h)</th><th class="colsep0 rowsep0" align="center" char=".">MRT (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/(kg·min))</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i>%</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">0.48</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">0.38</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">10.6</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Compound dosed as an oral suspension in 0.5% methylcellulose and 0.3% Tween-80.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Bolus injection prepared in 70% PEG-400/30% water.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last"><i>N</i>-Methylpyrrolidone (NMP, 1%) was added to the oral dosing solution.</p></div></div></div><div class="NLM_p">Compound <b>27</b> was profiled in dog and monkey to provide cross-species data for human PK predictions, and the results are compared with <b>1</b> in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Compound <b>27</b>’s PK parameters in dogs and monkeys were comparable to compound <b>1</b>. As in rats, a low volume of distribution was observed, but clearance was slightly reduced almost 2-fold in both species relative to <b>1</b>. While plasma exposures following oral administration were superior to compound <b>1</b> (likely as a result of reduced clearance), bioavailability for <b>27</b> in dogs was lower than and in monkeys was comparable to those previously reported for compound <b>1</b>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Based on its cross-species PK profile and following allometry principles,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> compound <b>27</b> was predicted to be a low clearance compound in human (estimated IV Cl = 0.7 mL/(min·kg), estimated <i>t</i><sub>1/2</sub> ≈ 8.5 h, suitable for BID or TID dosing regimens).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Dog and Rhesus Monkey PK Profiles for <b>1</b> and <b>27</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">oral parameters (10 mg/kg)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center">IV parameters (2 mg/kg)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center">AUC (μM·h)</th><th class="colsep0 rowsep0" align="center">MRT (h)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center">CL (mL/(kg·min))</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>F</i>%</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>1</b> (dog)</td><td class="colsep0 rowsep0" align="center">15.3</td><td class="colsep0 rowsep0" align="center">99</td><td class="colsep0 rowsep0" align="center">5.4</td><td class="colsep0 rowsep0" align="center">0.54</td><td class="colsep0 rowsep0" align="center">1.8</td><td class="colsep0 rowsep0" align="center">4.3</td><td class="colsep0 rowsep0" align="center">64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>27</b> (dog)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">8.1</td><td class="colsep0 rowsep0" align="center">76</td><td class="colsep0 rowsep0" align="center">8.0</td><td class="colsep0 rowsep0" align="center">0.38</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">4.5</td><td class="colsep0 rowsep0" align="center">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>1</b> (monkey)</td><td class="colsep0 rowsep0" align="center">6.4</td><td class="colsep0 rowsep0" align="center">20.5</td><td class="colsep0 rowsep0" align="center">2.9</td><td class="colsep0 rowsep0" align="center">0.70</td><td class="colsep0 rowsep0" align="center">9.5</td><td class="colsep0 rowsep0" align="center">1.7</td><td class="colsep0 rowsep0" align="center">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>27</b> (monkey)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">9.6</td><td class="colsep0 rowsep0" align="center">53</td><td class="colsep0 rowsep0" align="center">6.1</td><td class="colsep0 rowsep0" align="center">0.60</td><td class="colsep0 rowsep0" align="center">3.6</td><td class="colsep0 rowsep0" align="center">3.0</td><td class="colsep0 rowsep0" align="center">72</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Compound dosed as an oral suspension in 0.5% methylcellulose and 0.3% Tween-80.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Bolus injection prepared in 70% PEG-400/30% water.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last"><i>N</i>-Methylpyrrolidone (NMP, 1%) was added to the oral dosing solution.</p></div></div></div><div class="NLM_p">Additional profiling data for compound <b>27</b> (BI 207524) is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>. In a biochemical assay using a NS5BΔ21 polymerase construct,<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> compound <b>27</b> had an IC<sub>50</sub> = 84 nM (comparable to <b>1</b>) and was selective against poliovirus RNA-dependent RNA polymerase and a mammalian DNA-dependent RNA polymerase isolated from calf thymus (IC<sub>50</sub> = 124 and 70 μM, respectively).<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> In a gt1b replicon assay where subgenomic RNA was quantified by Taqman assay,<a onclick="showRef(event, 'cit14b'); return false;" href="javascript:void(0);" class="ref cit14b">(14b)</a><b>27</b> was approximately 7-fold more potent than <b>1</b> with an EC<sub>50</sub> = 11 nM. As expected for thumb pocket 1 NS5B inhibitors, a ∼3-fold shift was observed in a gt1a replicon assay (EC<sub>50</sub> = 29 nM) relative to gt1b. In Huh-7 cells, the compound was not significantly cytotoxic (CC<sub>50</sub> = 38 μM in a MTT assay). This class of compound is typically highly protein bound (>99% for <b>27</b> and <b>1</b> in human plasma), but only slight shifts in EC<sub>50</sub> values were observed in replicon assays performed in the presence of up to 40% human serum (3.8-fold for <b>27</b>). Compound <b>27</b> exhibited moderate lipophilicity as reflected by a measured log <i>D</i> (pH 7.4) = 4.1 and was only weakly acidic (p<i>K</i><sub>a</sub> = 6.5), which is in line with the observed improvements in cell-based potency and the high Caco-2 permeability value (13 × 10<sup>–6</sup> cm/s). Metabolic stability in human liver microsomes was moderate (<i>t</i><sub>1/2</sub> = 102 min) and comparable to that of compound <b>1</b>, while the CYP450 inhibition profile was improved with the lowest IC<sub>50</sub> values measured against the 2C9 isozyme (IC<sub>50</sub> = 13.5 μM).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Structure and Profile of Compound <b>27</b> (BI 207524)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0017.gif" alt="" id="fx9" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">compound <b>1</b></th><th class="colsep0 rowsep0" align="center">compound <b>27</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gt1b NS5BΔ21 IC<sub>50</sub> (nM)<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a></td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gt1a/1b replicon EC<sub>50</sub> (nM)<a onclick="showRef(event, 'cit14b'); return false;" href="javascript:void(0);" class="ref cit14b">(14b)</a></td><td class="colsep0 rowsep0" align="left">153/84</td><td class="colsep0 rowsep0" align="left">29/11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MTT TC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">93 μM</td><td class="colsep0 rowsep0" align="left">38 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">serum shift in 40% human serum</td><td class="colsep0 rowsep0" align="left">3-fold</td><td class="colsep0 rowsep0" align="left">3.8-fold</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human plasma protein binding</td><td class="colsep0 rowsep0" align="left">99.2%</td><td class="colsep0 rowsep0" align="left">99.6%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i> (pH 7.4)/p<i>K</i><sub>a</sub></td><td class="colsep0 rowsep0" align="left">3.3/4.5</td><td class="colsep0 rowsep0" align="left">4.1/6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM <i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP450 inhibition: IC<sub>50</sub> (μM) 1A2/2C9/2C19/2D6/3A4</td><td class="colsep0 rowsep0" align="left">13/3.5/2.9/>30/>30</td><td class="colsep0 rowsep0" align="left">>30/13.5/>30/>30/>30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 permeability (cm/s)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">11 × 10<sup>–6</sup></td><td class="colsep0 rowsep0" align="left">13 × 10<sup>–6</sup></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Apical pH 6.0/basolateral pH 7.4.</p></div></div></div><div class="NLM_p">Compound <b>27</b> was nonmutagenic in the Ames test in the presence or absence of metabolic activation at dose levels up to maximum solubility. The compound showed no inhibition of the hERG channel at 0.8 μM (solubility limit) and no effect in the action potential duration assay in isolated guinea pig papillary muscle at 90% repolarization (APD90). In conscious telemeterized dogs, no effects were observed on cardiovascular function and electrocardiographic parameters up to the highest dose of 200 mg/kg (plasma <i>C</i><sub>max</sub> = 18 μM). Results from <i>in vivo</i> general pharmacology studies performed in rats and a receptor binding assay screen did not lead to findings that would preclude advancement into more advanced toxicology studies and further development.</div><div class="NLM_p">We recently reported a model to predict the pharmacokinetic–pharmacodynamic relationship for direct acting anti-HCV agents in humans, based on the liver partition coefficient-corrected inhibitory quotient (LCIQ) derived from <i>in vitro</i> hepatocyte partition coefficients and animal <i>in vivo</i> liver/plasma exposures.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Available clinical data for HCV DAAs suggests that a <i>C</i><sub>min</sub> LCIQ ≥ 500 is generally predictive of a strong antiviral response. According to this model and based on its gt1a antiviral potency and predicted human liver partitioning coefficient, regimens of 400 mg of compound <b>27</b> administered twice a day or 230 mg administered three-times a day should maintain <i>C</i><sub>min</sub> liver concentrations 500-fold gt1a EC<sub>50</sub> (LCIQ<sub>500</sub>) predictive of a strong antiviral response in humans.</div><div class="NLM_p last">However, during <i>in vitro</i> and <i>in vivo</i> cross-species metabolite studies performed in support of the development of <b>27</b>, small amounts of a genotoxic 4-amino-2-ethoxycinnamic acid metabolite were observed. This metabolite resulted from cleavage of the anilide bond and was also detected in animal plasma samples from PK studies and upon incubation of <b>27</b> with simulated gastric fluids (SGF). In human liver microsomes, the metabolite was formed at a rate of ∼1 ppm/min in a NADPH-independent manner. In light of the challenges associated with the progression of such a compound,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> development of <b>27</b> was discontinued, and efforts were focused on compounds without liabilities associated with the formation of genotoxic metabolites.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Synthesis of Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inhibitors were synthesized in a convergent fashion through amide bond coupling between indole-6-carboxylic acid derivatives and amine fragments as shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and as previously described for compound <b>1</b>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Scheme</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">6-Indolecarboxylic acid derivatives <b>38</b> were prepared from protected 2-bromoindole <b>37</b> and commercially available aryl or heteroaryl halides using standard cross-coupling protocols as previously described.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Amide bond coupling with amines <b>40</b>, themselves derived from condensation of α,α-disubstituted amino acids with 4-aminocinnamate esters <b>39</b>, provided directly inhibitors <b>41</b> after deprotection of the carboxylic acid function by saponification. Alternatively, indoles <b>38</b> could be coupled in a stepwise fashion to protected α,α-disubstituted amino acid esters to provide azalactones <b>42</b> and then condensed with 4-amino cinnamate esters to provide <b>41</b> after deprotection.</div><div class="NLM_p">Cinnamate esters <b>39</b> for inhibitors <b>2</b>–<b>11</b> were prepared using a palladium-catalyzed Heck cross-coupling reaction using commercially available substituted 4-bromo- or 4-iodoanilines and methyl acrylate as shown in eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a>.</div><div class="NLM_p"><span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0001.gif" alt="" id="GRAPHIC-d4180e1793-autogenerated" /></img></span></div><div class="NLM_p">4-Amino-ethoxycinnamic acid methyl ester <b>46</b> was prepared from 2-ethoxy-4-nitrobenzoic acid <b>43</b> using a sequence involving reduction–oxidation to the corresponding aldehyde <b>44</b> followed by Horner–Wittig reaction to give nitrocinnamate <b>45</b> and reduction of the nitro group to the corresponding aniline using iron as described in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Cinnamate ester containing α-alkyl substituents (e.g., <b>35</b>) were prepared in the same manner using substituted phosphonoacetates.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of 4-Amino-2-ethoxycinnamic Acid Methyl Ester <b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BH<sub>3</sub>·Me<sub>2</sub>S, THF, 0 °C to RT; (b) MnO<sub>2</sub>, CHCl<sub>3</sub>, reflux; (c) trimethylphosphonoacetate, NaH, THF, RT; (d) Fe powder, NH<sub>4</sub>Cl, EtOH, reflux.</p></p></figure><div class="NLM_p">Alkoxycinnamic acid building blocks with variations of the alkoxy moiety for the synthesis of inhibitors <b>16</b>–<b>21</b> were prepared from 2-hydroxy-4-nitrobenzoic acid <b>47</b> through the sequence depicted in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a> using a similar reduction–oxidation sequence to generate benzaldehyde <b>48</b>, which served as a key intermediate providing access to chromene analog <b>49</b> or protected 2-hydroxycinnamate <b>52</b> following protection of <b>48</b> as the pivaloate ester and Horner–Wittig condensation. Phenol <b>52</b> was etherified to alkoxy derivatives <b>53</b> by direct alkylation using alkyl halides and Cs<sub>2</sub>CO<sub>3</sub> or via a Mitsunobu protocol. Subsequent reduction with sodium hydrosulfite or iron powder provided the corresponding aniline building blocks <b>54</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Chromene <b>49</b> and 2-Alkoxycinnamate Building Blocks (Inhibitors <b>16</b>–<b>21</b>) by Alkylation and Mitsunobu Etherification Protocols<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BH<sub>3</sub>·Me<sub>2</sub>S, THF, 0 °C to RT; (b) MnO<sub>2</sub>, CHCl<sub>3</sub>, reflux; (c) methyl acrylate, DABCO, 50 °C; (d) Fe powder, NH<sub>4</sub>Cl, EtOH, reflux; (e) Piv-Cl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT; (f) trimethylphosphonoacetate, NaH, THF, RT; (g) conc. H<sub>2</sub>SO<sub>4</sub>; (h) ROH, DEAD, Ph<sub>3</sub>P, THF, RT; (i) RI or RBr, Cs<sub>2</sub>CO<sub>3</sub>, DMF, RT or 60 °C; (j) Fe, NH<sub>4</sub>Cl, EtOH–water, 80 °C, or K<sub>2</sub>CO<sub>3</sub>, NaHSO<sub>3</sub>, EtOH–water, RT.</p></p></figure><div class="NLM_p">2,6-Dimethoxycinnamate analog <b>14</b> was prepared from amine <b>58</b> prepared as shown in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a> from methyl 4-amino-2,6-dimethoxybenzoate <b>55</b>,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> by condensation with N-Boc-1-aminocyclobutane carboxylic acid to provide protected amino acid derivative <b>56</b> followed by the usual reduction–oxidation–Horner/Wittig and deprotection to access <b>58</b> as the hydrochloride salt via intermediate benzaldehyde <b>57</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of 2,6-Dimethoxycinnamate Building Block for the Synthesis of Inhibitor <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TBTU, Et<sub>3</sub>N, DMSO, RT; (b) LiAlH<sub>4</sub>, THF, 0 °C to RT; (c) MnO<sub>2</sub>, THF, reflux; (d) trimethylphosphonoacetate, NaH, THF, RT; (e) 4 N HCl, dioxane, RT.</p></p></figure><div class="NLM_p">Inhibitors <b>16</b>–<b>21</b> were prepared using an alternative assembly sequence illustrated in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. 6-Indole carboxylic acid <b>59</b><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> was condensed with the ethyl ester of 1-aminocyclobutane carboxylic acid, and the resulting amide product was saponified to provide carboxylic acid <b>60</b>. Treatment with acetic anhydride provided azalactone <b>61</b> as a stable material that was used in condensation reactions with a variety of 4-aminocinnamic ester building blocks <b>39</b> (e.g., <b>62</b>) to provide final inhibitors (e.g., <b>21</b>) following deprotection of the cinnamate ester.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Alternative Assembly of Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TBTU, Et<sub>3</sub>N, DMF, RT; (b) 1 N NaOH, MeOH–THF–water, RT; (c) Ac<sub>2</sub>O, 100 °C; (d) aniline <b>62</b>, toluene, AcOH, 85 °C; (e) 1 N NaOH, DMSO.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67142" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67142" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described the discovery of a potent HCV NS5B thumb pocket 1 follow-up compound to our initial clinical candidate, <b>1</b>. Cell-based potency in the subgenomic replicon was improved 7–8-fold by decreasing the acidity of <b>1</b> by ∼100× (p<i>K</i><sub>a</sub> = 4.5 → 6.5) through electronic effects mediated by the introduction of alkoxy substituents in conjugation to the acrylic acid moiety. Subsequent ADME-PK optimization led to the discovery of <b>27</b>, an analog that was predicted to be a low clearance compound in man based on its cross-species PK profile. Based on its improved potency, cross-species PK profile, and predicted human liver partitioning, doses of 400 mg BID or 230 mg TID of <b>27</b> (corresponding to LCIQ = 500) are predicted to provide a stronger antiviral response in man than that achieved with <b>1</b> at 450 mg TID (LCIQ ≈ 100).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, the identification of a genotoxic aniline metabolite released through the action of liver peptidases or chemical hydrolysis of the anilide bond in biological fluids led to discontinuation of the development of <b>27</b>.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60241" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60241" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Experimental</h3><div class="NLM_p last">All commercially obtained solvents and reagents were used as received without further purification. All reactions were carried out under an atmosphere of argon. Temperatures are given in degrees Celsius. Solution percentages express a weight to volume relationship, and solution ratios express a volume to volume relationship, unless stated otherwise. NMR spectra were recorded on a Bruker AVANCEII (400 MHz for <sup>1</sup>H NMR) spectrometer and were referenced to either DMSO-<i>d</i><sub>6</sub> (2.50 ppm) or CDCl<sub>3</sub> (7.27 ppm). Data is reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, br = broad, m = multiplet), coupling constant (<i>J</i>, reported to the nearest 0.5 Hz), and integration. Low resolution mass spectra were obtained on a Micromass Platform LCZ model ZMD 4000 in electrospray mode. High-resolution mass spectra (HRMS) were obtained on a Bruker micrOTOF-Q II in electrospray positive (ES+) ionization mode. Purification of crude material was performed either by flash column chromatography or by using a CombiFlash Companion using RediSep Silica or SilicaSep columns according to preprogrammed gradient and flow rate separation conditions in hexane/EtOAc or DCM/MeOH. The final compounds were purified by preparative HPLC on a Waters 2767 sample manager with pumps 2525, column fluidics organizer (CFO), PDA detector 2996, and MassLynx 4.1 using either a Whatman Partisil 10-ODS-3 column, 2.2 × 50 cm<sup>2</sup> or a YMC Combi-Prep ODS-AQ column, 50 × 20 mm<sup>2</sup> ID, <i>S</i> = 5 μm, 120 Å, and a linear gradient program from 2% to 100% AcCN/water (0.06% TFA). Fractions were analyzed by analytical HPLC, and the pure fractions were combined, concentrated, frozen, and lyophilized to yield the desired compound as a neutral entity or the trifluoroacetate salt for basic analogues. Inhibitor HPLC purity was measured by using a Waters Alliance 2695 separation module with a Waters TUV 2487 UV detector. The column was a Combiscreen ODS-AQ, 5 μm, 4.6 × 50 mm<sup>2</sup>, linear gradient from 5% to 100% ACN/H<sub>2</sub>O + 0.06% TFA in 10.5 min, detection at 220 nm. All final inhibitors had HPLC homogeneity ≥95% unless noted otherwise (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 2-Iodo-5-chloropyrimidine</h3><div class="NLM_p">2-Hydroxypyrimidine hydrochloride (100 g, 0.754 mol) was dissolved in water (180 mL), and conc. H<sub>2</sub>SO<sub>4</sub> (42 mL, 0.788 mol) was added dropwise with vigorous stirring. After stirring for an additional 30 min, water was removed under reduced pressure at 70 °C, and the orange residue was dried under high vacuum (146 g). The residue was transferred into a 4 L flask, and water (500 mL) was added. A suspension of Ba(OH)<sub>2</sub> (129 g, 0.752 mol) in water (1200 mL) was added, and the cloudy suspension stirred for 30 min. The mixture was filtered through Celite, and the water removed under reduced pressure to provide 2-hydroxypyrimidine free base as a bright yellow solid (66.4 g).</div><div class="NLM_p">2-Hydroxypyrimidine free base (42 g, 0.44 mol) was added to AcOH (500 mL), and the mixture heated to 120 °C. <i>N</i>-Chlorosuccinimide (67 g, 0.5 mol, 1.15 equiv) was added cautiously (15 min) in small amounts to the hot solution. Stirring was continued for an additional 5 min, and the reaction mixture was cooled to RT. The material was concentrated under reduced pressure, and the residue was stirred overnight with CH<sub>2</sub>Cl<sub>2</sub> (200 mL). The suspended solid was removed by filtration, and the filtrate was evaporated under reduced pressure to give 2-hydroxy-5-chloropyrimidine as a beige solid (17.3 g).</div><div class="NLM_p">The 5-chloro-2-hydroxypyrimidine (8.0 g, 0.06 mol) was placed in a dry 500 mL flask under an Ar atmosphere, and POCl<sub>3</sub> (79.4 mL) was added followed by <i>N</i>,<i>N</i>-dimethylaniline (2.6 g). The mixture was heated to 120 °C and stirred for 1 h. The dark brown mixture was concentrated under reduced pressure at 50 °C. The residue was quenched carefully with ice water, and the precipitated material was extracted with pentane (3 × 200 mL). The extract was washed with water and aqueous NaHCO<sub>3</sub> solution and dried (Na<sub>2</sub>SO<sub>4</sub>). Volatiles were removed under reduced pressure with no external heating to prevent sublimation of the volatile product to provide 2,5-dichloropyrimidine as a white solid (6 g).</div><div class="NLM_p last">A flask was charged with 57% HI (48 mL) and cooled to 0 °C in an ice–salt mixture. The crude 2,5-dichloropyrimidine (6 g) was added, and the mixture was stirred for 4 h. The yellow suspension was treated carefully with K<sub>2</sub>CO<sub>3</sub> (32 g) in water (60 mL), and the pale yellow solid was collected by filtration. The solid was washed with water and dried to give the title compound (8 g): mp 71–73 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.47 (s, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.1, 132.2, 125.1.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 2-(5-Chloropyrimidin-2-yl)-3-cyclopentyl-1-methyl-1<i>H</i>-indole-6-carboxylic Acid, <b>38</b> (Het = 5-chloro-2-pyrimidinyl)</h3><div class="NLM_p">2-Bromoindole <b>37</b> was converted to the corresponding tributylstannane derivative as previously described.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The stannane (37.50 g, 69 mmol, 1 equiv) was charged in an oven-dried 2 L three-necked flask equipped with a mechanical stirrer and dissolved in dry DMF (300 mL). 5-Chloro-2-iodopyrimidine (91% content by <sup>1</sup>H NMR, 20.0 g, 76 mmol, 1.1 equiv) was added, and the solution was purged by bubbling argon gas for 1 h while stirring at RT. Solid cesium fluoride (22.50 g, 148 mmol, 2.2 equiv), solid Pd(Ph<sub>3</sub>)<sub>4</sub> (3.41 g, 2.95 mmol, 0.036 equiv), and CuI (1.37 g, 7.2 mmol, 0.10 equiv) were added in this order, and the light brown reaction mixture was stirred for 3 h at RT under an argon atmosphere, at which point a thick precipitate had formed and conversion was judged to be complete by HPLC analysis. The reaction mixture was then diluted with EtOAc (1 L), and the precipitate was removed by filtration using additional EtOAc for washings. Water (300 mL) was added to the filtrate, and the mixture was vigorously stirred to produce additional precipitate that was removed by filtration. The filtrate was again washed with water (3 × 200 mL) and brine (300 mL) and dried over MgSO<sub>4</sub>. After filtration, the solution was concentrated to about 300 mL under reduced pressure to give a white suspension that was cooled overnight at 5 °C. The solid was collected by filtration and dried under vacuum to give crude methyl ester as a white solid (10.76 g). The mother liquors were concentrated and partially purified by flash chromatography on silica gel using CHCl<sub>3</sub> as eluent (9.5 g). Both crops were combined and purified again by flash chromatography as described above to provide a total of 16.25 g (64% yield) of the desired indole methyl ester as a white solid that was used directly in the next step: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.15 (s, 2H), 8.17 (s, 1H), 7.82 (d, <i>J</i> = 8.6 Hz, 1H), 7.68 (dd, <i>J</i> = 1.2, 8.6 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.59–3.76 (m, 1H), 1.98–1.83 (m, 6H), 1.73–1.57 (br. m, 2H).</div><div class="NLM_p last">The indole methyl ester (16.10 g, 43.5 mmol, 1.0 equiv) was suspended in DMSO (400 mL), and the suspension was heated to 75 °C with stirring until all solids dissolved. The solution was then cooled to 33 °C (below this temperature, the material begins to crystallize again), and 2.5 N NaOH (70 mL, 175 mmol, 4equiv) was added dropwise over a 10 min period. The light yellow solution instantly became darker, and a white suspension slowly formed, which redissolved when the addition was complete. After stirring for 30 min at RT, the reaction was judged complete by HPLC analysis, and water (400 mL) was added to the reaction mixture. The solution was filtered through a 45 μm membrane to remove small amounts of undissolved material and added slowly with stirring to 0.5 N HCl (2 L) to provide an acidic suspension. After stirring for 10 min, the white-yellowish precipitate was collected by filtration, rinsed with water until neutral, and dried to provide the desired indole carboxylic acid derivative as a yellow solid (15.19 g, 98% yield): mp 190–195 °C dec.; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (br s, 1H), 9.12 (s, 2H), 8.15 (s, 1H), 7.78 (d, <i>J</i> = 8.6 Hz, 1H), 7.67 (dd, <i>J</i> = 1.4, 8.4 Hz, 1H), 3.85 (s, 3H), 3.63–3.75 (m, 1H), 1.81–1.99 (m, 6H), 1.58–1.68 (m, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.1, 157.7, 155.9, 137.3, 135.7, 128.8, 128.1, 125.0, 121.2, 120.4, 119.8, 112.6, 67.0, 36.3, 32.8, 31.6, 26.0, 25.1; HRMS calcd for C<sub>19</sub>H<sub>19</sub>ClN<sub>3</sub>O<sub>2</sub> (M + H) 356.1160; found 356.1177.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 4-Amino-2-ethoxycinnamic Acid Methyl Ester, <b>46</b></h3><div class="NLM_p">2-Ethoxy-4-nitrobenzoic acid, <b>43</b> (25.0 g, 118.3 mmol, 1.0 equiv), was dissolved in anhydrous THF (300 mL), and the solution was cooled to 0 °C in an ice bath under an argon atmosphere. Borane–dimethylsulfide complex (10 M, 26 mL, 260 mmol, 2.2 equiv) was added dropwise over 15 min (<i><b>caution</b></i>: gas evolution), and the solution was stirred for an additional 20 min at 0 °C. The ice bath was removed, and the mixture was stirred for 4 h at RT. The solution was cooled again to 0 °C, and water (40 mL) was added dropwise over 20 min (<i><b>caution</b></i>: vigorous gas evolution). After completion, the reaction mixture was stirred 30 min at RT, and volatiles were removed under reduced pressure. The residue was diluted with water and extracted with EtOAc, and the extract was washed with 1 N HCl followed by brine. After drying over MgSO<sub>4</sub>, filtration and removal of solvents yielded the crude benzylic alcohol as a yellow solid (22.4 g, 96% yield) that was sufficiently pure to use in the next step.</div><div class="NLM_p">The benzylic alcohol (22.0 g, 111.5 mmol, 1 equiv) was dissolved in CHCl<sub>3</sub> (1 L), and solid MnO<sub>2</sub> (60 g, 690 mmol, 6.2 equiv) was added in one portion. The suspension was stirred at reflux for 2.5 h, after which the reaction was judged complete by TLC. The suspension was filtered over Celite, and the solids were washed with CH<sub>2</sub>Cl<sub>2</sub>. Removal of volatiles under reduced pressure yielded the desired benzaldehyde intermediate <b>44</b> as a yellow solid (20.1 g, 92% yield) that was used directly in the next step: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 7.94 (d, <i>J</i> = 1.7 Hz, 1H), 7.90–7.92 (d, <i>J</i> = 8.4 Hz, 1H), 7.87 (dd, <i>J</i> = 1.7, 8.4 Hz, 1H), 4.34 (q, <i>J</i> = 7.0 Hz, 2H), 1.43 (t, <i>J</i> = 7.0 Hz, 3H).</div><div class="NLM_p">Note, the corresponding 4-nitro-2-methoxybenzaldehyde for the synthesis of the building block required for the preparation of inhibitor <b>13</b> was obtained from commercial sources.</div><div class="NLM_p">NaH (95%, 2.17 g, 86 mmol, 1.3 equiv) was added in small portions to a solution of trimethylphosphonoacetate (12.95 mL, 182 mmol, 1.2 equiv) in THF (550 mL) at 0 °C. After stirring for 30 min at 0 °C, a solution of aldehyde <b>44</b> (13.00 g, 66.6 mmol, 1.0 equiv) in THF (50 mL) was added dropwise to the white slurry, which progressively dissolved. The cooling bath was then removed, and after stirring for 4 h at RT, the reaction was judged complete by TLC. Volatiles were evaporated under reduced pressure, and the residue taken up in EtOAc. The solution was washed with 1 N HCl, aqueous NaHCO<sub>3</sub> (3×), and brine. After drying (MgSO<sub>4</sub>), removal of solvents provided nitrocinnamate ester <b>45</b> as a yellow solid (16.6 g, 100% yield) that could be purified further by trituration with ether to remove small amounts (∼3%) of the cis-isomer: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.01 (m, 1H), 7.86 (d, <i>J</i> = 16.2 Hz, 1H), 7.79–7.83 (m, 2H), 6.85 (d, <i>J</i> = 16.2 Hz, 1H), 4.28 (q, <i>J</i> = 7.0 Hz, 2H), 3.75 (s, 1H), 1.43 (t, <i>J</i> = 7.0 Hz, 3H).</div><div class="NLM_p last">Iron powder (7.30 g, 131 mmol, 3.1 equiv) and solid ammonium chloride (1.20 g, 22.4 mmol, 0.5 equiv) were added to a suspension of nitrocinnamate <b>45</b> (10.60 g, 42.2 mmol, 1.0 equiv) in a mixture of EtOH (150 mL) and water (40 mL). The resulting slurry was stirred at 85 °C for 1 h, at which point the reaction was complete by TLC. The mixture was filtered over Celite, and the solids were rinsed with several portions of EtOH. The combined filtrate and washings were evaporated under reduced pressure, the residue was taken up in CH<sub>2</sub>Cl<sub>2</sub>, and the solution was washed with water and brine. After drying (MgSO<sub>4</sub>), removal of volatiles under reduced pressure provided aniline <b>46</b> as an amber-colored gum that solidified upon standing (8.94 g, 96% yield): mp 95–98 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.73 (d, <i>J</i> = 16.0 Hz, 1H), 7.32 (d, <i>J</i> = 8.2 Hz, 1H), 6.25 (d, <i>J</i> = 16.0 Hz, 1H), 6.22–6.14 (m, 2H), 5.82 (br s, 2H), 4.00 (q, <i>J</i> = 7.0 Hz, 2H), 3.65 (s, 3H), 1.37 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.9, 159.2, 153.3, 140.7, 130.7, 110.2, 110.1, 106.6, 96.6, 63.1, 50.8, 14.6; HRMS calcd. for C<sub>12</sub>H<sub>16</sub>NO<sub>3</sub> (M + H) 222.1125; found 222.1134.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 7-Amino-2<i>H</i>-chromene-3-carboxylic Acid Methyl Ester, <b>49</b></h3><div class="NLM_p last">Following an analogous procedure as that described for the preparation of ethoxybenzaldehyde <b>44</b>, 2-hydroxy-4-nitrobenzoic acid, <b>47</b>, was reduced–oxidized to aldehyde <b>48</b> in 70% yield for the two steps. The hydroxynitroaldehyde <b>48</b> (2.50 g, 14.96 mmol) was suspended in methyl acrylate (13.5 mL, 150 mmol, 10 equiv), and the mixture heated to 50 °C to produce a yellow solution. DABCO (0.42 g, 3.74 mmol, 0.25 equiv) was added, and the mixture was heated to 90 °C for 2.5 days. The reaction mixture was cooled to room temperature and diluted with ether (150 mL). The solution was washed with 1 N NaOH (2 × 100 mL), 1 N HCl (100 mL), and brine (100 mL). After drying (Na<sub>2</sub>SO<sub>4</sub>), removal of volatiles gave an orange solid (0.5 g). The combined aqueous phases were re-extracted with EtOAc (2 × 300 mL) to give 2 g of solid that was purified by flash chromatography on silica gel using 15% EtOAc in hexane as eluent. The desired nitrochromene intermediate was obtained as an orange solid (0.47 g, 15% yield). Reduction of the nitro group to provide aniline <b>49</b> was carried out with Fe/NH<sub>4</sub>Cl as described for derivative <b>46</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.37 (s, 1H), 6.98 (d, <i>J</i> = 8.2 Hz, 1H), 6.16 (dd, <i>J</i> = 1.9, 8.2 Hz, 1H), 6.0 (d, <i>J</i> = 1.6 Hz, 1H), 5.83 (s, 2H), 4.79 (s, 2H), 3.69 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.7, 156.4, 153.4, 134.6, 130.7, 114.1, 109.2, 107.8, 99.5, 63.9, 51.3; HRMS calcd. for C<sub>11</sub>H<sub>12</sub>NO<sub>3</sub> (M + H) 206.0812; found 206.0817.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Conversion of Aldehyde <b>48</b> to Hydroxycinnamate <b>52</b></h3><div class="NLM_p">Aldehyde <b>48</b> (52.0 g, 0.31 mol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 L) under an argon atmosphere. Triethylamine (95 mL, 0.68 mol, 2.2 equiv) was added to the mixture producing a dark red coloration. Trimethylacetyl chloride (40.0 mL, 0.32 mol, 1.05 equiv) was then added dropwise over 25 min, and the reaction mixture was stirred for 3 h at room temperature until complete. The mixture was filtered to remove solids (CH<sub>2</sub>Cl<sub>2</sub> rinses), and the filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc, and the solution was washed with 0.5 M citric acid (500 mL), water (500 mL), NaHCO<sub>3</sub> (2 × 500 mL), and brine (500 mL). After drying (Na<sub>2</sub>SO<sub>4</sub>), volatiles were removed under reduced pressure to yield the desired pivalate <b>50</b> as an off-white solid (104.2 g): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.13 (s, 1H), 8.30 (dd, <i>J</i> = 2.0, 8.5 Hz, 1H), 8.23 (d, <i>J</i> = 2.0 Hz, 1H), 8.17 (d, <i>J</i> = 8.5 Hz, 1H), 1.38 (s, 9H).</div><div class="NLM_p">A 5 L three-necked flask equipped with a mechanical stirrer and addition funnel was charged with NaH (60% oil dispersion, 19.1 g, 0.478 mol, 1.5 equiv) under an argon atmosphere. Dry THF (1 L) was added, and the mixture was cooled in an ice–salt bath to −2 °C. Trimethylphosphonoacetate (69.5 g, 0.382 mol, 1.2 equiv) was added dropwise over 35 min. The thick slurry was stirred for an additional 20 min, and aldehyde <b>50</b> (80.0 g, 0.318 mol) in THF (600 mL) was added over 30 min followed by a THF rinse (400 mL). The orange slurry was then stirred overnight RT. The reaction mixture was quenched with water (50 mL), and THF was removed under reduced pressure. The residue was partitioned between EtOAc (800 mL) and water (800 mL), and the organic phase was separated. The aqueous phase was extracted again with EtOAc (1 L), and the organic extracts were combined and washed with NaHCO<sub>3</sub> (2 × 1 L) and brine (1 L). After drying (Na<sub>2</sub>SO<sub>4</sub>), solvents were removed under reduced pressure until crystallization of the product. After cooling, crystallized material was collected by filtration and washed with cold EtOAc and hexane. After drying, a first crop of product <b>51</b> (40 g) was obtained as a light yellow solid. Filtrates and washes were combined and concentrated to give an additional 10 g of product (total yield, 50 g): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.13–8.25 (m, 3H), 7.61 (d, <i>J</i> = 16.2 Hz, 1H), 6.90 (d, <i>J</i> = 16.2 Hz, 1H), 3.75 (s, 3H), 1.38 (s, 3H).</div><div class="NLM_p">The cinnamate derivative <b>51</b> (50.0 g, 0.162 mol) was charged into a flask that was immersed in an ice bath. Precooled conc. H<sub>2</sub>SO<sub>4</sub> (350 mL) was added, producing a dark red solution. After stirring in ice for 30 min, the clear solution was poured over ice (2.5 kg) to give a yellow solid. Hydroxycinnamate <b>52</b> was collected by filtration, washed with water, and dried (43.6 g): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.33 (s, 1H), 7.93 (d, <i>J</i> = 8.6 Hz, 1H), 7.86 (d, <i>J</i> = 16.4 Hz, 1H), 7.71 (d, <i>J</i> = 2.4 Hz, 1H), 7.66 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 6.84 (d, <i>J</i> = 16.4 Hz, 1H), 3.74 (s, 3H); FIA-MS <i>m</i>/<i>z</i> (M-H) 222.0.</div><div class="NLM_p last">Note, (<i>E</i>)-3-(2-hydroxy-4-nitro-phenyl)-2-methyl-acrylic acid ethyl ester was prepared in a similar way replacing trimethylphosphonoacetate by triethyl 2-phosphonopropionate and used to prepare cinnamate derivatives containing α-alkyl substituents (e.g., <b>35</b>).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure for the Preparation of 2-Alkoxycinnamates <b>53</b> from 2-Hydroxycinnamate <b>52</b> Using a Mitsunobu Etherification Protocol: Preparation of (<i>E</i>)-3-[2-(2-Methoxyethoxy)-4-nitrophenyl]acrylic Acid Methyl Ester, <b>53</b>, and Corresponding Aniline <b>54</b> (R = CH<sub>2</sub>CH<sub>2</sub>OMe)</h3><div class="NLM_p">Methyl-2-hydroxy-4-nitrocinnamate, <b>52</b> (1.01 g, 4.5 mmol), was combined with 2-methoxyethan-1-ol (0.53 mL, 6.8 mmol) and diethylazodicarboxylate (1.07 mL, 6.8 mmol) in THF (20 mL). Triphenylphosphine (1.78 g, 6.8 mmol) was added, and the solution was stirred 15 min at ambient temperature. The reaction mixture was diluted in EtOAc and washed with water and brine. The organic phase was dried with MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was subjected to flash chromatography (1:9 EtOAc/hexane; 1:4; 1:3), and the desired ether <b>53</b> (R = CH<sub>2</sub>CH<sub>2</sub>OMe) was recovered as a light yellow solid (1.01 g, 80% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.02 (d, <i>J</i> = 8.6 Hz, 1H), 7.82–7.90 (m, 3H), 6.89 (d, <i>J</i> = 16.2 Hz, 1H), 4.33–4.41 (m, 2H), 3.72–3.78 (m, 5H), 3.34 (s, 3H).</div><div class="NLM_p last">The nitrocinnamate ester <b>53</b> (353 mg, 1.3 mmol) was combined with iron powder (209 mg, 3.8 mmol) in absolute ethanol (5 mL). Saturated aqueous ammonium chloride (1 mL) and distilled water (1 mL) were added, and the heterogeneous mixture was heated at 80 °C with stirring. After 2 h, the rust colored mixture was diluted in EtOAc and washed with water and brine. The organic phase was dried with MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was subjected to flash chromatography (1:2 → 1:1 EtOAc/hexane) to afford 223 mg (71%) of desired aniline <b>54</b> (R = CH<sub>2</sub>CH<sub>2</sub>OMe) as a yellow solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.72 (d, <i>J</i> = 16.0 Hz, 1H), 7.33 (d, <i>J</i> = 8.0 Hz, 1H), 6.27 (d, <i>J</i> = 16.0 Hz, 1H), 6.14–6.22 (m, 2H), 5.85 (s, 2H), 3.99–4.11 (m, 2H), 3.70 (m, 2H), 3.64 (s, 3H), 3.34 (s, 3H); FIA-MS <i>m</i>/<i>z</i> = 252.1(MH<sup>+</sup>).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure for the Preparation of 2-Alkoxycinnamates <b>53</b> from 2-Hydroxycinnamate <b>52</b> Using an Alkylative Etherification Protocol: Preparation of 4-Amino-2-Cyclobutyloxycinnamate Methyl Ester, <b>54</b> (R = Cyclobutyl)</h3><div class="NLM_p">Methyl 2-hydroxy-4-nitro cinnamate <b>52</b> (0.30 g, 1.3 mmol, 1 equiv) and cesium carbonate (0.55 g, 1.7 mmol, 1.3 equiv) were suspended in DMF (2.5 mL), and bromocyclobutane (0.13 mL, 1.3 mmol, 1 equiv) was added. The mixture was stirred at 60 °C for 2 days, after which the mixture was poured into water (30 mL) and extracted with EtOAc (2 × 20 mL). The extract was washed with water (30 mL) and brine (30 mL) and dried (MgSO<sub>4</sub>). Removal of volatiles under reduced pressure gave the desired 2-cyclobutyloxy derivative as an orange gum (0.35 g, 94% yield) that was used without further purification: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.97–8.07 (m, 1H), 7.79–7.92 (m, 2H), 7.62 (d, <i>J</i> = 2.1 Hz, 1H), 6.86 (d, <i>J</i> = 16.0 Hz, 1H), 4.98 (m, 1H), 3.75 (s, 3H), 2.55–2.49 (m, 2H), 2.06–2.20 (m, 2H), 1.77–1.90 (m, 1H), 1.65–1.77 (m, 1H); FIA-MS <i>m</i>/<i>z</i> MH<sup>+</sup> not observed.</div><div class="NLM_p last">The crude nitrocinnamate from above (0.35 g, 1.25 mmol, 1 equiv) was suspended in EtOH (4.5 mL) and water (5 mL), and the suspension was stirred vigorously while potassium carbonate (1.04 g, 7.5 mmol, 6 equiv) and sodium hydrosulfite (85%, 1.31 g, 7.5 mmol, 6 equiv) were added. The mixture was stirred for 16 h at RT, diluted with water (50 mL), and extracted with EtOAc (2 × 25 mL). The extract was washed with saturated NaHCO<sub>3</sub> solution (2 × 50 mL) and brine (50 mL). The extract was dried (MgSO<sub>4</sub>) and concentrated to give the title compound as a yellow-brown syrup (115 mg) that was used without further purification: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.70 (d, <i>J</i> = 16.0 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 6.24 (d, <i>J</i> = 16.0 Hz, 1H), 6.15 (dd, <i>J</i> = 1.8, 8.4 Hz, 1H), 6.08–6.09 (m, 1H), 6.02–6.10 (m, 1H), 5.83 (br. s, 2H), 4.64–4.57 (m, 1H), 3.65 (s, 3H), 2.38–2.46 (m, 2H), 2.00–2.15 (m, 2H), 1.81 (m, 1H), 1.55–1.73 (m, 1H); FIA-MS <i>m</i>/<i>z</i> = 248.3 (MH<sup>+</sup>).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>E</i>)-3-{4-[(1-Amino-cyclobutanecarbonyl)-amino]-2-ethoxy-phenyl}-acrylic Acid Methyl Ester</h3><div class="NLM_p last">Aniline <b>46</b> (7.64 g, 34.5 mmol) was added portionwise over 3 min to a suspension of 1-amino cyclobutane acid chloride hydrochloride<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (6.80 g, 40 mmol) in MeCN (150 mL). The suspension was stirred for 20 h at room temperature. Solid K<sub>3</sub>PO<sub>4</sub> (18.50 g, 87 mmol) was added, and after 15 min, the suspension was poured into water. The oily product was extracted into EtOAc and washed with brine, and the solution was dried (Na<sub>2</sub>SO<sub>4</sub>). The material was purified by flash chromatography on silica gel using 90% EtOAc in hexane as eluent. The title compound was obtained as a white solid: mp 120–122.5 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.81 (d, <i>J</i> = 16.4 Hz, 1H), 7.62 (d, <i>J</i> = 8.2 Hz, 1H), 7.59 (d, <i>J</i> = 1.9 Hz, 1H), 7.33 (dd, <i>J</i> = 1.9, 8.2 Hz, 1H), 6.54 (d, <i>J</i> = 16.0 Hz, 1H), 4.10 (q, <i>J</i> = 7.0 Hz, 2H), 3.70 (s, 3H), 2.55–2.45 (m, 2H), 1.82–1.97 (m, 3H), 1.69–1.82 (m, 1H), 1.40 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.5, 167.3, 157.8, 142.6, 139.3, 129.6, 117.0, 115.6, 111.2, 102.8, 63.7, 59.4, 51.2, 33.7, 14.5, 13.8; HRMS calcd. for C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub> (M + H) 319.1652; found 319.1667.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Preparation of Amino Acid Derivative <b>56</b></h3><div class="NLM_p last">Methyl 4-amino-2,6-dimethoxybenzoate<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (2.00 g, 9.5 mmol) was dissolved in DMSO (20 mL). <i>N</i>-Boc-1-aminocyclobutane-1-carboxylic acid (2.07 g, 9.6 mmol) was added followed by triethylamine (4.18 mL, 30 mmol, 3.2 equiv) and TBTU (3.69 g, 11.5 mmol, 1.2 equiv). The mixture was stirred for 24 h at room temperature, after which it was added dropwise to a solution of AcOH (15 mL) in water (150 mL). The white precipitated <b>56</b> was collected by filtration, washed with water, and dried in vacuum (3.50 g, 71% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.47 (br s, 1H), 7.47 (br s, 1H), 7.15 (br s, 2H), 3.68–3.74 (m, 9H), 2.52–2.60 (m, 2H), 2.00–2.19 (m, 2H), 1.87 (m, 1H), 1.70–1.84 (m, 1H), 1.38–1.24 (m 9H); MS <i>m</i>/<i>z</i> 409.3 (MH<sup>+</sup>).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Preparation of Aldehyde <b>57</b></h3><div class="NLM_p">Methyl ester <b>56</b> from above (1.84 g, 4.5 mmol) was dissolved in THF (20 mL), and the solution was cooled in ice under an inert atmosphere. LiAlH<sub>4</sub> (1 M in ether, 27 mL, 27 mmol) was added dropwise, and the reaction mixture was allowed to warm to room temperature. After stirring for 3.5 h, the reaction was judged complete (HPLC analysis). It was quenched by careful addition of AcOH and diluted with CH<sub>2</sub>Cl<sub>2</sub> (250 mL), and 150 mL of 1 M sodium–potassium tartrate solution (Rochelle’s salt) was added. After stirring vigorously for 90 min, the mixture was filtered to remove solids, and the organic phase was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to a white solid. The residue was triturated with TBME (25 mL), and the white solid was collected and dried in air to give the desired benzylic alcohol intermediate (0.65 g, 38% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (br s, 1H), 7.43 (br s, 0.6H), 7.03 (br s, 2.4H), 4.37 (d, <i>J</i> = 5.5 Hz, 2H), 4.20 (t, <i>J</i> = 5.5 Hz, 1H), 3.71 (s, 6H), 2.43–2.58 (m, 2H), 2.08 (m, 2H), 1.86 (m, 1H), 1.68–1.82 (m, 1H), 1.37 (br s, 6H), 1.23 (br s, 3H); MS <i>m</i>/<i>z</i> 379.2 (M – H).</div><div class="NLM_p last">The benzylic alcohol (656 mg, 1.72 mmol) was suspended in THF (50 mL), and activated MnO<sub>2</sub> (85%, 2.12 g, 20 0.7 mmol) was added. The mixture was refluxed for 24 h, cooled, and diluted with additional THF (50 mL). The mixture was filtered through a small pad of silica gel using THF for washings, and the filtrate was concentrated to give a brown solid. The solid was suspended in TBME (10 mL), filtered, washed with fresh TBME, and dried in air to give benzaldehyde <b>57</b> (450 mg, 69% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (s, 1H), 9.69 (br s, 1H), 7.52 (br s, 1H), 7.21 (br s, 2H), 3.78 (s., 6H), 2.52–2.59 (m, 2H), 2.11 (m, 2H), 1.88 (m, 1H), 1.69–1.82 (m, 1H), 1.12–1.47 (m, 9H); MS <i>m</i>/<i>z</i> 379.2 (MH<sup>+</sup>).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Preparation of <i>N</i>-Boc-4-amino-2,6-dimethoxycinnamate, <b>58</b></h3><div class="NLM_p">Triethylphosphonoacetate (0.92 mL, 5.68 mmol) was added dropwise to a suspension of NaH (60% in oil, 0.227 g, 5.68 mmol) in dry THF (25 mL). The resulting thick, white suspension was stirred for 30 min at room temperature, and a solution of aldehyde derivative <b>57</b> (0.43 g, 1.14 mmol) in THF (5 mL + 2 mL rinse) was added. The reaction mixture was stirred for an additional 30 min at room temperature and then quenched by addition of AcOH (0.5 mL). THF was removed under reduced pressure, and the residue was dissolved in EtOAc (50 mL). The solution was washed with 10% NaHCO<sub>3</sub> (20 mL), dried (MgSO<sub>4</sub>), and concentrated. The residue was purified by flash chromatography on silica gel using 0–20% EtOAc in CHCl<sub>3</sub> as eluent. The <i>N</i>-Boc protected form of cinnamate <b>58</b> was obtained as a white solid (452 mg, 91% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.57 (br s, 1H), 7.93 (d, <i>J</i> = 16.2 Hz, 1H), 7.49 (br s, 1H), 7.22 (br s, 2H), 6.67 (d, <i>J</i> = 16.2 Hz, 1H), 3.83 (s, 6H), 3.68 (s, 3H), 2.52–2.67 (m, 2H), 2.10 (m, 2H), 1.88 (m, 1H), 1.70–1.84 (m, 1H), 1.38–1.23 (m, 9H); MS <i>m</i>/<i>z</i> 435.2 (MH<sup>+</sup>).</div><div class="NLM_p last">The Boc-protected derivative <b>58</b> (120 mg) was suspended in 4 M HCl in dioxane (4 mL), and the mixture stirred at room temperature for a few minutes until homogeneous. Reversed-phase HPLC analysis indicated complete conversion to the amine hydrochloride along with some decomposition. Volatiles were removed under reduced pressure, and the residue was dissolved in CHCl<sub>3</sub> (2 mL). While stirring, TBME (10 mL) was added slowly to produce a white precipitate that was stirred overnight. The solid was then collected, washed with TBME, and dried to provide 92 mg of impure material that was used directly to prepare inhibitor <b>14</b> by condensation with 6-indolecarboxylic acid <b>38</b> in the usual manner.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure for the Preparation of Final Inhibitors: (<i>E</i>)-3-{4-[(1-{[2-(5-Chloro-pyrimidin-2-yl)-3-cyclopentyl-1-methyl-1<i>H</i>-indole-6-carbonyl]-amino}-cyclobutanecarbonyl)-amino]-2-ethoxy-phenyl}-acrylic Acid Methyl Ester (<b>27</b> Ethyl Ester)</h3><div class="NLM_p last">2-(5-Chloro-pyrimidin-2-yl)-3-cyclopentyl-1-methyl-1<i>H</i>-indole-6-carboxylic acid (13.40 g, 37.7 mmol), (<i>E</i>)-3-{4-[(1-amino-cyclobutanecarbonyl)-amino]-2-ethoxy-phenyl}-acrylic acid methyl ester (12.00 g, 37.7 mmol), and TBTU (13.00 g, 40.5 mmol, 1.1 equiv) were dissolved in 300 mL of DMSO, and triethylamine (16 mL, 115 mmol, 3 equiv) was added. The yellow reaction mixture was stirred at RT for 2 h after which point conversion was complete as judged by HPLC. The reaction mixture was poured into vigorously stirred 5% aqueous Na<sub>2</sub>CO<sub>3</sub> (2.5 L) yielding a white-yellowish suspension that was allowed to stand for 30 min before the solids were collected by filtration. The white solid was washed with water (3 × 500 mL), and the wet cake was dissolved in warm EtOAc (2.2 L). The solution was filtered to remove insoluble particulates and cooled to 5 °C overnight to yield after filtration and drying in vacuum the desired <b>27</b> methyl ester as a white solid (22.5 g, 91% yield): mp 213-215.5 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.70 (s, 1H), 9.13 (s, 2H), 8.87 (s, 1H), 8.25 (s, 1H), 7.73–7.84 (m, 2H), 7.67 (dd, <i>J</i> = 1.2, 8.61 Hz, 1H), 7.60 (d, <i>J</i> = 8.6 Hz, 1H), 7.55 (d, <i>J</i> = 1.6 Hz, 1H), 7.24 (dd, <i>J</i> = 1.6, 8.6 Hz, 1H), 6.51 (d, <i>J</i> = 16.0 Hz, 1H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.90 (s, 3H), 3.69–3.78 (m, 1H), 3.68 (s, 3H), 2.64–2.86 (m, 2H), 2.27–2.44 (m, 2H), 1.80–2.07 (m, 8H), 1.53–1.74 (m, 2H), 1.26–1.47 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.3, 167.2, 166.7, 157.8, 157.7, 155.9, 143.1, 139.3, 137.4, 135.1, 129.4, 128.6, 128.1, 127.1, 121.4, 120.1, 118.7, 116.9, 115.5, 111.6, 110.8, 103.0, 63.7, 59.9, 51.2, 36.3, 32.8, 31.8, 30.8, 26.0, 15.0, 14.5; HRMS calcd. for C<sub>36</sub>H<sub>39</sub>ClN<sub>5</sub>O<sub>5</sub> (M + H) 656.2634; found 656.2642.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>E</i>)-3-{4-[(1-{[2-(5-Chloro-pyrimidin-2-yl)-3-cyclopentyl-1-methyl-1<i>H</i>-indole-6-carbonyl]-amino}-cyclobutanecarbonyl)-amino]-2-ethoxy-phenyl}-acrylic Acid, <b>27</b></h3><div class="NLM_p last">The methyl ester of <b>27</b> (22.20 g, 33.8 mmol) was dissolved in DMSO (500 mL) by heating to 75 °C. The solution was cooled to 28 °C, and 2.5 N NaOH (60 mL, 4 equiv) was added dropwise over a period of 15 min. Reaction progress was followed by HPLC, and saponification was complete after 2.5 h. Water (300 mL) was added, and the solution was filtered to remove insoluble particulates. The filtrate (approximately 1 L) was slowly added to 0.5 N HCl (3 L) at RT resulting in a fine yellowish suspension that was then allowed to stand for 20 min before filtration and copious washing with water. The resulting wet cake was then slurried with diethyl ether (2 L) to produce a white suspension that was filtered, rinsed with additional diethyl ether (2 × 500 mL) and then again with water (2 × 500 mL), and finally air-dried overnight to give a pale-yellowish solid (17.3 g, 77% yield): mp 170–175 °C. dec.; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.03 (br s, 1H), 9.69 (s, 1H), 9.14 (s, 2H), 8.89 (s, 1H), 8.26 (br s, 1H), 7.71–7.80 (m, 2H), 7.67 (dd, <i>J</i> = 1.6, 8.6 Hz, 1H), 7.58 (d, <i>J</i> = 8.6 Hz, 1H), 7.54 (d, <i>J</i> = 2.0 Hz, 1H), 7.23 (dd, <i>J</i> = 1.8, 8.4 Hz, 1H), 6.41 (d, <i>J</i> = 16.0 Hz, 1H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.90 (s, 3H), 3.72 (m, 1H), 2.58–2.83 (m, 2H), 2.32–2.44 (m, 2H), 1.85–2.01 (m, 8H), 1.66 (br s, 2H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.3, 172.0, 168.1, 166.7, 157.8, 157.5, 155.9, 142.8, 138.6, 137.4, 135.1, 129.0, 128.7, 128.2, 127.1, 121.4, 120.2, 118.7, 117.2, 117.0, 111.6, 110.8, 103.1, 63.7, 59.9, 36.3, 32.8, 31.8, 30.8, 26.0, 21.0, 15.0, 14.6; HRMS calcd. for C<sub>35</sub>H<sub>37</sub>ClN<sub>5</sub>O<sub>5</sub> (M + H) 642.2478; found 642.2483.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Preparation of Azalactone, <b>61</b></h3><div class="NLM_p">Indolecarboxylic acid <b>59</b><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (3.52 g, 11 mmol) and 1-aminocyclobutane carboxylic acid ethyl ester hydrochloride (1.72 g, 12 mmol, 1.1 equiv) were dissolved in DMSO (40 mL), and TBTU (4.49 g, 14 mmol, 1.3 equiv) and triethylamine (5 mL, 36 mmol, 3.3 equiv) were added. The resulting amber solution was stirred overnight at RT. The solution was then heated to 60 °C, and 5 N NaOH (11 mL) was added dropwise over 3 min. Saponification was complete by HPLC analysis after stirring for 20 min. The reaction mixture was then poured into water (300 mL) containing AcOH (60 mL), and the beige precipitate that formed was collected by filtration, washed with water, and dried. Carboxylic acid <b>60</b> was obtained as a beige solid (4.26 g, 93% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.22 (br s, 1H), 8.87 (s, 1H), 8.80 (d, <i>J</i> = 4.1 Hz, 1H), 8.12 (s, 1H), 7.98 (dt, <i>J</i> = 1.8, 7.7 Hz, 1H), 7.66–7.74 (m, 1H), 7.54–7.65 (m, 2H), 7.48 (dd, <i>J</i> = 4.9, 6.8 Hz, 1H), 3.70 (s, 3H), 3.15 (m, 1H), 2.55–2.66 (m, 2H), 2.21–2.43 (m, 2H), 1.75–2.05 (m, 8H), 1.62 (br s, 2H); FIA-MS <i>m</i>/<i>z</i> 418.2 (M + H).</div><div class="NLM_p last">Carboxylic acid <b>60</b> (3.50 g, 8.0 mmol) was added to acetic anhydride (30 mL), and the suspension was stirred at 100 °C. The material slowly dissolved, and after 40 min, TLC analysis showed complete conversion of starting material. Volatiles were removed under vacuum, and the gummy residue was triturated with diethyl ether to provide, after filtration and washing with ether, azalactone <b>61</b> as a beige solid (3.30 g, 85% yield): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.22 (br s, 1H), 8.87 (s, 1H), 8.80 (d, <i>J</i> = 4.1 Hz, 1H), 8.12 (s, 1H), 7.98 (dt, <i>J</i> = 1.8, 7.7 Hz, 1H), 7.66–7.74 (m, 1H), 7.54–7.65 (m, 2H), 7.48 (dd, <i>J</i> = 4.9, 6.8 Hz, 1H), 3.70 (s, 3H), 3.15 (m, 1H), 2.55–2.66 (m, 2H), 2.21–2.43 (m, 2H), 1.75–2.05 (m, 8H), 1.62 (br s, 2H); FIA-MS <i>m</i>/<i>z</i> 400.1 (M + H).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedure for Coupling of 4-Aminocinnamates with Azalactone <b>61</b>. Preparation of Inhibitor <b>13</b></h3><div class="NLM_p">Azalactone <b>61</b> (25.5 mg, 0.063 mmol, 1 equiv) and methyl 4-amino-2-methoxycinnamate (11.0 mg, 0.053 mmol, 0.8 equiv) were dissolved in glacial acetic acid (0.25 mL), and the mixture was stirred overnight at room temperature. The solution was then taken-up in EtOAc (20 mL) and washed with saturated aqueous NaHCO<sub>3</sub> (2 × 20 mL). The organic layer was dried (MgSO<sub>4</sub>) and evaporated to provide crude <b>13</b> methyl ester as a yellow solid (26 mg) that was used without further purification.</div><div class="NLM_p last">The crude ester (26 mg) was dissolved in DMSO (0.5 mL), and 2.5 N NaOH (172 μL, 10 equiv) was added followed by MeOH (0.3 mL). After stirring at RT for 2 h, saponification of the methyl ester was complete. AcOH (10 drops) was added to the reaction mixture, which was then purified directly on a reversed-phase preparative HPLC to provide inhibitor <b>13</b> trifluoroacetate salt (8.5 mg) as a white solid: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.70 (s, 1H), 8.70–8.87 (m, 2H), 8.21 (s, 1H), 8.01 (dt, <i>J</i> = 1.5, 7.7 Hz, 1H), 7.63–7.78 (m, 3H), 7.44–7.63 (m, 4H), 7.18–7.28 (m, 1H), 6.39 (m, <i>J</i> = 16.0 Hz 1H), 3.83 (s, 3H), 3.73 (s, 3H), 3.07–3.23 (m, 1H), 2.68–2.81 (m, 2H), 2.28–2.43 (m, 2H), 1.77–2.05 (m, 8H), 1.62 (m, 2H). FIA-MS <i>m</i>/<i>z</i> 593.3 (M + H).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Biological Testing</h3><div class="NLM_p last">Inhibition of HCV polymerase activity in a biochemical assay was performed as previously described using full-length NS5B or a C-terminal truncated NS5BΔ21 construct.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> Reported values are the average of duplicate measurements. EC<sub>50</sub> determinations using the cell-based 1b luciferase reporter assay<a onclick="showRef(event, 'cit14c cit14d'); return false;" href="javascript:void(0);" class="ref cit14c cit14d">(14c, 14d)</a> or replicon assays using RT-PCR for RNA quantification<a onclick="showRef(event, 'cit14b'); return false;" href="javascript:void(0);" class="ref cit14b">(14b)</a> were performed in duplicate as described elsewhere.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Pharmacokinetic Experiments</h3><div class="NLM_p">All rat PK studies were performed at Boehringer Ingelheim (Canada) Ltd. PK studies in dogs and monkeys were performed at LAB Pre-Clinical Research International Inc., Laval, QC. All protocols involving animal experimentation were reviewed and approved by the respective Animal Care and Use Committee of each test facility. In-life procedures were in compliance with the Guide for the Care and Use of Laboratory Animals from the Canadian Council of Animal Care. All chemicals used were reagent grade or better.</div><div class="NLM_p">Animals were fasted overnight prior to dosing. IV dose administration (2 mg/kg) was performed using a 70% PEG400/30% water dosing solution. Oral dose administration (10 mg/kg) was performed using a suspension containing 0.3% Tween-80 and 0.5% methylcellulose, with or without addition of 1% NMP as an additional solubilizer for poorly soluble compounds (<i>N</i> = 3 per dose and per route). In the cassette screen experiments, each “cassette” containing four compounds at 4 mg/kg for each compound was dosed to two rats. Blood samples collected from all time points were placed on ice and then centrifuged at 4 °C. The plasma was separated and stored frozen at approximately −20 °C until analysis.</div><div class="NLM_p last">Plasma samples were extracted by solid phase extraction. Samples were analyzed by HPLC using either a UV diode array detector between 200 and 400 nm with quantitative determination made by peak height at the wavelength representing the best signal-to-noise ratio or a LC/MS systems using the appropriate retention time and <i>m</i>/<i>z</i>+. Calibration standards were prepared in blank plasma. The calibration curve was linear to cover the time–concentration curve with <i>r</i><sup>2</sup> values > 0.99 and a limit of quantification (LOQ) at 7 ng/mL. The temporal profiles of drug concentrations in plasma were analyzed by noncompartmental methods using WinNonlin (version 3.1; Scientific Consulting, Inc., Cary, NC).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36"><a href="/doi/suppl/10.1021/jm501532z">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Mass spectral and <sup>1</sup>H NMR data for building blocks, mass spectral and HPLC homogeneity data in table format, and a copy of the <sup>1</sup>H NMR for all inhibitors. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501532z/suppl_file/jm501532z_si_001.pdf">jm501532z_si_001.pdf (573.49 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm501532z" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55682" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55682" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre L. Beaulieu</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7f0d1a0c181a111a0d1e1351131e093f1d101a170d1611181a0d521611181a13171a1612511c1012"><span class="__cf_email__" data-cfemail="b5c7d0c6d2d0dbd0c7d4d99bd9d4c3f5d7dad0ddc7dcdbd2d0c798dcdbd2d0d9ddd0dcd89bd6dad8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul C. Anderson</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Bethell</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Bös</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yves Bousquet</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Brochu</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael G. Cordingley</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gulrez Fazal</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michel Garneau</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Gillard</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Kawai</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Marquis</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ginette McKercher</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc-André Poupart</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy Stammers</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bounkham Thavonekham</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dominik Wernic</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianmin Duan</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Kukolj</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim (Canada)
Ltd., Research and Development, 2100 Cunard Street, Laval, Quebec H7S 2G5, Canada</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d4180e3424-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the following colleagues from Boehringer Ingelheim (Canada) Ltd. that participated in generating the data presented in this paper and contributed to the discovery of compound <b>27</b>: Nathalie Dansereau, Lisette Lagacée, and Charles Pellerin for IC<sub>50</sub> and EC<sub>50</sub> determinations; Josie De Marte, Francine Liard, Hélène Montpetit, and Christine Zouki for ADME-PK support; Norman Aubry, Sylvain Bordeleau, Colette Boucher, and Serge Valois for analytical support. We also acknowledge contributions from Boehringer Ingelheim Pharmaceuticals Inc., Ridgfield, CT, and Boehringer Ingelheim Pharma BIKG for their contributions to advance preclinical profiling of compound <b>27</b>.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i38" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i38"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i39" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i39"> Abbreviations Used</h2><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">DAA</td><td class="NLM_def"><p class="first last">direct acting antiviral</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">PegIFN</td><td class="NLM_def"><p class="first last">pegylated interferon</p></td></tr><tr><td class="NLM_term">RBV</td><td class="NLM_def"><p class="first last">ribavirin</p></td></tr><tr><td class="NLM_term">gt1</td><td class="NLM_def"><p class="first last">genotype 1</p></td></tr><tr><td class="NLM_term">SVR</td><td class="NLM_def"><p class="first last">sustained viral response</p></td></tr><tr><td class="NLM_term">SoC</td><td class="NLM_def"><p class="first last">standard of care</p></td></tr><tr><td class="NLM_term">RdRp</td><td class="NLM_def"><p class="first last">RNA-dependent RNA polymerase</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption–distribution–metabolism–excretion</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P-450</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TBME</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl methyl ether</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HOAt</td><td class="NLM_def"><p class="first last">1-hydroxy-7-azabenzotriazole</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 19 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lavanchy, D.</span><span> </span><span class="NLM_article-title">Evolving epidemiology of hepatitis C virus</span> <span class="citation_source-journal">Clin. Microbiol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1111%2Fj.1469-0691.2010.03432.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=21091831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A280%3ADC%252BC3M7islSrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=107-115&author=D.+Lavanchy&title=Evolving+epidemiology+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving epidemiology of hepatitis C virus</span></div><div class="casAuthors">Lavanchy D</div><div class="citationInfo"><span class="NLM_cas:title">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than 20 years after the discovery of the hepatitis C virus (HCV), it is now well established that HCV is of global importance affecting all countries, leading to a major global health problem that requires widespread active interventions for its prevention and control.  Chronic hepatitis C was linked to the development of cirrhosis and hepatocellular carcinoma in many areas of the world.  Current epidemiological assessments have identified complex patterns with highly variable local prevalence rates between countries and within countries.  HCV infection patterns have not significantly changed in most parts of the world since 1997, when first analyzed, partly due to the lack of new and more accurate data.  The assessment of the national HCV prevalence and transmission modes should be completed to enable national authorities to prioritize preventive measures and to make the most appropriate use of available resources.  The 'patchy' epidemiological situation in some areas will continue to complicate the task of the establishment of global, regional and national base line data.  The present assessment finds a global prevalence of 2.35%, affecting 160 million chronically infected individuals.  There is an urgent need for more accurate Information on the costs and burden of HCV to society.  Twenty-one year after the discovery of HCV, the assessment is far from being complete and little progress has been made in the past 10 years in many countries.  In some countries significant increases have been reported and this may also apply to countries were insufficient data exist.  A safe and efficient vaccine against HCV is urgently needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYetk_zmER_suCWE5mhx1RfW6udTcc2ea2Y_9S0-Pxmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7islSrtQ%253D%253D&md5=b77d9df38203d7a5dd060cc1bc3bc487</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1469-0691.2010.03432.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1469-0691.2010.03432.x%26sid%3Dliteratum%253Aachs%26aulast%3DLavanchy%26aufirst%3DD.%26atitle%3DEvolving%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2011%26volume%3D17%26spage%3D107%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Choo, Q.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">244</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1126%2Fscience.2523562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=2523562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1989&pages=359-362&author=Q.-L.+Chooauthor=G.+Kuoauthor=A.+J.+Weinerauthor=L.+R.+Overbyauthor=D.+W.+Bradleyauthor=M.+Houghton&title=Isolation+of+a+cDNA+clone+derived+from+a+blood-borne+non-A%2C+non-B+viral+hepatitis+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span></div><div class="casAuthors">Choo, Qui Lim; Kuo, George; Weiner, Amy J.; Overby, Lacy R.; Bradley, Daniel W.; Houghton, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">4902</span>),
    <span class="NLM_cas:pages">359-62</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A random-primed cDNA library was constructed from plasma contg. the uncharacterized non-A, non-B hepatitis (NANBH) agent and screened with serum from a patient diagnosed with NANBH.  A cDNA clone was isolated that was shown to encode an antigen assocd. specifically with NANBH infections.  This clone is not derived from host DNA but from an RNA mol. present in NANBH infections that consists of ≥10,000 nucleotides, and that is pos.-stranded with respect to the encoded NANBH antigen.  These data indicate that this clone is derived from the genome of the NANBH agent and are consistent with the agent being similar to the togaviridae or flaviviridae.  This mol. approach should be of great value in the isolation and characterization of other unidentified infectious agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorpVFx7nEkrVg90H21EOLACvtfcHk0ljDUob-GuLLng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D&md5=25161cf212790856dd29d3aaf78f20b8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.2523562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2523562%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DQ.-L.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DWeiner%26aufirst%3DA.%2BJ.%26aulast%3DOverby%26aufirst%3DL.%2BR.%26aulast%3DBradley%26aufirst%3DD.%2BW.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520a%2520cDNA%2520clone%2520derived%2520from%2520a%2520blood-borne%2520non-A%252C%2520non-B%2520viral%2520hepatitis%2520genome%26jtitle%3DScience%26date%3D1989%26volume%3D244%26spage%3D359%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Lindenbach, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, M. C.</span><span> </span><span class="NLM_article-title">Unraveling hepatitis C virus replication from genome to function</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">938</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2005&pages=933-938&author=B.+D.+Lindenbachauthor=M.+C.+Rice&title=Unraveling+hepatitis+C+virus+replication+from+genome+to+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DRice%26aufirst%3DM.%2BC.%26atitle%3DUnraveling%2520hepatitis%2520C%2520virus%2520replication%2520from%2520genome%2520to%2520function%26jtitle%3DNature%26date%3D2005%26volume%3D436%26spage%3D933%26epage%3D938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gentile, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carleo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaldo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, G.</span><span> </span><span class="NLM_article-title">The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus</span> <span class="citation_source-journal">Expert Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=151-159&author=I.+Gentileauthor=M.+A.+Carleoauthor=F.+Borgiaauthor=G.+Castaldoauthor=G.+Borgia&title=The+efficacy+and+safety+of+telaprevir+%E2%80%93+a+new+protease+inhibitor+against+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DCarleo%26aufirst%3DM.%2BA.%26aulast%3DBorgia%26aufirst%3DF.%26aulast%3DCastaldo%26aufirst%3DG.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DThe%2520efficacy%2520and%2520safety%2520of%2520telaprevir%2520%25E2%2580%2593%2520a%2520new%2520protease%2520inhibitor%2520against%2520hepatitis%2520C%2520virus%26jtitle%3DExpert%2520Opin.%2520Investig.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D151%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kwong, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, P.</span><span> </span><span class="NLM_article-title">Discovery and development of telaprevir: An NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=D.+A.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Mueller&title=Discovery+and+development+of+telaprevir%3A+An+NS3%E2%80%934A+protease+inhibitor+for+treating+genotype+1+chronic+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DD.%2BA.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520development%2520of%2520telaprevir%253A%2520An%2520NS3%25E2%2580%25934A%2520protease%2520inhibitor%2520for%2520treating%2520genotype%25201%2520chronic%2520hepatitis%2520C%2520virus%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Berman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P. Y.</span><span> </span><span class="NLM_article-title">Boceprevir, an NS3 protease inhibitor of HCV</span> <span class="citation_source-journal">Clin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=429-439&author=K.+Bermanauthor=P.+Y.+Kwo&title=Boceprevir%2C+an+NS3+protease+inhibitor+of+HCV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DK.%26aulast%3DKwo%26aufirst%3DP.%2BY.%26atitle%3DBoceprevir%252C%2520an%2520NS3%2520protease%2520inhibitor%2520of%2520HCV%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2009%26volume%3D13%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">New direct-acting antivirals combination for the treatment of chronic hepatitis C</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=68-77&author=T.+Asselahauthor=P.+Marcellin&title=New+direct-acting+antivirals+combination+for+the+treatment+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DNew%2520direct-acting%2520antivirals%2520combination%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DLiver%2520Int.%26date%3D2011%26volume%3D31%26spage%3D68%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">447</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sarrazin%2C+C.%3B+Zeuzem%2C+S.Gastroenterology+2010%2C+138%2C+447"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DZeuzem%26aufirst%3DS.%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D138%26spage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dieterich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratziu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maieron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datsenko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böcher, W. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmann, G.</span><span> </span><span class="NLM_article-title">SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naı̈ve hepatitis C virus genotype 1-infected patients</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3429</span><span class="NLM_x">–</span> <span class="NLM_lpage">3436</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3429-3436&author=D.+Dieterichauthor=T.+Y.+Asselahauthor=D.+Guyaderauthor=T.+Bergauthor=M.+Schuchmannauthor=S.+Maussauthor=V.+Ratziuauthor=P.+Ferenciauthor=D.+Larreyauthor=A.+Maieronauthor=J.+O.+Sternauthor=M.+Ozanauthor=Y.+Datsenkoauthor=W.+O.+B%C3%B6cherauthor=G.+Steinmann&title=SILEN-C3%2C+a+phase+2+randomized+trial+with+faldaprevir+plus+pegylated+interferon+%CE%B1-2a+and+ribavirin+in+treatment-na%C4%B1%CC%88ve+hepatitis+C+virus+genotype+1-infected+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDieterich%26aufirst%3DD.%26aulast%3DAsselah%26aufirst%3DT.%2BY.%26aulast%3DGuyader%26aufirst%3DD.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DSchuchmann%26aufirst%3DM.%26aulast%3DMauss%26aufirst%3DS.%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DMaieron%26aufirst%3DA.%26aulast%3DStern%26aufirst%3DJ.%2BO.%26aulast%3DOzan%26aufirst%3DM.%26aulast%3DDatsenko%26aufirst%3DY.%26aulast%3DB%25C3%25B6cher%26aufirst%3DW.%2BO.%26aulast%3DSteinmann%26aufirst%3DG.%26atitle%3DSILEN-C3%252C%2520a%2520phase%25202%2520randomized%2520trial%2520with%2520faldaprevir%2520plus%2520pegylated%2520interferon%2520%25CE%25B1-2a%2520and%2520ribavirin%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520hepatitis%2520C%2520virus%2520genotype%25201-infected%2520patients%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3429%26epage%3D3436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafalsky, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moroz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craxi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwerkerk-Mahadevan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De La Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span> </span><span class="NLM_article-title">Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naı̈ve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomized, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">413</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=403-413&author=I.+M.+Jacobsonauthor=G.+J.+Doreauthor=G.+R.+Fosterauthor=M.+W.+Friedauthor=M.+Raduauthor=V.+V.+Rafalskyauthor=L.+Morozauthor=A.+Craxiauthor=M.+Peetersauthor=O.+Lenzauthor=S.+Ouwerkerk-Mahadevanauthor=G.+De+La+Rosaauthor=R.+Kalmeijerauthor=J.+Scottauthor=R.+Sinhaauthor=M.+Beumont-Mauviel&title=Simeprevir+with+pegylated+interferon+alfa+2a+plus+ribavirin+in+treatment-na%C4%B1%CC%88ve+patients+with+chronic+hepatitis+C+virus+genotype+1+infection+%28QUEST-1%29%3A+A+phase+3%2C+randomized%2C+double-blind%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DRadu%26aufirst%3DM.%26aulast%3DRafalsky%26aufirst%3DV.%2BV.%26aulast%3DMoroz%26aufirst%3DL.%26aulast%3DCraxi%26aufirst%3DA.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DOuwerkerk-Mahadevan%26aufirst%3DS.%26aulast%3DDe%2BLa%2BRosa%26aufirst%3DG.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DJ.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26atitle%3DSimeprevir%2520with%2520pegylated%2520interferon%2520alfa%25202a%2520plus%2520ribavirin%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%2520%2528QUEST-1%2529%253A%2520A%2520phase%25203%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D403%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Manns, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanislau Affonso de Araujo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsmans, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janczewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villamil, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwerkerk-Mahadevan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De La Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span> </span><span class="NLM_article-title">Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naı̈ve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=414-426&author=M.+Mannsauthor=P.+Marcellinauthor=F.+Poordadauthor=E.+Stanislau+Affonso+de+Araujoauthor=M.+Butiauthor=Y.+Horsmansauthor=E.+Janczewskaauthor=F.+Villamilauthor=J.+Scottauthor=M.+Peetersauthor=O.+Lenzauthor=S.+Ouwerkerk-Mahadevanauthor=G.+De+La+Rosaauthor=R.+Kalmeijerauthor=R.+Sinhaauthor=M.+Beumont-Mauviel&title=Simeprevir+with+pegylated+interferon+alfa+2a+or+2b+plus+ribavirin+in+treatment-na%C4%B1%CC%88ve+patients+with+chronic+hepatitis+C+virus+genotype+1+infection+%28QUEST-2%29%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManns%26aufirst%3DM.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DStanislau%2BAffonso%2Bde%2BAraujo%26aufirst%3DE.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DHorsmans%26aufirst%3DY.%26aulast%3DJanczewska%26aufirst%3DE.%26aulast%3DVillamil%26aufirst%3DF.%26aulast%3DScott%26aufirst%3DJ.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DOuwerkerk-Mahadevan%26aufirst%3DS.%26aulast%3DDe%2BLa%2BRosa%26aufirst%3DG.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26atitle%3DSimeprevir%2520with%2520pegylated%2520interferon%2520alfa%25202a%2520or%25202b%2520plus%2520ribavirin%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%2520%2528QUEST-2%2529%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D414%26epage%3D426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Keating, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidya, A.</span><span> </span><span class="NLM_article-title">Sofosbuvir: First global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=273-282&author=G.+M.+Keatingauthor=A.+Vaidya&title=Sofosbuvir%3A+First+global+approval"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DVaidya%26aufirst%3DA.%26atitle%3DSofosbuvir%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D273%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulombe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thavonekham, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y.</span><span> </span><span class="NLM_article-title">Conformation-based restrictions and scaffold replacements in the design of HCV polymerase inhibitor: Discovery of deleobuvir (BI 207127)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1845</span><span class="NLM_x">–</span> <span class="NLM_lpage">1854</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4011862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1845-1854&author=S.+R.+LaPlanteauthor=M.+B%C3%B6sauthor=C.+Brochuauthor=C.+Chabotauthor=R.+Coulombeauthor=J.+R.+Gillardauthor=A.+Jakalianauthor=M.+Poirierauthor=J.+Rancourtauthor=T.+Stammersauthor=B.+Thavonekhamauthor=P.+L.+Beaulieuauthor=G.+Kukoljauthor=Y.+Tsantrizos&title=Conformation-based+restrictions+and+scaffold+replacements+in+the+design+of+HCV+polymerase+inhibitor%3A+Discovery+of+deleobuvir+%28BI+207127%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1021%2Fjm4011862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011862%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DCoulombe%26aufirst%3DR.%26aulast%3DGillard%26aufirst%3DJ.%2BR.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DStammers%26aufirst%3DT.%26aulast%3DThavonekham%26aufirst%3DB.%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DTsantrizos%26aufirst%3DY.%26atitle%3DConformation-based%2520restrictions%2520and%2520scaffold%2520replacements%2520in%2520the%2520design%2520of%2520HCV%2520polymerase%2520inhibitor%253A%2520Discovery%2520of%2520deleobuvir%2520%2528BI%2520207127%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1845%26epage%3D1854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müllhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinisko, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallivan, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böcher, W.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mensa, F. J.</span><span> </span><span class="NLM_article-title">Faldaprevir and deleobuvir for HCV genotype infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">630</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1056%2FNEJMoa1213557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=23944300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlClsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=630-639&author=S.+Zeuzemauthor=V.+Sorianoauthor=T.+Asselahauthor=J.-P.+Bronowickiauthor=A.+W.+Lohseauthor=B.+M%C3%BCllhauptauthor=M.+Schuchmannauthor=M.+Bourli%C3%A8reauthor=M.+Butiauthor=S.+K.+Robertsauthor=E.+J.+Ganeauthor=J.+O.+Sternauthor=R.+Viniskoauthor=G.+Kukoljauthor=J.-P.+Gallivanauthor=W.-O.+B%C3%B6cherauthor=F.+J.+Mensa&title=Faldaprevir+and+deleobuvir+for+HCV+genotype+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Faldaprevir and deleobuvir for HCV genotype 1 infection</span></div><div class="casAuthors">Zeuzem, Stefan; Soriano, Vincent; Asselah, Tarik; Bronowicki, Jean-Pierre; Lohse, Ansgar W.; Muellhaupt, Beat; Schuchmann, Marcus; Bourliere, Marc; Buti, Maria; Roberts, Stuart K.; Gane, Ed J.; Stern, Jerry O.; Vinisko, Richard; Kukolj, George; Gallivan, John-Paul; Boecher, Wulf-Otto; Mensa, Federico J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">630-639</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus (HCV) infection.  In this phase 2b, randomized, open-label trial of faldaprevir (a protease inhibitor) and deleobuvir (a nonnucleoside polymerase inhibitor), we randomly assigned 362 previously untreated patients with HCV genotype 1 infection to one of five groups: faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg three times daily, plus ribavirin, for 16, 28, or 40 wk (TID16W, TID28W, or TID40W, resp.); faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg twice daily, plus ribavirin, for 28 wk (BID28W); or faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg three times daily, without ribavirin, for 28 wk (TID28W-NR).  The primary end point was a sustained virol. response 12 wk after the completion of therapy.  The primary end point was met in 59% of patients in the TID16W group, 59% of patients in the TID28W group, 52% of patients in the TID40W group, 69% of patients in the BID28W group, and 39% of patients in the TID28W-NR group.  The sustained virol. response 12 wk after the completion of therapy did not differ significantly according to treatment duration or dosage among ribavirin-contg. regimens.  This response was significantly higher with TID28W than with TID28W-NR (P = 0.03).  Rates of a sustained virol. response 12 wk after the completion of therapy were 56 to 85% among patients with genotype 1b infection vs. 11 to 47% among patients with genotype 1a infection and 58 to 84% among patients with IL28B CC vs. 33 to 64% with non-CC genotypes.  Rash, photosensitivity, nausea, vomiting, and diarrhea were the most common adverse events.  The rate of a sustained virol. response 12 wk after the completion of therapy was 52 to 69% among patients who received interferon-free treatment with faldaprevir in combination with deleobuvir plus ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1_F80GH0n0LVg90H21EOLACvtfcHk0lgW7DR8HqjGgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlClsrvJ&md5=38355557fa942e4017129c159e5a25cd</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1213557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1213557%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DSoriano%26aufirst%3DV.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26aulast%3DLohse%26aufirst%3DA.%2BW.%26aulast%3DM%25C3%25BCllhaupt%26aufirst%3DB.%26aulast%3DSchuchmann%26aufirst%3DM.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DStern%26aufirst%3DJ.%2BO.%26aulast%3DVinisko%26aufirst%3DR.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DGallivan%26aufirst%3DJ.-P.%26aulast%3DB%25C3%25B6cher%26aufirst%3DW.-O.%26aulast%3DMensa%26aufirst%3DF.%2BJ.%26atitle%3DFaldaprevir%2520and%2520deleobuvir%2520for%2520HCV%2520genotype%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D630%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojkier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puoti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Gomez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarski, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggisch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">–</span> <span class="NLM_lpage">1898</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1056%2FNEJMoa1402454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=24725239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1889-1898&author=N.+Afdhalauthor=S.+Zeuzemauthor=P.+Kwoauthor=M.+Chojkierauthor=N.+Gitlinauthor=M.+Puotiauthor=M.+Romero-Gomezauthor=J.-P.+Zarskiauthor=K.+Agarwalauthor=P.+Buggischauthor=G.+R.+Fosterauthor=N.+Br%C3%A4uauthor=M.+Butiauthor=I.+M.+Jacobsonauthor=M.+Subramanianauthor=X.+Dingauthor=H.+Moauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=A.+Mangiaauthor=P.+Marcellin&title=Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span></div><div class="casAuthors">Afdhal, Nezam; Zeuzem, Stefan; Kwo, Paul; Chojkier, Mario; Gitlin, Norman; Puoti, Massimo; Romero-Gomez, Manuel; Zarski, Jean-Pierre; Agarwal, Kosh; Buggisch, Peter; Foster, Graham R.; Brau, Norbert; Buti, Maria; Jacobson, Ira M.; Subramanian, G. Mani; Ding, Xiao; Mo, Hongmei; Yang, Jenny C.; Pang, Phillip S.; Symonds, William T.; McHutchison, John G.; Muir, Andrew J.; Mangia, Alessandra; Marcellin, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1889-1898, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virol. response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection.  Methods: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection.  Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 wk, ledipasvir-sofosbuvir plus ribavirin for 12 wk, ledipasvir- sofosbuvir for 24 wk, or ledipasvir-sofosbuvir plus ribavirin for 24 wk.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Results: Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection.  The rates of sustained virol. response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 wk of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 wk of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 wk of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 wk of ledipasvir-sofosbuvir plus ribavirin.  No patient in either 12-wk group discontinued ledipasvir-sofosbuvir owing to an adverse event.  The most common adverse events were fatigue, headache, insomnia, and nausea.  Conculsions: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 wk was highly effective in previously untreated patients with HCV genotype 1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroadkxw2jRR7Vg90H21EOLACvtfcHk0lj8hH0SqqvEWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM&md5=e433fd7d493c1c0f9dfef37c1527388f</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402454%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DPuoti%26aufirst%3DM.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DZarski%26aufirst%3DJ.-P.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DBuggisch%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%2520untreated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1889%26epage%3D1898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span> </span><span class="NLM_article-title">Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">736</span><span class="NLM_x">–</span> <span class="NLM_lpage">743</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=736-743&author=E.+J.+Ganeauthor=C.+A.+Stedmanauthor=R.+H.+Hylandauthor=X.+Dingauthor=E.+Svarovskaiaauthor=G.+M.+Subramanianauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=P.+S.+Pang&title=Efficacy+of+nucleotide+polymerase+inhibitor+sofosbuvir+plus+the+NS5A+inhibitor+ledipasvir+or+the+NS5B+non-nucleoside+inhibitor+GS-9669+against+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DStedman%26aufirst%3DC.%2BA.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DPang%26aufirst%3DP.%2BS.%26atitle%3DEfficacy%2520of%2520nucleotide%2520polymerase%2520inhibitor%2520sofosbuvir%2520plus%2520the%2520NS5A%2520inhibitor%2520ledipasvir%2520or%2520the%2520NS5B%2520non-nucleoside%2520inhibitor%2520GS-9669%2520against%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D736%26epage%3D743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Feld, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coakley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiland, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DaSilva-Tillmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, B.</span><span> </span><span class="NLM_article-title">Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1594</span><span class="NLM_x">–</span> <span class="NLM_lpage">1603</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1056%2FNEJMoa1315722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=24720703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1594-1603&author=J.+J.+Feldauthor=K.+V.+Kowdleyauthor=E.+Coakleyauthor=S.+Sigalauthor=D.+R.+Nelsonauthor=D.+Crawfordauthor=O.+Weilandauthor=H.+Aguilarauthor=J.+Xiongauthor=T.+Pilot-Matiasauthor=B.+DaSilva-Tillmannauthor=L.+Larsenauthor=T.+Podsadeckiauthor=B.+Bernstein&title=Treatment+of+HCV+with+ABT-450%2Fr-ombitasvir+and+dasabuvir+with+ribavirin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7eR"><div class="casContent"><span class="casTitleNuber">7e</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span></div><div class="casAuthors">Feld, Jordan J.; Kowdley, Kris V.; Coakley, Eoin; Sigal, Samuel; Nelson, David R.; Crawford, Darrell; Weiland, Ola; Aguilar, Humberto; Xiong, Junyuan; Pilot-Matias, Tami; Da Silva-Tillmann, Barbara; Larsen, Lois; Podsadecki, Thomas; Bernstein, Barry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1594-1603</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 With ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the non-nucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus (HCV) in patients with HCV genotype 1 infection.  In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.  METHODS In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned previously untreated patients with HCV genotype 1 infection, in a 3:1 ratio, to an active regimen consisting of a single-tablet coformulation of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), and dasabuvir (250 mg twice daily) with ribavirin (in doses detd. according to body wt.) (group A) or matching placebos (group B).  The patients received the study treatment during a 12-wk double-blind period.  The primary end point was sustained virol. response at 12 wk after the end of treatment.  The primary anal. compared the response rate in group A with the response rate (78%) in a historical control group of previously untreated patients without cirrhosis who received telaprevir with peginterferon and ribavirin.  Adverse events occurring during the double-blind period were compared between group A and group B.  RESULTS A total of 631 patients received at least one dose of the study drugs.  The rate of sustained virol. response in group A was 96.2% (95% confidence interval, 94.5 to 97.9), which was superior to the historical control rate.  Virol. failure during treatment and relapse after treatment occurred in 0.2% and 1.5%, resp., of the patients in group A.  The response rates in group A were 95.3% among patients with HCV genotype 1a infection and 98.0% among those with HCV genotype 1b infection.  The rate of discontinuation due to adverse events was 0.6% in each study group.  Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in significantly more patients in group A than in group B (P < 0.05 for all comparisons).  Redns. in the Hb level were all of grade 1 or 2; redns. of grade 1 and 2 occurred in 47.5% and 5.8%, resp., of the patients in group A, whereas grade 1 redns. occurred in 2.5% of the patients in group B.  CONCLUSIONS In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 12-wk multitargeted regimen of ABT-450/r-ombitasvir and dasabuvir with ribavirin was highly effective and was assocd. with a low rate of treatment discontinuation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvK9K2P4sJ7Vg90H21EOLACvtfcHk0lj8hH0SqqvEWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrg%253D&md5=0e5e8ff9c7ebd43fe755c3d3c77f3462</span></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1315722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1315722%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DSigal%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DCrawford%26aufirst%3DD.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DAguilar%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DDaSilva-Tillmann%26aufirst%3DB.%26aulast%3DLarsen%26aufirst%3DL.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DBernstein%26aufirst%3DB.%26atitle%3DTreatment%2520of%2520HCV%2520with%2520ABT-450%252Fr-ombitasvir%2520and%2520dasabuvir%2520with%2520ribavirin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1594%26epage%3D1603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loustaud-Ratti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span> </span><span class="NLM_article-title">Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naı̈ve patients with HCV genotype 1 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1053%2Fj.gastro.2013.10.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=24184132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=420-429&author=G.+T.+Eversonauthor=K.+D.+Simsauthor=M.+Rodriguez-Torresauthor=C.+H%C3%A9zodeauthor=E.+Lawitzauthor=M.+Bourli%C3%A8reauthor=V.+Loustaud-Rattiauthor=V.+Rustgiauthor=H.+Schwartzauthor=H.+Tatumauthor=P.+Marcellinauthor=S.+Polauthor=P.+J.+Thuluvathauthor=T.+Eleyauthor=X.+Wangauthor=S.-P.+Huangauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=E.+Chungauthor=C.+Pasquinelliauthor=D.+M.+Graselaauthor=D.+F.+Gardiner&title=Efficacy+of+an+interferon-+and+ribavirin-free+regimen+of+daclatasvir%2C+asunaprevir%2C+and+BMS-791325+in+treatment-na%C4%B1%CC%88ve+patients+with+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7fR"><div class="casContent"><span class="casTitleNuber">7f</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection</span></div><div class="casAuthors">Everson, Gregory T.; Sims, Karen D.; Rodriguez-Torres, Maribel; Hezode, Christophe; Lawitz, Eric; Bourliere, Marc; Loustaud-Ratti, Veronique; Rustgi, Vinod; Schwartz, Howard; Tatum, Harvey; Marcellin, Patrick; Pol, Stanislas; Thuluvath, Paul J.; Eley, Timothy; Wang, Xiaodong; Huang, Shu-Pang; McPhee, Fiona; Wind-Rotolo, Megan; Chung, Ellen; Pasquinelli, Claudio; Grasela, Dennis M.; Gardiner, David F.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-429</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The combination of peginterferon and ribavirin with telaprevir or boceprevir is the std. treatment of hepatitis C virus (HCV) genotype 1 infection.  However, these drugs are not well tolerated because of their side effects and suboptimal virol. responses.  In a phase 2a, open-label study, we examd. the safety and efficacy of an interferon-free, ribavirin-free regimen of direct-acting antivirals, comprising daclatasvir (an NS5A replication complex inhibitor), asunaprevir (an NS3 protease inhibitor), and BMS-791325 (a non-nucleoside NS5B inhibitor), in patients with chronic HCV infection.  We analyzed data from 66 treatment-naive patients with HCV genotype 1 infection without cirrhosis who were assigned randomly to groups given daclatasvir (60 mg, once daily), asunaprevir (200 mg, twice daily), and BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 wk.  The primary end point was an HCV-RNA level less than 25 IU/mL at 12 wk after treatment (sustained virol. response at 12 wk [SVR12]).  In 64 patients, HCV-RNA levels were less than 25 IU/mL by week 4 of treatment (including 48 of 49 patients with HCV genotype 1a infection and 45 of 46 patients with the non-CC interleukin 28B genotype).  Sixty-one patients (92%) achieved SVR12, based on a modified intention-to-treat anal.  Virol. responses were similar between 12 and 24 wk of treatment.  During the study, 2 patients experienced viral breakthrough and 1 patient relapsed.  There were no grade 3-4 increases in levels of alanine or aspartate aminotransferases or bilirubin; there were no deaths or discontinuations resulting from serious adverse events or adverse events related to the treatment regimen.  The most common adverse events were headache, asthenia, and gastrointestinal symptoms.  In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection.  Further studies of this regimen are warranted.  ClinicalTrials.gov, no. NCT01455090.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGYjuJmkQI8rVg90H21EOLACvtfcHk0lhFMT-LAN8zMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyitr4%253D&md5=c8f83094f49ce5d5d116d75414ab3d93</span></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.10.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.10.057%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DLoustaud-Ratti%26aufirst%3DV.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DTatum%26aufirst%3DH.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26atitle%3DEfficacy%2520of%2520an%2520interferon-%2520and%2520ribavirin-free%2520regimen%2520of%2520daclatasvir%252C%2520asunaprevir%252C%2520and%2520BMS-791325%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D420%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagging, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balart, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossaro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaughnessy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, B.</span><span> </span><span class="NLM_article-title">Efficacy and safety of MK-5172 and MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: The C-WORTHY study</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">S25</span><span class="NLM_x">–</span> <span class="NLM_lpage">S26</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=S25-S26&author=E.+Lawitzauthor=C.+Hezodeauthor=E.+Ganeauthor=E.+Tamauthor=M.+Laggingauthor=L.+Balartauthor=L.+Rossaroauthor=R.+Ghalibauthor=M.+Shaughnessyauthor=P.+Hwangauthor=J.+Wahlauthor=M.+N.+Robertsonauthor=B.+Haber&title=Efficacy+and+safety+of+MK-5172+and+MK-8742+%C2%B1+ribavirin+in+hepatitis+C+genotype+1+infected+patients+with+cirrhosis+or+previous+null-response%3A+The+C-WORTHY+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DLagging%26aufirst%3DM.%26aulast%3DBalart%26aufirst%3DL.%26aulast%3DRossaro%26aufirst%3DL.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DShaughnessy%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DP.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DM.%2BN.%26aulast%3DHaber%26aufirst%3DB.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520MK-5172%2520and%2520MK-8742%2520%25C2%25B1%2520ribavirin%2520in%2520hepatitis%2520C%2520genotype%25201%2520infected%2520patients%2520with%2520cirrhosis%2520or%2520previous%2520null-response%253A%2520The%2520C-WORTHY%2520study%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3DS25%26epage%3DS26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="note"><p class="first last">For reviews on NS5B inhibitors, see, for example:</p></div><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span> </span><span class="NLM_article-title">Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">Expert Opin.Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1517%2F13543770802672598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=145-164&author=P.+L.+Beaulieu&title=Recent+advances+in+the+development+of+NS5B+polymerase+inhibitors+for+the+treatment+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection</span></div><div class="casAuthors">Beaulieu, Pierre L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-164</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  170 To 200 million people worldwide are believed to suffer from chronic hepatitis C virus (HCV) infection, a blood-born disease that targets the liver and progresses to organ cirrhosis and primary cancer in a significant proportion of patients.  The currently available treatment has limited efficacy and suffers from restricting side effects.  HCV infection is the principal cause of liver transplant in industrialized nations and between 8000 and 10,000 deaths result annually from the disease in the United States alone.  Virus-specific, more efficacious, and better-tolerated anti-HCV therapies are thus required to address the unmet medical need.  Objective: To review progress achieved since 2005 in the development of HCV NS5B polymerase inhibitors as potential therapy for the treatment of HCV infection with a primary focus on available patent and medical literature.  Results/conclusion: Several classes of small-mol. inhibitors of HCV NS5B have progressed into clin. development and demonstrated efficacy in reducing viral load in infected patients.  The results so far provide an encouraging foundation for the development of novel, more tolerable therapies and addressing emergence of resistance through combination of antiviral agents with complementary mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8VVFJs4oSbVg90H21EOLACvtfcHk0lhFMT-LAN8zMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCks74%253D&md5=64b78562e2b4e3e8a166fdabf14f7efe</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1517%2F13543770802672598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770802672598%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520NS5B%2520polymerase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DExpert%2520Opin.Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D145%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Watkins, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L. S.</span><span> </span><span class="NLM_article-title">HCV NS5B polymerase inhibitors</span> <span class="citation_source-journal">Cur. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=20597029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSju7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=441-465&author=W.+J.+Watkinsauthor=A.+S.+Rayauthor=L.+S.+Chong&title=HCV+NS5B+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5B polymerase inhibitors</span></div><div class="casAuthors">Watkins, William J.; Ray, Adrian S.; Chong, Lee S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-465</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  In the past decade, intensive efforts have focused on the discovery of both nucleos(t)ide and non-nucleoside inhibitors of the HCV NS5B polymerase.  These efforts have resulted in several promising agents advancing in clin. development.  This review traces the history of optimization of the chem. series that have led to the development of clin. candidates, and summarizes recent developments in the field, with emphasis on clin. efficacy and impact for future combination studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6PfCo0V5R7Vg90H21EOLACvtfcHk0liK7QIB0JICWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSju7zJ&md5=f0e5144b72864e6eb1a2f4b13b1b916e</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DChong%26aufirst%3DL.%2BS.%26atitle%3DHCV%2520NS5B%2520polymerase%2520inhibitors%26jtitle%3DCur.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D441%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span> </span><span class="NLM_article-title">Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2532</span><span class="NLM_x">–</span> <span class="NLM_lpage">2531</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2532-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+nucleotide%2C+and+non-nucleoside+inhibitors+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA-polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520nucleotide%252C%2520and%2520non-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA-polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2532%26epage%3D2531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Brown, N. A.</span><span> </span><span class="NLM_article-title">Progress towards improving antiviral therapy for hepatitis C virus polymerase inhibitors. Part 1: Nucleoside analogues</span> <span class="citation_source-journal">Expert Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=709-725&author=N.+A.+Brown&title=Progress+towards+improving+antiviral+therapy+for+hepatitis+C+virus+polymerase+inhibitors.+Part+1%3A+Nucleoside+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%2BA.%26atitle%3DProgress%2520towards%2520improving%2520antiviral%2520therapy%2520for%2520hepatitis%2520C%2520virus%2520polymerase%2520inhibitors.%2520Part%25201%253A%2520Nucleoside%2520analogues%26jtitle%3DExpert%2520Opin.%2520Investig.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D709%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, E.</span><span> </span><span class="NLM_article-title">Nucleoside analog inhibitors of hepatitis C virus replication: Recent advances, challenges and trends</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1429</span><span class="NLM_x">–</span> <span class="NLM_lpage">1452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.4155%2Ffmc.09.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=21426058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSit77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=1429-1452&author=P.+A.+Furmanauthor=A.+M.+Lamauthor=E.+Murakami&title=Nucleoside+analog+inhibitors+of+hepatitis+C+virus+replication%3A+Recent+advances%2C+challenges+and+trends"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends</span></div><div class="casAuthors">Furman, Phillip A.; Lam, Angela M.; Murakami, Eisuke</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1429-1452</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic hepatitis C virus (HCV) infection is a global health problem, with over 170 million people infected worldwide.  The current therapy, pegylated interferon (PEG-IFN) plus ribavirin (RBV), provides only approx. a 40% sustained virol. response (undetectable HCV RNA for greater than 24 wk after cessation of therapy), in genotype I-infected individuals.  In addn. to the limited sustained virol. response, PEG-IFN/RBV treatment is assocd. with serious adverse effects.  Nucleosides have long been the cornerstone of antiviral therapy because of their proven efficacy and high barrier to resistance.  Through the use of surrogate viruses or the HCV subgenomic replicon, several classes of nucleoside analogs or their monophosphate prodrugs have been identified that inhibit HCV RNA replication.  Nucleoside analogs that possess the 2'-C-Me modification vary in their ability to be phosphorylated and to act as alternative substrate inhibitors of the HCV RNA polymerase.  Herein, we discuss various classes of nucleoside inhibitors, with a focus on available structure-activity relationships, their mode of action and resistance profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuFIjUiU5KFbVg90H21EOLACvtfcHk0liK7QIB0JICWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSit77F&md5=d512189b8d8f1380f8bc10a5c0438c1c</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.88%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DMurakami%26aufirst%3DE.%26atitle%3DNucleoside%2520analog%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520replication%253A%2520Recent%2520advances%252C%2520challenges%2520and%2520trends%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2009%26volume%3D1%26spage%3D1429%26epage%3D1452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sofia, M. J.</span><span> </span><span class="NLM_article-title">Nucleotide prodrugs for HCV therapy</span> <span class="citation_source-journal">Antiviral Chem. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=23-49&author=M.+J.+Sofia&title=Nucleotide+prodrugs+for+HCV+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DNucleotide%2520prodrugs%2520for%2520HCV%2520therapy%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2011%26volume%3D22%26spage%3D23%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theilmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1126%2Fscience.285.5424.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=10390360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=110-113&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=J.+O.+Kochauthor=U.+Herianauthor=L.+Theilmannauthor=R.+Bartenschlager&title=Replication+of+subgenomic+hepatitis+C+virus+RNAs+in+a+hepatoma+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span></div><div class="casAuthors">Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5424</span>),
    <span class="NLM_cas:pages">110-113</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An estd. 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease.  Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems.  A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons.  Upon transfection into a human hepatoma cell line, these RNAs replicated to high levels, permitting metabolic radiolabeling of viral RNA and proteins.  This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed mol. studies of HCV and the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X754RT8y1LVg90H21EOLACvtfcHk0liK7QIB0JICWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D&md5=b075621b316209ecf4498c9b5b33e4b5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.285.5424.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.285.5424.110%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%2BO.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DTheilmann%26aufirst%3DL.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DReplication%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNAs%2520in%2520a%2520hepatoma%2520cell%2520line%26jtitle%3DScience%26date%3D1999%26volume%3D285%26spage%3D110%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fillard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity inpatients chronically infected with genotype 1 hepatitis C virus (HCV)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7650</span><span class="NLM_x">–</span> <span class="NLM_lpage">7666</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3006788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7650-7666&author=P.+L.+Beaulieuauthor=M.+B%C3%B6sauthor=M.+G.+Cordingleyauthor=C.+Chabotauthor=G.+Fazalauthor=M.+Garneauauthor=J.+R.+Fillardauthor=E.+Jolicoeurauthor=S.+LaPlanteauthor=G.+McKercherauthor=M.+Poirierauthor=M.-A.+Poupartauthor=Y.+S.+Tsantrizosauthor=J.+Duanauthor=G.+Kukolj&title=Discovery+of+the+first+thumb+pocket+1+NS5B+polymerase+inhibitor+%28BILB+1941%29+with+demonstrated+antiviral+activity+inpatients+chronically+infected+with+genotype+1+hepatitis+C+virus+%28HCV%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm3006788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3006788%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DFazal%26aufirst%3DG.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DFillard%26aufirst%3DJ.%2BR.%26aulast%3DJolicoeur%26aufirst%3DE.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520the%2520first%2520thumb%2520pocket%25201%2520NS5B%2520polymerase%2520inhibitor%2520%2528BILB%25201941%2529%2520with%2520demonstrated%2520antiviral%2520activity%2520inpatients%2520chronically%2520infected%2520with%2520genotype%25201%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7650%26epage%3D7666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Erhardt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benhamou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forns, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calleja, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangenberg, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Samaniego, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enriquez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehmiz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffgen, J.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=23-32&author=A.+Erhardtauthor=K.+Deterdingauthor=Y.+Benhamouauthor=M.+Reiserauthor=X.+Fornsauthor=S.+Polauthor=J.+L.+Callejaauthor=S.+Rossauthor=H.+C.+Spangenbergauthor=J.+Garcia-Samaniegoauthor=M.+Fuchsauthor=J.+Enriquezauthor=J.+Wiegandauthor=J.+Sternauthor=K.+Wuauthor=G.+Kukoljauthor=M.+Marquisauthor=P.+Beaulieuauthor=G.+Nehmizauthor=J.+Steffgen&title=Safety%2C+pharmacokinetics+and+antiviral+effect+of+BILB+1941%2C+a+novel+hepatitis+C+virus+RNA+polymerase+inhibitor%2C+after+5+days+oral+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErhardt%26aufirst%3DA.%26aulast%3DDeterding%26aufirst%3DK.%26aulast%3DBenhamou%26aufirst%3DY.%26aulast%3DReiser%26aufirst%3DM.%26aulast%3DForns%26aufirst%3DX.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DCalleja%26aufirst%3DJ.%2BL.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSpangenberg%26aufirst%3DH.%2BC.%26aulast%3DGarcia-Samaniego%26aufirst%3DJ.%26aulast%3DFuchs%26aufirst%3DM.%26aulast%3DEnriquez%26aufirst%3DJ.%26aulast%3DWiegand%26aufirst%3DJ.%26aulast%3DStern%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DMarquis%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DNehmiz%26aufirst%3DG.%26aulast%3DSteffgen%26aufirst%3DJ.%26atitle%3DSafety%252C%2520pharmacokinetics%2520and%2520antiviral%2520effect%2520of%2520BILB%25201941%252C%2520a%2520novel%2520hepatitis%2520C%2520virus%2520RNA%2520polymerase%2520inhibitor%252C%2520after%25205%2520days%2520oral%2520treatment%26jtitle%3DAntiviral%2520Ther.%26date%3D2009%26volume%3D14%26spage%3D23%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bykowski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansereau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duceppe, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haché, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagacé, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4987</span><span class="NLM_x">–</span> <span class="NLM_lpage">4993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4987-4993&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=D.+Bykowskiauthor=C.+Brochuauthor=N.+Dansereauauthor=J.-S.+Duceppeauthor=B.+Hach%C3%A9author=A.+Jakalianauthor=L.+Lagac%C3%A9author=S.+LaPlanteauthor=G.+McKercherauthor=E.+Moreauauthor=S.+Perreaultauthor=T.+Stammersauthor=L.+Thauvetteauthor=J.+Warringtonauthor=G.+Kukolj&title=Improved+replicon+cellular+activity+of+non-nucleoside+allosteric+inhibitors+of+HCV+NS5B+polymerase%3A+From+benzimidazole+to+indole+scaffolds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBykowski%26aufirst%3DD.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DDansereau%26aufirst%3DN.%26aulast%3DDuceppe%26aufirst%3DJ.-S.%26aulast%3DHach%25C3%25A9%26aufirst%3DB.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DLagac%25C3%25A9%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DStammers%26aufirst%3DT.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DWarrington%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DImproved%2520replicon%2520cellular%2520activity%2520of%2520non-nucleoside%2520allosteric%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%253A%2520From%2520benzimidazole%2520to%2520indole%2520scaffolds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4987%26epage%3D4993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="note"><p class="first last">Enzymatic NS5B assays and subgenomic cell-based replicon assays are described elsewhere:<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></p></div><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellerin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Specific inhibitors of HCV polymerase identified using a NS5B with lower affinity for template/primer substrate</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=422-431&author=G.+McKercherauthor=P.+L.+Beaulieuauthor=D.+Lamarreauthor=S.+LaPlanteauthor=S.+Lefebvreauthor=C.+Pellerinauthor=L.+Thauvetteauthor=G.+Kukolj&title=Specific+inhibitors+of+HCV+polymerase+identified+using+a+NS5B+with+lower+affinity+for+template%2Fprimer+substrate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DPellerin%26aufirst%3DC.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DSpecific%2520inhibitors%2520of%2520HCV%2520polymerase%2520identified%2520using%2520a%2520NS5B%2520with%2520lower%2520affinity%2520for%2520template%252Fprimer%2520substrate%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2004%26volume%3D32%26spage%3D422%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Beaulieu, P. L.; Fazal, G.; Goulet, S.; Kukolj, G.; Poirier, M.; Tsantrizos, Y.; Jolicoeur, E.; Gillard, J.; Poupart, M.-A.; Rancourt, J.</span> WO Patent WO 03/010141,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Beaulieu%2C+P.+L.%3B+Fazal%2C+G.%3B+Goulet%2C+S.%3B+Kukolj%2C+G.%3B+Poirier%2C+M.%3B+Tsantrizos%2C+Y.%3B+Jolicoeur%2C+E.%3B+Gillard%2C+J.%3B+Poupart%2C+M.-A.%3B+Rancourt%2C+J.+WO+Patent+WO+03%2F010141%2C+2003."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhardwaj, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordeleau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingely, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forgione, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6466</span><span class="NLM_x">–</span> <span class="NLM_lpage">6476</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100690x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6466-6476&author=M.+Llin%C3%A0s-Brunetauthor=M.+D.+Baileyauthor=N.+Goudreauauthor=P.+K.+Bhardwajauthor=J.+Bordeleauauthor=M.+B%C3%B6sauthor=Y.+Bousquetauthor=M.+G.+Cordingelyauthor=J.+Duanauthor=P.+Forgioneauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=S.+Gouletauthor=T.+Halmosauthor=S.+H.+Kawaiauthor=J.+Naudauthor=M.-A.+Poupartauthor=P.+W.+White&title=Discovery+of+a+potent+and+selective+noncovalent+linear+inhibitor+of+the+hepatitis+C+virus+NS3+protease+%28BI+201335%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1021%2Fjm100690x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100690x%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DBhardwaj%26aufirst%3DP.%2BK.%26aulast%3DBordeleau%26aufirst%3DJ.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DBousquet%26aufirst%3DY.%26aulast%3DCordingely%26aufirst%3DM.%2BG.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DForgione%26aufirst%3DP.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DNaud%26aufirst%3DJ.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520noncovalent%2520linear%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520%2528BI%2520201335%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6466%26epage%3D6476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Vaillancourt, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilote, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liuzzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethell, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=5-10&author=F.+H.+Vaillancourtauthor=L.+Piloteauthor=M.+Cartierauthor=J.+Lippensauthor=M.+Liuzziauthor=R.+C.+Bethellauthor=M.+G.+Cordingleyauthor=G.+Kukolj&title=Identification+of+a+lipid+kinase+as+a+host+factor+involved+in+hepatitis+C+virus+RNA+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVaillancourt%26aufirst%3DF.%2BH.%26aulast%3DPilote%26aufirst%3DL.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DLippens%26aufirst%3DJ.%26aulast%3DLiuzzi%26aufirst%3DM.%26aulast%3DBethell%26aufirst%3DR.%2BC.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520a%2520lipid%2520kinase%2520as%2520a%2520host%2520factor%2520involved%2520in%2520hepatitis%2520C%2520virus%2520RNA%2520replication%26jtitle%3DVirology%26date%3D2009%26volume%3D387%26spage%3D5%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulombe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span> </span><span class="NLM_article-title">Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">15204</span><span class="NLM_x">–</span> <span class="NLM_lpage">15212</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja101358s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=15204-15212&author=S.+R.+LaPlanteauthor=J.+R.+Gillardauthor=A.+Jakalianauthor=N.+Aubryauthor=R.+Coulombeauthor=C.+Brochuauthor=Y.+S.+Tsantrizosauthor=M.+Poirierauthor=G.+Kukoljauthor=P.+L.+Beaulieu&title=Importance+of+ligand+bioactive+conformation+in+the+discovery+of+potent+indole-diamide+inhibitors+of+the+hepatitis+C+virus+NS5B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fja101358s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja101358s%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DGillard%26aufirst%3DJ.%2BR.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DCoulombe%26aufirst%3DR.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DImportance%2520of%2520ligand%2520bioactive%2520conformation%2520in%2520the%2520discovery%2520of%2520potent%2520indole-diamide%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D15204%26epage%3D15212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Marte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montpetit, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jutras, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethell, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span> </span><span class="NLM_article-title">Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=164-172&author=J.+Duanauthor=C.-L.+Yongauthor=M.+Garneauauthor=M.+Amadauthor=G.+Bolgerauthor=J.+De+Marteauthor=H.+Montpetitauthor=F.+Otisauthor=M.+Jutrasauthor=M.+Rh%C3%A9aumeauthor=P.+W.+Whiteauthor=M.+Llin%C3%A0s-Brunetauthor=R.+C.+Bethellauthor=M.+G.+Cordingley&title=Cross-species+absorption%2C+metabolism%2C+distribution+and+pharmacokinetics+of+BI+201335%2C+a+potent+HCV+genotype+1+NS3%2F4A+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DYong%26aufirst%3DC.-L.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DAmad%26aufirst%3DM.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DDe%2BMarte%26aufirst%3DJ.%26aulast%3DMontpetit%26aufirst%3DH.%26aulast%3DOtis%26aufirst%3DF.%26aulast%3DJutras%26aufirst%3DM.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBethell%26aufirst%3DR.%2BC.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26atitle%3DCross-species%2520absorption%252C%2520metabolism%252C%2520distribution%2520and%2520pharmacokinetics%2520of%2520BI%2520201335%252C%2520a%2520potent%2520HCV%2520genotype%25201%2520NS3%252F4A%2520protease%2520inhibitor%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D164%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batonga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montpetit, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jutras, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapeyre, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethell, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span> </span><span class="NLM_article-title">The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in human</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5381</span><span class="NLM_x">–</span> <span class="NLM_lpage">5386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5381-5386&author=J.+Duanauthor=G.+Bolgerauthor=M.+Garneauauthor=M.+Amadauthor=J.+Batongaauthor=H.+Montpetitauthor=F.+Otisauthor=M.+Jutrasauthor=N.+Lapeyreauthor=M.+Rh%C3%A9aumeauthor=G.+Kukoljauthor=P.+W.+Whiteauthor=R.+C.+Bethellauthor=M.+G.+Cordingley&title=The+liver+partition+coefficient-corrected+inhibitory+quotient+and+the+pharmacokinetic-pharmacodynamic+relationship+of+directly+acting+anti-hepatitis+C+virus+agents+in+human"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DAmad%26aufirst%3DM.%26aulast%3DBatonga%26aufirst%3DJ.%26aulast%3DMontpetit%26aufirst%3DH.%26aulast%3DOtis%26aufirst%3DF.%26aulast%3DJutras%26aufirst%3DM.%26aulast%3DLapeyre%26aufirst%3DN.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DBethell%26aufirst%3DR.%2BC.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26atitle%3DThe%2520liver%2520partition%2520coefficient-corrected%2520inhibitory%2520quotient%2520and%2520the%2520pharmacokinetic-pharmacodynamic%2520relationship%2520of%2520directly%2520acting%2520anti-hepatitis%2520C%2520virus%2520agents%2520in%2520human%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5381%26epage%3D5386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Müller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauthe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andino, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Antonis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beels, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGeorge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Knaep, A. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagerland, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritschel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galloway, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humfrey, C. D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacks, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagota, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackinnon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ness, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vudathala, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yotti, L.</span><span> </span><span class="NLM_article-title">A rational for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity</span> <span class="citation_source-journal">Regul. Toxicol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1016%2Fj.yrtph.2005.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=16412543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A280%3ADC%252BD287osFeqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2006&pages=198-211&author=L.+M%C3%BCllerauthor=R.+J.+Mautheauthor=C.+M.+Rileyauthor=M.+M.+Andinoauthor=D.+De+Antonisauthor=C.+Beelsauthor=J.+DeGeorgeauthor=A.+G.+M.+De+Knaepauthor=D.+Ellisonauthor=J.+A.+Fagerlandauthor=R.+Frankauthor=B.+Fritschelauthor=S.+Gallowayauthor=E.+Harpurauthor=C.+D.+N.+Humfreyauthor=A.+S.+Jacksauthor=N.+Jagotaauthor=J.+Mackinnonauthor=G.+Mohanauthor=D.+K.+Nessauthor=M.+R.+O%E2%80%99Donovanauthor=M.+D.+Smithauthor=G.+Vudathalaauthor=L.+Yotti&title=A+rational+for+determining%2C+testing%2C+and+controlling+specific+impurities+in+pharmaceuticals+that+possess+potential+for+genotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity</span></div><div class="casAuthors">Muller Lutz; Mauthe Robert J; Riley Christopher M; Andino Marta M; Antonis David De; Beels Chris; DeGeorge Joseph; De Knaep Alfons G M; Ellison Dean; Fagerland Jane A; Frank Rebecca; Fritschel Betsy; Galloway Sheila; Harpur Ernie; Humfrey Charles D N; Jacks Alexander S; Jagota Nirdosh; Mackinnon John; Mohan Ganapathy; Ness Daniel K; O'Donovan Michael R; Smith Mark D; Vudathala Gopi; Yotti Larry</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory toxicology and pharmacology : RTP</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-211</span>
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    </div><div class="casAbstract">The synthesis of pharmaceutical products frequently involves the use of reactive reagents and the formation of intermediates and by-products.  Low levels of some of these may be present in the final drug substance and drug product as impurities.  Such chemically reactive impurities may have at the same time the potential for unwanted toxicities including genotoxicity and carcinogenicity and hence can have an impact on product risk assessment.  This paper outlines a procedure for testing, classification, qualification, toxicological risk assessment, and control of impurities possessing genotoxic potential in pharmaceutical products.  Referencing accepted principles of cancer risk assessment, this document proposes a staged threshold of toxicological concern (TTC) approach for the intake of genotoxic impurities over various periods of exposure.  This staged TTC is based on knowledge about tumorigenic potency of a wide range of genotoxic carcinogens and can be used for genotoxic compounds, for which cancer data are limited or not available.  The delineated acceptable daily intake values of between approximately 1.5 microg/day for approximately lifetime intake and approximately 120 microg/day for < or = 1 month are virtually safe doses.  Based on sound scientific reasoning, these virtually safe intake values do not pose an unacceptable risk to either human volunteers or patients at any stage of clinical development and marketing of a pharmaceutical product.  The intake levels are estimated to give an excess cancer risk of 1 in 100,000 to 1 in a million over a lifetime, and are extremely conservative given the current lifetime cancer risk in the population of over 1 in 4 (http://seer.cancer.gov/statfacts/html.all.html).  The proposals in this document apply to all clinical routes of administration and to compounds at all stages of clinical development.  It is important to note that certain types of products, such as those for life-threatening indications for which there are no safer alternatives, allow for special considerations using adaptations of the principles outlined in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzrrxAZj7F1Ubxh97K6Vt6fW6udTcc2eZI5doADdO55bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287osFeqtw%253D%253D&md5=198b45bde3ed1df54be3595618311c22</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2005.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2005.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DL.%26aulast%3DMauthe%26aufirst%3DR.%2BJ.%26aulast%3DRiley%26aufirst%3DC.%2BM.%26aulast%3DAndino%26aufirst%3DM.%2BM.%26aulast%3DDe%2BAntonis%26aufirst%3DD.%26aulast%3DBeels%26aufirst%3DC.%26aulast%3DDeGeorge%26aufirst%3DJ.%26aulast%3DDe%2BKnaep%26aufirst%3DA.%2BG.%2BM.%26aulast%3DEllison%26aufirst%3DD.%26aulast%3DFagerland%26aufirst%3DJ.%2BA.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DFritschel%26aufirst%3DB.%26aulast%3DGalloway%26aufirst%3DS.%26aulast%3DHarpur%26aufirst%3DE.%26aulast%3DHumfrey%26aufirst%3DC.%2BD.%2BN.%26aulast%3DJacks%26aufirst%3DA.%2BS.%26aulast%3DJagota%26aufirst%3DN.%26aulast%3DMackinnon%26aufirst%3DJ.%26aulast%3DMohan%26aufirst%3DG.%26aulast%3DNess%26aufirst%3DD.%2BK.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DVudathala%26aufirst%3DG.%26aulast%3DYotti%26aufirst%3DL.%26atitle%3DA%2520rational%2520for%2520determining%252C%2520testing%252C%2520and%2520controlling%2520specific%2520impurities%2520in%2520pharmaceuticals%2520that%2520possess%2520potential%2520for%2520genotoxicity%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2006%26volume%3D44%26spage%3D198%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Broadhurst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G. J.</span><span> </span><span class="NLM_article-title">Tetracycline studies. Part 5. New syntheses of anthracenes and anthraquinones through benzophenone carbanions</span> <span class="citation_source-journal">J. Chem. Soc., Perkin 1 Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_fpage">2502</span><span class="NLM_x">–</span> <span class="NLM_lpage">2512</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1039%2Fp19770002502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADyaE1cXhtlKgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&pages=2502-2512&author=M.+J.+Broadhurstauthor=C.+H.+Hassallauthor=G.+J.+Thomas&title=Tetracycline+studies.+Part+5.+New+syntheses+of+anthracenes+and+anthraquinones+through+benzophenone+carbanions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tetracycline studies.  Part 5.  New syntheses of anthracenes and anthraquinones through benzophenone carbanions</span></div><div class="casAuthors">Broadhurst, Michael J.; Hassall, Cedric H.; Thomas, Gareth J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1:  Organic and Bio-Organic Chemistry (1972-1999)</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2502-12</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    </div><div class="casAbstract">The title syntheses are of wide applicability and gave good yields of products.  E.g., the benzophenone I (R = CN) with Me3COK in DMF at 90° for 1 h gave 95% anthrol II (R = Me, R1 = PhCH2, R2 = R4 = OMe, R3 = CO2Me) which with H2O2 and NaOH gave 96% anthraquinone III.  I (R = CO2Me) with Me3COK in DMF followed by H2O2-NaOH treatment gave 41% III.  Regiospecificity of cyclization was achieved by preferential displacement of Cl-.  E.g., 2-(2,4-dichlorobenzoyl)-3,5-dimethoxyphenylacetonitrile with Me3COK in DMF gave 46% II (R = R2 = R3 = H, R1 = Me, R4 = Cl).  In some circumstances 2-cyanomethylbenzophenones with (F3CCO)2O gave isoquinolin-3-one derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps0Di-H8gl_LVg90H21EOLACvtfcHk0lgG2FZ4NjVNSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXhtlKgt74%253D&md5=33d31545d472a951b9f74d9180760a2b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1039%2Fp19770002502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp19770002502%26sid%3Dliteratum%253Aachs%26aulast%3DBroadhurst%26aufirst%3DM.%2BJ.%26aulast%3DHassall%26aufirst%3DC.%2BH.%26aulast%3DThomas%26aufirst%3DG.%2BJ.%26atitle%3DTetracycline%2520studies.%2520Part%25205.%2520New%2520syntheses%2520of%2520anthracenes%2520and%2520anthraquinones%2520through%2520benzophenone%2520carbanions%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%25201%2520Trans.%26date%3D1977%26spage%3D2502%26epage%3D2512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c','cit4d'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c','cit6d'],'ref7':['cit7a','cit7b','cit7c','cit7d','cit7e','cit7f','cit7g'],'ref8':['cit8a','cit8b','cit8c'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b','cit14c','cit14d'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ganga Reddy  Gaddam</span>, <span class="hlFld-ContribAuthor ">Pramod Kumar  Dubey</span>, <span class="hlFld-ContribAuthor ">Venkata Ramana Reddy  Chittireddy</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Indolyl Pyrazole Scaffolds as Potential Anti-cancer Agents and their Molecular Modelling Studies. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (7)
                                     , 828-839. <a href="https://doi.org/10.2174/1570180816666191024103534" title="DOI URL">https://doi.org/10.2174/1570180816666191024103534</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180816666191024103534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180816666191024103534%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DSynthesis%252Bof%252BIndolyl%252BPyrazole%252BScaffolds%252Bas%252BPotential%252BAnti-cancer%252BAgents%252Band%252Btheir%252BMolecular%252BModelling%252BStudies%26aulast%3DGaddam%26aufirst%3DGanga%2BReddy%26date%3D2020%26volume%3D17%26issue%3D7%26spage%3D828%26epage%3D839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Narayana Murthy  Ganta</span>, <span class="hlFld-ContribAuthor ">Gangaraju  Gedda</span>, <span class="hlFld-ContribAuthor ">Bethi  Rathnakar</span>, <span class="hlFld-ContribAuthor ">Mavurapu  Satyanarayana</span>, <span class="hlFld-ContribAuthor ">Bhaskar  Yamajala</span>, <span class="hlFld-ContribAuthor ">Mohamed Jawed  Ahsan</span>, <span class="hlFld-ContribAuthor ">Surender Singh  Jadav</span>, <span class="hlFld-ContribAuthor ">Tuniki  Balaraju</span>. </span><span class="cited-content_cbyCitation_article-title">A review on HCV inhibitors: Significance of non-structural polyproteins. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>164 </em>, 576-601. <a href="https://doi.org/10.1016/j.ejmech.2018.12.045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Breview%252Bon%252BHCV%252Binhibitors%25253A%252BSignificance%252Bof%252Bnon-structural%252Bpolyproteins%26aulast%3DGanta%26aufirst%3DNarayana%2BMurthy%26date%3D2019%26volume%3D164%26spage%3D576%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srikanta  Dash</span>, <span class="hlFld-ContribAuthor ">Yucel  Aydin</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Stephens</span>. </span><span class="cited-content_cbyCitation_article-title">Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 211-235. <a href="https://doi.org/10.1016/B978-0-12-815422-9.00008-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-815422-9.00008-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-815422-9.00008-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-815422-9.00008-5%26sid%3Dliteratum%253Aachs%26atitle%3DHepatitis%252BC%252BVirus%252BNS5B%252BRNA-Dependent%252BRNA%252BPolymerase%252BInhibitor%26aulast%3DDash%26aufirst%3DSrikanta%26date%3D2019%26spage%3D211%26epage%3D235%26pub%3DElsevier%26atitle%3DViral%252BPolymerases%26date%3D2019%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 553-627. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12406-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12406-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12406-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12406-0%26sid%3Dliteratum%253Aachs%26atitle%3DDirect-Acting%252BAntiviral%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D553%26epage%3D627%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George  Chang</span>, <span class="hlFld-ContribAuthor ">Kim  Huard</span>, <span class="hlFld-ContribAuthor ">Gregory W.  Kauffman</span>, <span class="hlFld-ContribAuthor ">Antonia F.  Stepan</span>, <span class="hlFld-ContribAuthor ">Christopher E.  Keefer</span>. </span><span class="cited-content_cbyCitation_article-title">A multi-endpoint matched molecular pair (MMP) analysis of 6-membered heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (1)
                                     , 381-388. <a href="https://doi.org/10.1016/j.bmc.2016.11.004" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DA%252Bmulti-endpoint%252Bmatched%252Bmolecular%252Bpair%252B%252528MMP%252529%252Banalysis%252Bof%252B6-membered%252Bheterocycles%26aulast%3DChang%26aufirst%3DGeorge%26date%3D2017%26volume%3D25%26issue%3D1%26spage%3D381%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pooja R.  Kamath</span>, <span class="hlFld-ContribAuthor ">Dhanya  Sunil</span>, <span class="hlFld-ContribAuthor ">A. Abdul  Ajees</span>, <span class="hlFld-ContribAuthor ">K.S.R.  Pai</span>, <span class="hlFld-ContribAuthor ">Shubankar  Biswas</span>. </span><span class="cited-content_cbyCitation_article-title">N′-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>120 </em>, 134-147. <a href="https://doi.org/10.1016/j.ejmech.2016.05.010" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN%2525E2%252580%2525B2-%252528%2525282-%2525286-bromo-2-oxo-2H-chromen-3-yl%252529-1H-indol-3-yl%252529methylene%252529benzohydrazide%252Bas%252Ba%252Bprobable%252BBcl-2%25252FBcl-xL%252Binhibitor%252Bwith%252Bapoptotic%252Band%252Banti-metastatic%252Bpotential%26aulast%3DKamath%26aufirst%3DPooja%2BR.%26date%3D2016%26volume%3D120%26spage%3D134%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pooja R.  Kamath</span>, <span class="hlFld-ContribAuthor ">Dhanya  Sunil</span>, <span class="hlFld-ContribAuthor ">A. Abdul  Ajees</span>, <span class="hlFld-ContribAuthor ">K.S.R.  Pai</span>, <span class="hlFld-ContribAuthor ">Shubhankar  Das</span>. </span><span class="cited-content_cbyCitation_article-title">Some new indole–coumarin hybrids; Synthesis, anticancer and Bcl-2 docking studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2015,</strong> <em>63 </em>, 101-109. <a href="https://doi.org/10.1016/j.bioorg.2015.10.001" title="DOI URL">https://doi.org/10.1016/j.bioorg.2015.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2015.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2015.10.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSome%252Bnew%252Bindole%2525E2%252580%252593coumarin%252Bhybrids%25253B%252BSynthesis%25252C%252Banticancer%252Band%252BBcl-2%252Bdocking%252Bstudies%26aulast%3DKamath%26aufirst%3DPooja%2BR.%26date%3D2015%26volume%3D63%26spage%3D101%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre L.  Beaulieu</span>, <span class="hlFld-ContribAuthor ">Gordon  Bolger</span>, <span class="hlFld-ContribAuthor ">Martin  Duplessis</span>, <span class="hlFld-ContribAuthor ">Alexandre  Gagnon</span>, <span class="hlFld-ContribAuthor ">Michel  Garneau</span>, <span class="hlFld-ContribAuthor ">Timothy  Stammers</span>, <span class="hlFld-ContribAuthor ">George  Kukolj</span>, <span class="hlFld-ContribAuthor ">Jianmin  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Aza follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 1: Mitigating the genotoxic liability of an aniline metabolite. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (5)
                                     , 1135-1139. <a href="https://doi.org/10.1016/j.bmcl.2014.12.028" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.12.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.12.028%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAza%252Bfollow-ups%252Bto%252BBI%252B207524%25252C%252Ba%252Bthumb%252Bpocket%252B1%252BHCV%252BNS5B%252Bpolymerase%252Binhibitor.%252BPart%252B1%25253A%252BMitigating%252Bthe%252Bgenotoxic%252Bliability%252Bof%252Ban%252Baniline%252Bmetabolite%26aulast%3DBeaulieu%26aufirst%3DPierre%2BL.%26date%3D2015%26volume%3D25%26issue%3D5%26spage%3D1135%26epage%3D1139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre L.  Beaulieu</span>, <span class="hlFld-ContribAuthor ">Gordon  Bolger</span>, <span class="hlFld-ContribAuthor ">Dan  Deon</span>, <span class="hlFld-ContribAuthor ">Martin  Duplessis</span>, <span class="hlFld-ContribAuthor ">Gulrez  Fazal</span>, <span class="hlFld-ContribAuthor ">Alexandre  Gagnon</span>, <span class="hlFld-ContribAuthor ">Michel  Garneau</span>, <span class="hlFld-ContribAuthor ">Steven  LaPlante</span>, <span class="hlFld-ContribAuthor ">Timothy  Stammers</span>, <span class="hlFld-ContribAuthor ">George  Kukolj</span>, <span class="hlFld-ContribAuthor ">Jianmin  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (5)
                                     , 1140-1145. <a href="https://doi.org/10.1016/j.bmcl.2014.12.078" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.12.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.12.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.12.078%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMulti-parameter%252Boptimization%252Bof%252Baza-follow-ups%252Bto%252BBI%252B207524%25252C%252Ba%252Bthumb%252Bpocket%252B1%252BHCV%252BNS5B%252Bpolymerase%252Binhibitor.%252BPart%252B2%25253A%252BImpact%252Bof%252Blipophilicity%252Bon%252Bpromiscuity%252Band%252Bin%252Bvivo%252Btoxicity%26aulast%3DBeaulieu%26aufirst%3DPierre%2BL.%26date%3D2015%26volume%3D25%26issue%3D5%26spage%3D1140%26epage%3D1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre L.  Beaulieu</span>, <span class="hlFld-ContribAuthor ">Josie  De Marte</span>, <span class="hlFld-ContribAuthor ">Michel  Garneau</span>, <span class="hlFld-ContribAuthor ">Laibin  Luo</span>, <span class="hlFld-ContribAuthor ">Timothy  Stammers</span>, <span class="hlFld-ContribAuthor ">Chitra  Telang</span>, <span class="hlFld-ContribAuthor ">Dominik  Wernic</span>, <span class="hlFld-ContribAuthor ">George  Kukolj</span>, <span class="hlFld-ContribAuthor ">Jianmin  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">A prodrug strategy for the oral delivery of a poorly soluble HCV NS5B thumb pocket 1 polymerase inhibitor using self-emulsifying drug delivery systems (SEDDS). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (2)
                                     , 210-215. <a href="https://doi.org/10.1016/j.bmcl.2014.11.071" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.11.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.11.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.11.071%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DA%252Bprodrug%252Bstrategy%252Bfor%252Bthe%252Boral%252Bdelivery%252Bof%252Ba%252Bpoorly%252Bsoluble%252BHCV%252BNS5B%252Bthumb%252Bpocket%252B1%252Bpolymerase%252Binhibitor%252Busing%252Bself-emulsifying%252Bdrug%252Bdelivery%252Bsystems%252B%252528SEDDS%252529%26aulast%3DBeaulieu%26aufirst%3DPierre%2BL.%26date%3D2015%26volume%3D25%26issue%3D2%26spage%3D210%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of the first thumb pocket 1 NS5B inhibitor with antiviral activity in man.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cinnamic acid double bond substitution and rigidification.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Scheme</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of 4-Amino-2-ethoxycinnamic Acid Methyl Ester <b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BH<sub>3</sub>·Me<sub>2</sub>S, THF, 0 °C to RT; (b) MnO<sub>2</sub>, CHCl<sub>3</sub>, reflux; (c) trimethylphosphonoacetate, NaH, THF, RT; (d) Fe powder, NH<sub>4</sub>Cl, EtOH, reflux.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Chromene <b>49</b> and 2-Alkoxycinnamate Building Blocks (Inhibitors <b>16</b>–<b>21</b>) by Alkylation and Mitsunobu Etherification Protocols<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BH<sub>3</sub>·Me<sub>2</sub>S, THF, 0 °C to RT; (b) MnO<sub>2</sub>, CHCl<sub>3</sub>, reflux; (c) methyl acrylate, DABCO, 50 °C; (d) Fe powder, NH<sub>4</sub>Cl, EtOH, reflux; (e) Piv-Cl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT; (f) trimethylphosphonoacetate, NaH, THF, RT; (g) conc. H<sub>2</sub>SO<sub>4</sub>; (h) ROH, DEAD, Ph<sub>3</sub>P, THF, RT; (i) RI or RBr, Cs<sub>2</sub>CO<sub>3</sub>, DMF, RT or 60 °C; (j) Fe, NH<sub>4</sub>Cl, EtOH–water, 80 °C, or K<sub>2</sub>CO<sub>3</sub>, NaHSO<sub>3</sub>, EtOH–water, RT.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of 2,6-Dimethoxycinnamate Building Block for the Synthesis of Inhibitor <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TBTU, Et<sub>3</sub>N, DMSO, RT; (b) LiAlH<sub>4</sub>, THF, 0 °C to RT; (c) MnO<sub>2</sub>, THF, reflux; (d) trimethylphosphonoacetate, NaH, THF, RT; (e) 4 N HCl, dioxane, RT.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/medium/jm-2014-01532z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Alternative Assembly of Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-23/jm501532z/20141205/images/large/jm-2014-01532z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501532z&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TBTU, Et<sub>3</sub>N, DMF, RT; (b) 1 N NaOH, MeOH–THF–water, RT; (c) Ac<sub>2</sub>O, 100 °C; (d) aniline <b>62</b>, toluene, AcOH, 85 °C; (e) 1 N NaOH, DMSO.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 19 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lavanchy, D.</span><span> </span><span class="NLM_article-title">Evolving epidemiology of hepatitis C virus</span> <span class="citation_source-journal">Clin. Microbiol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1111%2Fj.1469-0691.2010.03432.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=21091831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A280%3ADC%252BC3M7islSrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=107-115&author=D.+Lavanchy&title=Evolving+epidemiology+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Evolving epidemiology of hepatitis C virus</span></div><div class="casAuthors">Lavanchy D</div><div class="citationInfo"><span class="NLM_cas:title">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than 20 years after the discovery of the hepatitis C virus (HCV), it is now well established that HCV is of global importance affecting all countries, leading to a major global health problem that requires widespread active interventions for its prevention and control.  Chronic hepatitis C was linked to the development of cirrhosis and hepatocellular carcinoma in many areas of the world.  Current epidemiological assessments have identified complex patterns with highly variable local prevalence rates between countries and within countries.  HCV infection patterns have not significantly changed in most parts of the world since 1997, when first analyzed, partly due to the lack of new and more accurate data.  The assessment of the national HCV prevalence and transmission modes should be completed to enable national authorities to prioritize preventive measures and to make the most appropriate use of available resources.  The 'patchy' epidemiological situation in some areas will continue to complicate the task of the establishment of global, regional and national base line data.  The present assessment finds a global prevalence of 2.35%, affecting 160 million chronically infected individuals.  There is an urgent need for more accurate Information on the costs and burden of HCV to society.  Twenty-one year after the discovery of HCV, the assessment is far from being complete and little progress has been made in the past 10 years in many countries.  In some countries significant increases have been reported and this may also apply to countries were insufficient data exist.  A safe and efficient vaccine against HCV is urgently needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYetk_zmER_suCWE5mhx1RfW6udTcc2ebSJIYF3OPip7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7islSrtQ%253D%253D&md5=b77d9df38203d7a5dd060cc1bc3bc487</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1469-0691.2010.03432.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1469-0691.2010.03432.x%26sid%3Dliteratum%253Aachs%26aulast%3DLavanchy%26aufirst%3DD.%26atitle%3DEvolving%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2011%26volume%3D17%26spage%3D107%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Choo, Q.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">244</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1126%2Fscience.2523562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=2523562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1989&pages=359-362&author=Q.-L.+Chooauthor=G.+Kuoauthor=A.+J.+Weinerauthor=L.+R.+Overbyauthor=D.+W.+Bradleyauthor=M.+Houghton&title=Isolation+of+a+cDNA+clone+derived+from+a+blood-borne+non-A%2C+non-B+viral+hepatitis+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span></div><div class="casAuthors">Choo, Qui Lim; Kuo, George; Weiner, Amy J.; Overby, Lacy R.; Bradley, Daniel W.; Houghton, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">4902</span>),
    <span class="NLM_cas:pages">359-62</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A random-primed cDNA library was constructed from plasma contg. the uncharacterized non-A, non-B hepatitis (NANBH) agent and screened with serum from a patient diagnosed with NANBH.  A cDNA clone was isolated that was shown to encode an antigen assocd. specifically with NANBH infections.  This clone is not derived from host DNA but from an RNA mol. present in NANBH infections that consists of ≥10,000 nucleotides, and that is pos.-stranded with respect to the encoded NANBH antigen.  These data indicate that this clone is derived from the genome of the NANBH agent and are consistent with the agent being similar to the togaviridae or flaviviridae.  This mol. approach should be of great value in the isolation and characterization of other unidentified infectious agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorpVFx7nEkrVg90H21EOLACvtfcHk0ljelgMQd3mPGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D&md5=25161cf212790856dd29d3aaf78f20b8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.2523562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2523562%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DQ.-L.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DWeiner%26aufirst%3DA.%2BJ.%26aulast%3DOverby%26aufirst%3DL.%2BR.%26aulast%3DBradley%26aufirst%3DD.%2BW.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520a%2520cDNA%2520clone%2520derived%2520from%2520a%2520blood-borne%2520non-A%252C%2520non-B%2520viral%2520hepatitis%2520genome%26jtitle%3DScience%26date%3D1989%26volume%3D244%26spage%3D359%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Lindenbach, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, M. C.</span><span> </span><span class="NLM_article-title">Unraveling hepatitis C virus replication from genome to function</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">938</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2005&pages=933-938&author=B.+D.+Lindenbachauthor=M.+C.+Rice&title=Unraveling+hepatitis+C+virus+replication+from+genome+to+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DRice%26aufirst%3DM.%2BC.%26atitle%3DUnraveling%2520hepatitis%2520C%2520virus%2520replication%2520from%2520genome%2520to%2520function%26jtitle%3DNature%26date%3D2005%26volume%3D436%26spage%3D933%26epage%3D938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gentile, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carleo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaldo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, G.</span><span> </span><span class="NLM_article-title">The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus</span> <span class="citation_source-journal">Expert Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=151-159&author=I.+Gentileauthor=M.+A.+Carleoauthor=F.+Borgiaauthor=G.+Castaldoauthor=G.+Borgia&title=The+efficacy+and+safety+of+telaprevir+%E2%80%93+a+new+protease+inhibitor+against+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DCarleo%26aufirst%3DM.%2BA.%26aulast%3DBorgia%26aufirst%3DF.%26aulast%3DCastaldo%26aufirst%3DG.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DThe%2520efficacy%2520and%2520safety%2520of%2520telaprevir%2520%25E2%2580%2593%2520a%2520new%2520protease%2520inhibitor%2520against%2520hepatitis%2520C%2520virus%26jtitle%3DExpert%2520Opin.%2520Investig.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D151%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kwong, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, P.</span><span> </span><span class="NLM_article-title">Discovery and development of telaprevir: An NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=D.+A.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Mueller&title=Discovery+and+development+of+telaprevir%3A+An+NS3%E2%80%934A+protease+inhibitor+for+treating+genotype+1+chronic+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DD.%2BA.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520development%2520of%2520telaprevir%253A%2520An%2520NS3%25E2%2580%25934A%2520protease%2520inhibitor%2520for%2520treating%2520genotype%25201%2520chronic%2520hepatitis%2520C%2520virus%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Berman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P. Y.</span><span> </span><span class="NLM_article-title">Boceprevir, an NS3 protease inhibitor of HCV</span> <span class="citation_source-journal">Clin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=429-439&author=K.+Bermanauthor=P.+Y.+Kwo&title=Boceprevir%2C+an+NS3+protease+inhibitor+of+HCV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DK.%26aulast%3DKwo%26aufirst%3DP.%2BY.%26atitle%3DBoceprevir%252C%2520an%2520NS3%2520protease%2520inhibitor%2520of%2520HCV%26jtitle%3DClin.%2520Liver%2520Dis.%26date%3D2009%26volume%3D13%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">New direct-acting antivirals combination for the treatment of chronic hepatitis C</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=68-77&author=T.+Asselahauthor=P.+Marcellin&title=New+direct-acting+antivirals+combination+for+the+treatment+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DNew%2520direct-acting%2520antivirals%2520combination%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DLiver%2520Int.%26date%3D2011%26volume%3D31%26spage%3D68%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">447</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sarrazin%2C+C.%3B+Zeuzem%2C+S.Gastroenterology+2010%2C+138%2C+447"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DZeuzem%26aufirst%3DS.%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D138%26spage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dieterich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratziu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maieron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datsenko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böcher, W. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmann, G.</span><span> </span><span class="NLM_article-title">SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naı̈ve hepatitis C virus genotype 1-infected patients</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3429</span><span class="NLM_x">–</span> <span class="NLM_lpage">3436</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3429-3436&author=D.+Dieterichauthor=T.+Y.+Asselahauthor=D.+Guyaderauthor=T.+Bergauthor=M.+Schuchmannauthor=S.+Maussauthor=V.+Ratziuauthor=P.+Ferenciauthor=D.+Larreyauthor=A.+Maieronauthor=J.+O.+Sternauthor=M.+Ozanauthor=Y.+Datsenkoauthor=W.+O.+B%C3%B6cherauthor=G.+Steinmann&title=SILEN-C3%2C+a+phase+2+randomized+trial+with+faldaprevir+plus+pegylated+interferon+%CE%B1-2a+and+ribavirin+in+treatment-na%C4%B1%CC%88ve+hepatitis+C+virus+genotype+1-infected+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDieterich%26aufirst%3DD.%26aulast%3DAsselah%26aufirst%3DT.%2BY.%26aulast%3DGuyader%26aufirst%3DD.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DSchuchmann%26aufirst%3DM.%26aulast%3DMauss%26aufirst%3DS.%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DMaieron%26aufirst%3DA.%26aulast%3DStern%26aufirst%3DJ.%2BO.%26aulast%3DOzan%26aufirst%3DM.%26aulast%3DDatsenko%26aufirst%3DY.%26aulast%3DB%25C3%25B6cher%26aufirst%3DW.%2BO.%26aulast%3DSteinmann%26aufirst%3DG.%26atitle%3DSILEN-C3%252C%2520a%2520phase%25202%2520randomized%2520trial%2520with%2520faldaprevir%2520plus%2520pegylated%2520interferon%2520%25CE%25B1-2a%2520and%2520ribavirin%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520hepatitis%2520C%2520virus%2520genotype%25201-infected%2520patients%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3429%26epage%3D3436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafalsky, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moroz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craxi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwerkerk-Mahadevan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De La Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span> </span><span class="NLM_article-title">Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naı̈ve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomized, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">413</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=403-413&author=I.+M.+Jacobsonauthor=G.+J.+Doreauthor=G.+R.+Fosterauthor=M.+W.+Friedauthor=M.+Raduauthor=V.+V.+Rafalskyauthor=L.+Morozauthor=A.+Craxiauthor=M.+Peetersauthor=O.+Lenzauthor=S.+Ouwerkerk-Mahadevanauthor=G.+De+La+Rosaauthor=R.+Kalmeijerauthor=J.+Scottauthor=R.+Sinhaauthor=M.+Beumont-Mauviel&title=Simeprevir+with+pegylated+interferon+alfa+2a+plus+ribavirin+in+treatment-na%C4%B1%CC%88ve+patients+with+chronic+hepatitis+C+virus+genotype+1+infection+%28QUEST-1%29%3A+A+phase+3%2C+randomized%2C+double-blind%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DRadu%26aufirst%3DM.%26aulast%3DRafalsky%26aufirst%3DV.%2BV.%26aulast%3DMoroz%26aufirst%3DL.%26aulast%3DCraxi%26aufirst%3DA.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DOuwerkerk-Mahadevan%26aufirst%3DS.%26aulast%3DDe%2BLa%2BRosa%26aufirst%3DG.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DJ.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26atitle%3DSimeprevir%2520with%2520pegylated%2520interferon%2520alfa%25202a%2520plus%2520ribavirin%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%2520%2528QUEST-1%2529%253A%2520A%2520phase%25203%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D403%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Manns, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanislau Affonso de Araujo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsmans, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janczewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villamil, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwerkerk-Mahadevan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De La Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span> </span><span class="NLM_article-title">Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naı̈ve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=414-426&author=M.+Mannsauthor=P.+Marcellinauthor=F.+Poordadauthor=E.+Stanislau+Affonso+de+Araujoauthor=M.+Butiauthor=Y.+Horsmansauthor=E.+Janczewskaauthor=F.+Villamilauthor=J.+Scottauthor=M.+Peetersauthor=O.+Lenzauthor=S.+Ouwerkerk-Mahadevanauthor=G.+De+La+Rosaauthor=R.+Kalmeijerauthor=R.+Sinhaauthor=M.+Beumont-Mauviel&title=Simeprevir+with+pegylated+interferon+alfa+2a+or+2b+plus+ribavirin+in+treatment-na%C4%B1%CC%88ve+patients+with+chronic+hepatitis+C+virus+genotype+1+infection+%28QUEST-2%29%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManns%26aufirst%3DM.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DStanislau%2BAffonso%2Bde%2BAraujo%26aufirst%3DE.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DHorsmans%26aufirst%3DY.%26aulast%3DJanczewska%26aufirst%3DE.%26aulast%3DVillamil%26aufirst%3DF.%26aulast%3DScott%26aufirst%3DJ.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DOuwerkerk-Mahadevan%26aufirst%3DS.%26aulast%3DDe%2BLa%2BRosa%26aufirst%3DG.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26atitle%3DSimeprevir%2520with%2520pegylated%2520interferon%2520alfa%25202a%2520or%25202b%2520plus%2520ribavirin%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%2520%2528QUEST-2%2529%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D414%26epage%3D426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Keating, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidya, A.</span><span> </span><span class="NLM_article-title">Sofosbuvir: First global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=273-282&author=G.+M.+Keatingauthor=A.+Vaidya&title=Sofosbuvir%3A+First+global+approval"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DVaidya%26aufirst%3DA.%26atitle%3DSofosbuvir%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D273%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulombe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thavonekham, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y.</span><span> </span><span class="NLM_article-title">Conformation-based restrictions and scaffold replacements in the design of HCV polymerase inhibitor: Discovery of deleobuvir (BI 207127)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1845</span><span class="NLM_x">–</span> <span class="NLM_lpage">1854</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4011862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1845-1854&author=S.+R.+LaPlanteauthor=M.+B%C3%B6sauthor=C.+Brochuauthor=C.+Chabotauthor=R.+Coulombeauthor=J.+R.+Gillardauthor=A.+Jakalianauthor=M.+Poirierauthor=J.+Rancourtauthor=T.+Stammersauthor=B.+Thavonekhamauthor=P.+L.+Beaulieuauthor=G.+Kukoljauthor=Y.+Tsantrizos&title=Conformation-based+restrictions+and+scaffold+replacements+in+the+design+of+HCV+polymerase+inhibitor%3A+Discovery+of+deleobuvir+%28BI+207127%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1021%2Fjm4011862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011862%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DCoulombe%26aufirst%3DR.%26aulast%3DGillard%26aufirst%3DJ.%2BR.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DStammers%26aufirst%3DT.%26aulast%3DThavonekham%26aufirst%3DB.%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DTsantrizos%26aufirst%3DY.%26atitle%3DConformation-based%2520restrictions%2520and%2520scaffold%2520replacements%2520in%2520the%2520design%2520of%2520HCV%2520polymerase%2520inhibitor%253A%2520Discovery%2520of%2520deleobuvir%2520%2528BI%2520207127%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1845%26epage%3D1854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müllhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinisko, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallivan, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böcher, W.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mensa, F. J.</span><span> </span><span class="NLM_article-title">Faldaprevir and deleobuvir for HCV genotype infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">630</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1056%2FNEJMoa1213557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=23944300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlClsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=630-639&author=S.+Zeuzemauthor=V.+Sorianoauthor=T.+Asselahauthor=J.-P.+Bronowickiauthor=A.+W.+Lohseauthor=B.+M%C3%BCllhauptauthor=M.+Schuchmannauthor=M.+Bourli%C3%A8reauthor=M.+Butiauthor=S.+K.+Robertsauthor=E.+J.+Ganeauthor=J.+O.+Sternauthor=R.+Viniskoauthor=G.+Kukoljauthor=J.-P.+Gallivanauthor=W.-O.+B%C3%B6cherauthor=F.+J.+Mensa&title=Faldaprevir+and+deleobuvir+for+HCV+genotype+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Faldaprevir and deleobuvir for HCV genotype 1 infection</span></div><div class="casAuthors">Zeuzem, Stefan; Soriano, Vincent; Asselah, Tarik; Bronowicki, Jean-Pierre; Lohse, Ansgar W.; Muellhaupt, Beat; Schuchmann, Marcus; Bourliere, Marc; Buti, Maria; Roberts, Stuart K.; Gane, Ed J.; Stern, Jerry O.; Vinisko, Richard; Kukolj, George; Gallivan, John-Paul; Boecher, Wulf-Otto; Mensa, Federico J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">630-639</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus (HCV) infection.  In this phase 2b, randomized, open-label trial of faldaprevir (a protease inhibitor) and deleobuvir (a nonnucleoside polymerase inhibitor), we randomly assigned 362 previously untreated patients with HCV genotype 1 infection to one of five groups: faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg three times daily, plus ribavirin, for 16, 28, or 40 wk (TID16W, TID28W, or TID40W, resp.); faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg twice daily, plus ribavirin, for 28 wk (BID28W); or faldaprevir at a dose of 120 mg once daily and deleobuvir at a dose of 600 mg three times daily, without ribavirin, for 28 wk (TID28W-NR).  The primary end point was a sustained virol. response 12 wk after the completion of therapy.  The primary end point was met in 59% of patients in the TID16W group, 59% of patients in the TID28W group, 52% of patients in the TID40W group, 69% of patients in the BID28W group, and 39% of patients in the TID28W-NR group.  The sustained virol. response 12 wk after the completion of therapy did not differ significantly according to treatment duration or dosage among ribavirin-contg. regimens.  This response was significantly higher with TID28W than with TID28W-NR (P = 0.03).  Rates of a sustained virol. response 12 wk after the completion of therapy were 56 to 85% among patients with genotype 1b infection vs. 11 to 47% among patients with genotype 1a infection and 58 to 84% among patients with IL28B CC vs. 33 to 64% with non-CC genotypes.  Rash, photosensitivity, nausea, vomiting, and diarrhea were the most common adverse events.  The rate of a sustained virol. response 12 wk after the completion of therapy was 52 to 69% among patients who received interferon-free treatment with faldaprevir in combination with deleobuvir plus ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1_F80GH0n0LVg90H21EOLACvtfcHk0lgtrK9yh7LVHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlClsrvJ&md5=38355557fa942e4017129c159e5a25cd</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1213557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1213557%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DSoriano%26aufirst%3DV.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26aulast%3DLohse%26aufirst%3DA.%2BW.%26aulast%3DM%25C3%25BCllhaupt%26aufirst%3DB.%26aulast%3DSchuchmann%26aufirst%3DM.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DStern%26aufirst%3DJ.%2BO.%26aulast%3DVinisko%26aufirst%3DR.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DGallivan%26aufirst%3DJ.-P.%26aulast%3DB%25C3%25B6cher%26aufirst%3DW.-O.%26aulast%3DMensa%26aufirst%3DF.%2BJ.%26atitle%3DFaldaprevir%2520and%2520deleobuvir%2520for%2520HCV%2520genotype%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D630%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojkier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puoti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Gomez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarski, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggisch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">–</span> <span class="NLM_lpage">1898</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1056%2FNEJMoa1402454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=24725239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1889-1898&author=N.+Afdhalauthor=S.+Zeuzemauthor=P.+Kwoauthor=M.+Chojkierauthor=N.+Gitlinauthor=M.+Puotiauthor=M.+Romero-Gomezauthor=J.-P.+Zarskiauthor=K.+Agarwalauthor=P.+Buggischauthor=G.+R.+Fosterauthor=N.+Br%C3%A4uauthor=M.+Butiauthor=I.+M.+Jacobsonauthor=M.+Subramanianauthor=X.+Dingauthor=H.+Moauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=A.+Mangiaauthor=P.+Marcellin&title=Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span></div><div class="casAuthors">Afdhal, Nezam; Zeuzem, Stefan; Kwo, Paul; Chojkier, Mario; Gitlin, Norman; Puoti, Massimo; Romero-Gomez, Manuel; Zarski, Jean-Pierre; Agarwal, Kosh; Buggisch, Peter; Foster, Graham R.; Brau, Norbert; Buti, Maria; Jacobson, Ira M.; Subramanian, G. Mani; Ding, Xiao; Mo, Hongmei; Yang, Jenny C.; Pang, Phillip S.; Symonds, William T.; McHutchison, John G.; Muir, Andrew J.; Mangia, Alessandra; Marcellin, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1889-1898, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virol. response among previously untreated patients with hepatitis C virus (HCV) genotype 1 infection.  Methods: We conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection.  Patients were randomly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for 12 wk, ledipasvir-sofosbuvir plus ribavirin for 12 wk, ledipasvir- sofosbuvir for 24 wk, or ledipasvir-sofosbuvir plus ribavirin for 24 wk.  The primary end point was a sustained virol. response at 12 wk after the end of therapy.  Results: Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection.  The rates of sustained virol. response were 99% (95% confidence interval [CI], 96 to 100) in the group that received 12 wk of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the group that received 12 wk of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 wk of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in the group that received 24 wk of ledipasvir-sofosbuvir plus ribavirin.  No patient in either 12-wk group discontinued ledipasvir-sofosbuvir owing to an adverse event.  The most common adverse events were fatigue, headache, insomnia, and nausea.  Conculsions: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 wk was highly effective in previously untreated patients with HCV genotype 1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroadkxw2jRR7Vg90H21EOLACvtfcHk0lgtrK9yh7LVHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnM&md5=e433fd7d493c1c0f9dfef37c1527388f</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402454%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DPuoti%26aufirst%3DM.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DZarski%26aufirst%3DJ.-P.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DBuggisch%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%2520untreated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1889%26epage%3D1898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span> </span><span class="NLM_article-title">Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">736</span><span class="NLM_x">–</span> <span class="NLM_lpage">743</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=736-743&author=E.+J.+Ganeauthor=C.+A.+Stedmanauthor=R.+H.+Hylandauthor=X.+Dingauthor=E.+Svarovskaiaauthor=G.+M.+Subramanianauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=P.+S.+Pang&title=Efficacy+of+nucleotide+polymerase+inhibitor+sofosbuvir+plus+the+NS5A+inhibitor+ledipasvir+or+the+NS5B+non-nucleoside+inhibitor+GS-9669+against+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DStedman%26aufirst%3DC.%2BA.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DPang%26aufirst%3DP.%2BS.%26atitle%3DEfficacy%2520of%2520nucleotide%2520polymerase%2520inhibitor%2520sofosbuvir%2520plus%2520the%2520NS5A%2520inhibitor%2520ledipasvir%2520or%2520the%2520NS5B%2520non-nucleoside%2520inhibitor%2520GS-9669%2520against%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D736%26epage%3D743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Feld, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coakley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiland, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DaSilva-Tillmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, B.</span><span> </span><span class="NLM_article-title">Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1594</span><span class="NLM_x">–</span> <span class="NLM_lpage">1603</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1056%2FNEJMoa1315722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=24720703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1594-1603&author=J.+J.+Feldauthor=K.+V.+Kowdleyauthor=E.+Coakleyauthor=S.+Sigalauthor=D.+R.+Nelsonauthor=D.+Crawfordauthor=O.+Weilandauthor=H.+Aguilarauthor=J.+Xiongauthor=T.+Pilot-Matiasauthor=B.+DaSilva-Tillmannauthor=L.+Larsenauthor=T.+Podsadeckiauthor=B.+Bernstein&title=Treatment+of+HCV+with+ABT-450%2Fr-ombitasvir+and+dasabuvir+with+ribavirin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7eR"><div class="casContent"><span class="casTitleNuber">7e</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span></div><div class="casAuthors">Feld, Jordan J.; Kowdley, Kris V.; Coakley, Eoin; Sigal, Samuel; Nelson, David R.; Crawford, Darrell; Weiland, Ola; Aguilar, Humberto; Xiong, Junyuan; Pilot-Matias, Tami; Da Silva-Tillmann, Barbara; Larsen, Lois; Podsadecki, Thomas; Bernstein, Barry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1594-1603</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 With ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the non-nucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus (HCV) in patients with HCV genotype 1 infection.  In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.  METHODS In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned previously untreated patients with HCV genotype 1 infection, in a 3:1 ratio, to an active regimen consisting of a single-tablet coformulation of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), and dasabuvir (250 mg twice daily) with ribavirin (in doses detd. according to body wt.) (group A) or matching placebos (group B).  The patients received the study treatment during a 12-wk double-blind period.  The primary end point was sustained virol. response at 12 wk after the end of treatment.  The primary anal. compared the response rate in group A with the response rate (78%) in a historical control group of previously untreated patients without cirrhosis who received telaprevir with peginterferon and ribavirin.  Adverse events occurring during the double-blind period were compared between group A and group B.  RESULTS A total of 631 patients received at least one dose of the study drugs.  The rate of sustained virol. response in group A was 96.2% (95% confidence interval, 94.5 to 97.9), which was superior to the historical control rate.  Virol. failure during treatment and relapse after treatment occurred in 0.2% and 1.5%, resp., of the patients in group A.  The response rates in group A were 95.3% among patients with HCV genotype 1a infection and 98.0% among those with HCV genotype 1b infection.  The rate of discontinuation due to adverse events was 0.6% in each study group.  Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in significantly more patients in group A than in group B (P < 0.05 for all comparisons).  Redns. in the Hb level were all of grade 1 or 2; redns. of grade 1 and 2 occurred in 47.5% and 5.8%, resp., of the patients in group A, whereas grade 1 redns. occurred in 2.5% of the patients in group B.  CONCLUSIONS In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 12-wk multitargeted regimen of ABT-450/r-ombitasvir and dasabuvir with ribavirin was highly effective and was assocd. with a low rate of treatment discontinuation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvK9K2P4sJ7Vg90H21EOLACvtfcHk0lhsYM-yy481VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrg%253D&md5=0e5e8ff9c7ebd43fe755c3d3c77f3462</span></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1315722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1315722%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DSigal%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DCrawford%26aufirst%3DD.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DAguilar%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DDaSilva-Tillmann%26aufirst%3DB.%26aulast%3DLarsen%26aufirst%3DL.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DBernstein%26aufirst%3DB.%26atitle%3DTreatment%2520of%2520HCV%2520with%2520ABT-450%252Fr-ombitasvir%2520and%2520dasabuvir%2520with%2520ribavirin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1594%26epage%3D1603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loustaud-Ratti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span> </span><span class="NLM_article-title">Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naı̈ve patients with HCV genotype 1 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1053%2Fj.gastro.2013.10.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=24184132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=420-429&author=G.+T.+Eversonauthor=K.+D.+Simsauthor=M.+Rodriguez-Torresauthor=C.+H%C3%A9zodeauthor=E.+Lawitzauthor=M.+Bourli%C3%A8reauthor=V.+Loustaud-Rattiauthor=V.+Rustgiauthor=H.+Schwartzauthor=H.+Tatumauthor=P.+Marcellinauthor=S.+Polauthor=P.+J.+Thuluvathauthor=T.+Eleyauthor=X.+Wangauthor=S.-P.+Huangauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=E.+Chungauthor=C.+Pasquinelliauthor=D.+M.+Graselaauthor=D.+F.+Gardiner&title=Efficacy+of+an+interferon-+and+ribavirin-free+regimen+of+daclatasvir%2C+asunaprevir%2C+and+BMS-791325+in+treatment-na%C4%B1%CC%88ve+patients+with+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7fR"><div class="casContent"><span class="casTitleNuber">7f</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection</span></div><div class="casAuthors">Everson, Gregory T.; Sims, Karen D.; Rodriguez-Torres, Maribel; Hezode, Christophe; Lawitz, Eric; Bourliere, Marc; Loustaud-Ratti, Veronique; Rustgi, Vinod; Schwartz, Howard; Tatum, Harvey; Marcellin, Patrick; Pol, Stanislas; Thuluvath, Paul J.; Eley, Timothy; Wang, Xiaodong; Huang, Shu-Pang; McPhee, Fiona; Wind-Rotolo, Megan; Chung, Ellen; Pasquinelli, Claudio; Grasela, Dennis M.; Gardiner, David F.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-429</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The combination of peginterferon and ribavirin with telaprevir or boceprevir is the std. treatment of hepatitis C virus (HCV) genotype 1 infection.  However, these drugs are not well tolerated because of their side effects and suboptimal virol. responses.  In a phase 2a, open-label study, we examd. the safety and efficacy of an interferon-free, ribavirin-free regimen of direct-acting antivirals, comprising daclatasvir (an NS5A replication complex inhibitor), asunaprevir (an NS3 protease inhibitor), and BMS-791325 (a non-nucleoside NS5B inhibitor), in patients with chronic HCV infection.  We analyzed data from 66 treatment-naive patients with HCV genotype 1 infection without cirrhosis who were assigned randomly to groups given daclatasvir (60 mg, once daily), asunaprevir (200 mg, twice daily), and BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 wk.  The primary end point was an HCV-RNA level less than 25 IU/mL at 12 wk after treatment (sustained virol. response at 12 wk [SVR12]).  In 64 patients, HCV-RNA levels were less than 25 IU/mL by week 4 of treatment (including 48 of 49 patients with HCV genotype 1a infection and 45 of 46 patients with the non-CC interleukin 28B genotype).  Sixty-one patients (92%) achieved SVR12, based on a modified intention-to-treat anal.  Virol. responses were similar between 12 and 24 wk of treatment.  During the study, 2 patients experienced viral breakthrough and 1 patient relapsed.  There were no grade 3-4 increases in levels of alanine or aspartate aminotransferases or bilirubin; there were no deaths or discontinuations resulting from serious adverse events or adverse events related to the treatment regimen.  The most common adverse events were headache, asthenia, and gastrointestinal symptoms.  In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection.  Further studies of this regimen are warranted.  ClinicalTrials.gov, no. NCT01455090.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGYjuJmkQI8rVg90H21EOLACvtfcHk0lhsYM-yy481VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyitr4%253D&md5=c8f83094f49ce5d5d116d75414ab3d93</span></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.10.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.10.057%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DLoustaud-Ratti%26aufirst%3DV.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DTatum%26aufirst%3DH.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26atitle%3DEfficacy%2520of%2520an%2520interferon-%2520and%2520ribavirin-free%2520regimen%2520of%2520daclatasvir%252C%2520asunaprevir%252C%2520and%2520BMS-791325%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D420%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagging, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balart, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossaro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaughnessy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, B.</span><span> </span><span class="NLM_article-title">Efficacy and safety of MK-5172 and MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: The C-WORTHY study</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">S25</span><span class="NLM_x">–</span> <span class="NLM_lpage">S26</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=S25-S26&author=E.+Lawitzauthor=C.+Hezodeauthor=E.+Ganeauthor=E.+Tamauthor=M.+Laggingauthor=L.+Balartauthor=L.+Rossaroauthor=R.+Ghalibauthor=M.+Shaughnessyauthor=P.+Hwangauthor=J.+Wahlauthor=M.+N.+Robertsonauthor=B.+Haber&title=Efficacy+and+safety+of+MK-5172+and+MK-8742+%C2%B1+ribavirin+in+hepatitis+C+genotype+1+infected+patients+with+cirrhosis+or+previous+null-response%3A+The+C-WORTHY+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DLagging%26aufirst%3DM.%26aulast%3DBalart%26aufirst%3DL.%26aulast%3DRossaro%26aufirst%3DL.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DShaughnessy%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DP.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DRobertson%26aufirst%3DM.%2BN.%26aulast%3DHaber%26aufirst%3DB.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520MK-5172%2520and%2520MK-8742%2520%25C2%25B1%2520ribavirin%2520in%2520hepatitis%2520C%2520genotype%25201%2520infected%2520patients%2520with%2520cirrhosis%2520or%2520previous%2520null-response%253A%2520The%2520C-WORTHY%2520study%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3DS25%26epage%3DS26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="note"><p class="first last">For reviews on NS5B inhibitors, see, for example:</p></div><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span> </span><span class="NLM_article-title">Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">Expert Opin.Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1517%2F13543770802672598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=145-164&author=P.+L.+Beaulieu&title=Recent+advances+in+the+development+of+NS5B+polymerase+inhibitors+for+the+treatment+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection</span></div><div class="casAuthors">Beaulieu, Pierre L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-164</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  170 To 200 million people worldwide are believed to suffer from chronic hepatitis C virus (HCV) infection, a blood-born disease that targets the liver and progresses to organ cirrhosis and primary cancer in a significant proportion of patients.  The currently available treatment has limited efficacy and suffers from restricting side effects.  HCV infection is the principal cause of liver transplant in industrialized nations and between 8000 and 10,000 deaths result annually from the disease in the United States alone.  Virus-specific, more efficacious, and better-tolerated anti-HCV therapies are thus required to address the unmet medical need.  Objective: To review progress achieved since 2005 in the development of HCV NS5B polymerase inhibitors as potential therapy for the treatment of HCV infection with a primary focus on available patent and medical literature.  Results/conclusion: Several classes of small-mol. inhibitors of HCV NS5B have progressed into clin. development and demonstrated efficacy in reducing viral load in infected patients.  The results so far provide an encouraging foundation for the development of novel, more tolerable therapies and addressing emergence of resistance through combination of antiviral agents with complementary mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8VVFJs4oSbVg90H21EOLACvtfcHk0lilYumQOMqz9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCks74%253D&md5=64b78562e2b4e3e8a166fdabf14f7efe</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1517%2F13543770802672598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770802672598%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520NS5B%2520polymerase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DExpert%2520Opin.Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D145%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Watkins, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L. S.</span><span> </span><span class="NLM_article-title">HCV NS5B polymerase inhibitors</span> <span class="citation_source-journal">Cur. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=20597029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSju7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=441-465&author=W.+J.+Watkinsauthor=A.+S.+Rayauthor=L.+S.+Chong&title=HCV+NS5B+polymerase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5B polymerase inhibitors</span></div><div class="casAuthors">Watkins, William J.; Ray, Adrian S.; Chong, Lee S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-465</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">2040-3437</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  In the past decade, intensive efforts have focused on the discovery of both nucleos(t)ide and non-nucleoside inhibitors of the HCV NS5B polymerase.  These efforts have resulted in several promising agents advancing in clin. development.  This review traces the history of optimization of the chem. series that have led to the development of clin. candidates, and summarizes recent developments in the field, with emphasis on clin. efficacy and impact for future combination studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6PfCo0V5R7Vg90H21EOLACvtfcHk0lilYumQOMqz9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSju7zJ&md5=f0e5144b72864e6eb1a2f4b13b1b916e</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DChong%26aufirst%3DL.%2BS.%26atitle%3DHCV%2520NS5B%2520polymerase%2520inhibitors%26jtitle%3DCur.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D441%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span> </span><span class="NLM_article-title">Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2532</span><span class="NLM_x">–</span> <span class="NLM_lpage">2531</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2532-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+nucleotide%2C+and+non-nucleoside+inhibitors+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA-polymerase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520nucleotide%252C%2520and%2520non-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA-polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2532%26epage%3D2531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Brown, N. A.</span><span> </span><span class="NLM_article-title">Progress towards improving antiviral therapy for hepatitis C virus polymerase inhibitors. Part 1: Nucleoside analogues</span> <span class="citation_source-journal">Expert Opin. Investig. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=709-725&author=N.+A.+Brown&title=Progress+towards+improving+antiviral+therapy+for+hepatitis+C+virus+polymerase+inhibitors.+Part+1%3A+Nucleoside+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%2BA.%26atitle%3DProgress%2520towards%2520improving%2520antiviral%2520therapy%2520for%2520hepatitis%2520C%2520virus%2520polymerase%2520inhibitors.%2520Part%25201%253A%2520Nucleoside%2520analogues%26jtitle%3DExpert%2520Opin.%2520Investig.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D709%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, E.</span><span> </span><span class="NLM_article-title">Nucleoside analog inhibitors of hepatitis C virus replication: Recent advances, challenges and trends</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1429</span><span class="NLM_x">–</span> <span class="NLM_lpage">1452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.4155%2Ffmc.09.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=21426058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSit77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=1429-1452&author=P.+A.+Furmanauthor=A.+M.+Lamauthor=E.+Murakami&title=Nucleoside+analog+inhibitors+of+hepatitis+C+virus+replication%3A+Recent+advances%2C+challenges+and+trends"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends</span></div><div class="casAuthors">Furman, Phillip A.; Lam, Angela M.; Murakami, Eisuke</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1429-1452</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic hepatitis C virus (HCV) infection is a global health problem, with over 170 million people infected worldwide.  The current therapy, pegylated interferon (PEG-IFN) plus ribavirin (RBV), provides only approx. a 40% sustained virol. response (undetectable HCV RNA for greater than 24 wk after cessation of therapy), in genotype I-infected individuals.  In addn. to the limited sustained virol. response, PEG-IFN/RBV treatment is assocd. with serious adverse effects.  Nucleosides have long been the cornerstone of antiviral therapy because of their proven efficacy and high barrier to resistance.  Through the use of surrogate viruses or the HCV subgenomic replicon, several classes of nucleoside analogs or their monophosphate prodrugs have been identified that inhibit HCV RNA replication.  Nucleoside analogs that possess the 2'-C-Me modification vary in their ability to be phosphorylated and to act as alternative substrate inhibitors of the HCV RNA polymerase.  Herein, we discuss various classes of nucleoside inhibitors, with a focus on available structure-activity relationships, their mode of action and resistance profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuFIjUiU5KFbVg90H21EOLACvtfcHk0lilYumQOMqz9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSit77F&md5=d512189b8d8f1380f8bc10a5c0438c1c</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.88%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DMurakami%26aufirst%3DE.%26atitle%3DNucleoside%2520analog%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520replication%253A%2520Recent%2520advances%252C%2520challenges%2520and%2520trends%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2009%26volume%3D1%26spage%3D1429%26epage%3D1452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sofia, M. J.</span><span> </span><span class="NLM_article-title">Nucleotide prodrugs for HCV therapy</span> <span class="citation_source-journal">Antiviral Chem. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=23-49&author=M.+J.+Sofia&title=Nucleotide+prodrugs+for+HCV+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DNucleotide%2520prodrugs%2520for%2520HCV%2520therapy%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2011%26volume%3D22%26spage%3D23%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theilmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1126%2Fscience.285.5424.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=10390360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=110-113&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=J.+O.+Kochauthor=U.+Herianauthor=L.+Theilmannauthor=R.+Bartenschlager&title=Replication+of+subgenomic+hepatitis+C+virus+RNAs+in+a+hepatoma+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span></div><div class="casAuthors">Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5424</span>),
    <span class="NLM_cas:pages">110-113</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An estd. 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease.  Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems.  A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons.  Upon transfection into a human hepatoma cell line, these RNAs replicated to high levels, permitting metabolic radiolabeling of viral RNA and proteins.  This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed mol. studies of HCV and the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X754RT8y1LVg90H21EOLACvtfcHk0lh1ghZNgZFOOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D&md5=b075621b316209ecf4498c9b5b33e4b5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.285.5424.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.285.5424.110%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%2BO.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DTheilmann%26aufirst%3DL.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DReplication%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNAs%2520in%2520a%2520hepatoma%2520cell%2520line%26jtitle%3DScience%26date%3D1999%26volume%3D285%26spage%3D110%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fillard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity inpatients chronically infected with genotype 1 hepatitis C virus (HCV)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7650</span><span class="NLM_x">–</span> <span class="NLM_lpage">7666</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3006788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7650-7666&author=P.+L.+Beaulieuauthor=M.+B%C3%B6sauthor=M.+G.+Cordingleyauthor=C.+Chabotauthor=G.+Fazalauthor=M.+Garneauauthor=J.+R.+Fillardauthor=E.+Jolicoeurauthor=S.+LaPlanteauthor=G.+McKercherauthor=M.+Poirierauthor=M.-A.+Poupartauthor=Y.+S.+Tsantrizosauthor=J.+Duanauthor=G.+Kukolj&title=Discovery+of+the+first+thumb+pocket+1+NS5B+polymerase+inhibitor+%28BILB+1941%29+with+demonstrated+antiviral+activity+inpatients+chronically+infected+with+genotype+1+hepatitis+C+virus+%28HCV%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm3006788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3006788%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DFazal%26aufirst%3DG.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DFillard%26aufirst%3DJ.%2BR.%26aulast%3DJolicoeur%26aufirst%3DE.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520the%2520first%2520thumb%2520pocket%25201%2520NS5B%2520polymerase%2520inhibitor%2520%2528BILB%25201941%2529%2520with%2520demonstrated%2520antiviral%2520activity%2520inpatients%2520chronically%2520infected%2520with%2520genotype%25201%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7650%26epage%3D7666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Erhardt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benhamou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forns, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calleja, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangenberg, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Samaniego, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enriquez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehmiz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffgen, J.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=23-32&author=A.+Erhardtauthor=K.+Deterdingauthor=Y.+Benhamouauthor=M.+Reiserauthor=X.+Fornsauthor=S.+Polauthor=J.+L.+Callejaauthor=S.+Rossauthor=H.+C.+Spangenbergauthor=J.+Garcia-Samaniegoauthor=M.+Fuchsauthor=J.+Enriquezauthor=J.+Wiegandauthor=J.+Sternauthor=K.+Wuauthor=G.+Kukoljauthor=M.+Marquisauthor=P.+Beaulieuauthor=G.+Nehmizauthor=J.+Steffgen&title=Safety%2C+pharmacokinetics+and+antiviral+effect+of+BILB+1941%2C+a+novel+hepatitis+C+virus+RNA+polymerase+inhibitor%2C+after+5+days+oral+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErhardt%26aufirst%3DA.%26aulast%3DDeterding%26aufirst%3DK.%26aulast%3DBenhamou%26aufirst%3DY.%26aulast%3DReiser%26aufirst%3DM.%26aulast%3DForns%26aufirst%3DX.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DCalleja%26aufirst%3DJ.%2BL.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSpangenberg%26aufirst%3DH.%2BC.%26aulast%3DGarcia-Samaniego%26aufirst%3DJ.%26aulast%3DFuchs%26aufirst%3DM.%26aulast%3DEnriquez%26aufirst%3DJ.%26aulast%3DWiegand%26aufirst%3DJ.%26aulast%3DStern%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DMarquis%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DNehmiz%26aufirst%3DG.%26aulast%3DSteffgen%26aufirst%3DJ.%26atitle%3DSafety%252C%2520pharmacokinetics%2520and%2520antiviral%2520effect%2520of%2520BILB%25201941%252C%2520a%2520novel%2520hepatitis%2520C%2520virus%2520RNA%2520polymerase%2520inhibitor%252C%2520after%25205%2520days%2520oral%2520treatment%26jtitle%3DAntiviral%2520Ther.%26date%3D2009%26volume%3D14%26spage%3D23%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bykowski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansereau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duceppe, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haché, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagacé, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4987</span><span class="NLM_x">–</span> <span class="NLM_lpage">4993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4987-4993&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=D.+Bykowskiauthor=C.+Brochuauthor=N.+Dansereauauthor=J.-S.+Duceppeauthor=B.+Hach%C3%A9author=A.+Jakalianauthor=L.+Lagac%C3%A9author=S.+LaPlanteauthor=G.+McKercherauthor=E.+Moreauauthor=S.+Perreaultauthor=T.+Stammersauthor=L.+Thauvetteauthor=J.+Warringtonauthor=G.+Kukolj&title=Improved+replicon+cellular+activity+of+non-nucleoside+allosteric+inhibitors+of+HCV+NS5B+polymerase%3A+From+benzimidazole+to+indole+scaffolds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBykowski%26aufirst%3DD.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DDansereau%26aufirst%3DN.%26aulast%3DDuceppe%26aufirst%3DJ.-S.%26aulast%3DHach%25C3%25A9%26aufirst%3DB.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DLagac%25C3%25A9%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DStammers%26aufirst%3DT.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DWarrington%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DImproved%2520replicon%2520cellular%2520activity%2520of%2520non-nucleoside%2520allosteric%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%253A%2520From%2520benzimidazole%2520to%2520indole%2520scaffolds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4987%26epage%3D4993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="note"><p class="first last">Enzymatic NS5B assays and subgenomic cell-based replicon assays are described elsewhere:<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></p></div><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellerin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Specific inhibitors of HCV polymerase identified using a NS5B with lower affinity for template/primer substrate</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=422-431&author=G.+McKercherauthor=P.+L.+Beaulieuauthor=D.+Lamarreauthor=S.+LaPlanteauthor=S.+Lefebvreauthor=C.+Pellerinauthor=L.+Thauvetteauthor=G.+Kukolj&title=Specific+inhibitors+of+HCV+polymerase+identified+using+a+NS5B+with+lower+affinity+for+template%2Fprimer+substrate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DPellerin%26aufirst%3DC.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DSpecific%2520inhibitors%2520of%2520HCV%2520polymerase%2520identified%2520using%2520a%2520NS5B%2520with%2520lower%2520affinity%2520for%2520template%252Fprimer%2520substrate%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2004%26volume%3D32%26spage%3D422%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Beaulieu, P. L.; Fazal, G.; Goulet, S.; Kukolj, G.; Poirier, M.; Tsantrizos, Y.; Jolicoeur, E.; Gillard, J.; Poupart, M.-A.; Rancourt, J.</span> WO Patent WO 03/010141,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Beaulieu%2C+P.+L.%3B+Fazal%2C+G.%3B+Goulet%2C+S.%3B+Kukolj%2C+G.%3B+Poirier%2C+M.%3B+Tsantrizos%2C+Y.%3B+Jolicoeur%2C+E.%3B+Gillard%2C+J.%3B+Poupart%2C+M.-A.%3B+Rancourt%2C+J.+WO+Patent+WO+03%2F010141%2C+2003."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhardwaj, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordeleau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingely, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forgione, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6466</span><span class="NLM_x">–</span> <span class="NLM_lpage">6476</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100690x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6466-6476&author=M.+Llin%C3%A0s-Brunetauthor=M.+D.+Baileyauthor=N.+Goudreauauthor=P.+K.+Bhardwajauthor=J.+Bordeleauauthor=M.+B%C3%B6sauthor=Y.+Bousquetauthor=M.+G.+Cordingelyauthor=J.+Duanauthor=P.+Forgioneauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=S.+Gouletauthor=T.+Halmosauthor=S.+H.+Kawaiauthor=J.+Naudauthor=M.-A.+Poupartauthor=P.+W.+White&title=Discovery+of+a+potent+and+selective+noncovalent+linear+inhibitor+of+the+hepatitis+C+virus+NS3+protease+%28BI+201335%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1021%2Fjm100690x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100690x%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DBhardwaj%26aufirst%3DP.%2BK.%26aulast%3DBordeleau%26aufirst%3DJ.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DBousquet%26aufirst%3DY.%26aulast%3DCordingely%26aufirst%3DM.%2BG.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DForgione%26aufirst%3DP.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DNaud%26aufirst%3DJ.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520noncovalent%2520linear%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520%2528BI%2520201335%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6466%26epage%3D6476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Vaillancourt, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilote, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liuzzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethell, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=5-10&author=F.+H.+Vaillancourtauthor=L.+Piloteauthor=M.+Cartierauthor=J.+Lippensauthor=M.+Liuzziauthor=R.+C.+Bethellauthor=M.+G.+Cordingleyauthor=G.+Kukolj&title=Identification+of+a+lipid+kinase+as+a+host+factor+involved+in+hepatitis+C+virus+RNA+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVaillancourt%26aufirst%3DF.%2BH.%26aulast%3DPilote%26aufirst%3DL.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DLippens%26aufirst%3DJ.%26aulast%3DLiuzzi%26aufirst%3DM.%26aulast%3DBethell%26aufirst%3DR.%2BC.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520a%2520lipid%2520kinase%2520as%2520a%2520host%2520factor%2520involved%2520in%2520hepatitis%2520C%2520virus%2520RNA%2520replication%26jtitle%3DVirology%26date%3D2009%26volume%3D387%26spage%3D5%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulombe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span> </span><span class="NLM_article-title">Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">15204</span><span class="NLM_x">–</span> <span class="NLM_lpage">15212</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja101358s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=15204-15212&author=S.+R.+LaPlanteauthor=J.+R.+Gillardauthor=A.+Jakalianauthor=N.+Aubryauthor=R.+Coulombeauthor=C.+Brochuauthor=Y.+S.+Tsantrizosauthor=M.+Poirierauthor=G.+Kukoljauthor=P.+L.+Beaulieu&title=Importance+of+ligand+bioactive+conformation+in+the+discovery+of+potent+indole-diamide+inhibitors+of+the+hepatitis+C+virus+NS5B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fja101358s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja101358s%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DGillard%26aufirst%3DJ.%2BR.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DCoulombe%26aufirst%3DR.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26atitle%3DImportance%2520of%2520ligand%2520bioactive%2520conformation%2520in%2520the%2520discovery%2520of%2520potent%2520indole-diamide%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D15204%26epage%3D15212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Marte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montpetit, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jutras, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethell, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span> </span><span class="NLM_article-title">Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=164-172&author=J.+Duanauthor=C.-L.+Yongauthor=M.+Garneauauthor=M.+Amadauthor=G.+Bolgerauthor=J.+De+Marteauthor=H.+Montpetitauthor=F.+Otisauthor=M.+Jutrasauthor=M.+Rh%C3%A9aumeauthor=P.+W.+Whiteauthor=M.+Llin%C3%A0s-Brunetauthor=R.+C.+Bethellauthor=M.+G.+Cordingley&title=Cross-species+absorption%2C+metabolism%2C+distribution+and+pharmacokinetics+of+BI+201335%2C+a+potent+HCV+genotype+1+NS3%2F4A+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DYong%26aufirst%3DC.-L.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DAmad%26aufirst%3DM.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DDe%2BMarte%26aufirst%3DJ.%26aulast%3DMontpetit%26aufirst%3DH.%26aulast%3DOtis%26aufirst%3DF.%26aulast%3DJutras%26aufirst%3DM.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBethell%26aufirst%3DR.%2BC.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26atitle%3DCross-species%2520absorption%252C%2520metabolism%252C%2520distribution%2520and%2520pharmacokinetics%2520of%2520BI%2520201335%252C%2520a%2520potent%2520HCV%2520genotype%25201%2520NS3%252F4A%2520protease%2520inhibitor%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D164%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batonga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montpetit, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jutras, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapeyre, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethell, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span> </span><span class="NLM_article-title">The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in human</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5381</span><span class="NLM_x">–</span> <span class="NLM_lpage">5386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5381-5386&author=J.+Duanauthor=G.+Bolgerauthor=M.+Garneauauthor=M.+Amadauthor=J.+Batongaauthor=H.+Montpetitauthor=F.+Otisauthor=M.+Jutrasauthor=N.+Lapeyreauthor=M.+Rh%C3%A9aumeauthor=G.+Kukoljauthor=P.+W.+Whiteauthor=R.+C.+Bethellauthor=M.+G.+Cordingley&title=The+liver+partition+coefficient-corrected+inhibitory+quotient+and+the+pharmacokinetic-pharmacodynamic+relationship+of+directly+acting+anti-hepatitis+C+virus+agents+in+human"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DAmad%26aufirst%3DM.%26aulast%3DBatonga%26aufirst%3DJ.%26aulast%3DMontpetit%26aufirst%3DH.%26aulast%3DOtis%26aufirst%3DF.%26aulast%3DJutras%26aufirst%3DM.%26aulast%3DLapeyre%26aufirst%3DN.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DWhite%26aufirst%3DP.%2BW.%26aulast%3DBethell%26aufirst%3DR.%2BC.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26atitle%3DThe%2520liver%2520partition%2520coefficient-corrected%2520inhibitory%2520quotient%2520and%2520the%2520pharmacokinetic-pharmacodynamic%2520relationship%2520of%2520directly%2520acting%2520anti-hepatitis%2520C%2520virus%2520agents%2520in%2520human%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5381%26epage%3D5386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Müller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauthe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andino, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Antonis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beels, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGeorge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Knaep, A. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagerland, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritschel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galloway, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humfrey, C. D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacks, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagota, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackinnon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ness, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vudathala, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yotti, L.</span><span> </span><span class="NLM_article-title">A rational for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity</span> <span class="citation_source-journal">Regul. Toxicol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1016%2Fj.yrtph.2005.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm501532z&amp;key=16412543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A280%3ADC%252BD287osFeqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2006&pages=198-211&author=L.+M%C3%BCllerauthor=R.+J.+Mautheauthor=C.+M.+Rileyauthor=M.+M.+Andinoauthor=D.+De+Antonisauthor=C.+Beelsauthor=J.+DeGeorgeauthor=A.+G.+M.+De+Knaepauthor=D.+Ellisonauthor=J.+A.+Fagerlandauthor=R.+Frankauthor=B.+Fritschelauthor=S.+Gallowayauthor=E.+Harpurauthor=C.+D.+N.+Humfreyauthor=A.+S.+Jacksauthor=N.+Jagotaauthor=J.+Mackinnonauthor=G.+Mohanauthor=D.+K.+Nessauthor=M.+R.+O%E2%80%99Donovanauthor=M.+D.+Smithauthor=G.+Vudathalaauthor=L.+Yotti&title=A+rational+for+determining%2C+testing%2C+and+controlling+specific+impurities+in+pharmaceuticals+that+possess+potential+for+genotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity</span></div><div class="casAuthors">Muller Lutz; Mauthe Robert J; Riley Christopher M; Andino Marta M; Antonis David De; Beels Chris; DeGeorge Joseph; De Knaep Alfons G M; Ellison Dean; Fagerland Jane A; Frank Rebecca; Fritschel Betsy; Galloway Sheila; Harpur Ernie; Humfrey Charles D N; Jacks Alexander S; Jagota Nirdosh; Mackinnon John; Mohan Ganapathy; Ness Daniel K; O'Donovan Michael R; Smith Mark D; Vudathala Gopi; Yotti Larry</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory toxicology and pharmacology : RTP</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-211</span>
        ISSN:<span class="NLM_cas:issn">0273-2300</span>.
    </div><div class="casAbstract">The synthesis of pharmaceutical products frequently involves the use of reactive reagents and the formation of intermediates and by-products.  Low levels of some of these may be present in the final drug substance and drug product as impurities.  Such chemically reactive impurities may have at the same time the potential for unwanted toxicities including genotoxicity and carcinogenicity and hence can have an impact on product risk assessment.  This paper outlines a procedure for testing, classification, qualification, toxicological risk assessment, and control of impurities possessing genotoxic potential in pharmaceutical products.  Referencing accepted principles of cancer risk assessment, this document proposes a staged threshold of toxicological concern (TTC) approach for the intake of genotoxic impurities over various periods of exposure.  This staged TTC is based on knowledge about tumorigenic potency of a wide range of genotoxic carcinogens and can be used for genotoxic compounds, for which cancer data are limited or not available.  The delineated acceptable daily intake values of between approximately 1.5 microg/day for approximately lifetime intake and approximately 120 microg/day for < or = 1 month are virtually safe doses.  Based on sound scientific reasoning, these virtually safe intake values do not pose an unacceptable risk to either human volunteers or patients at any stage of clinical development and marketing of a pharmaceutical product.  The intake levels are estimated to give an excess cancer risk of 1 in 100,000 to 1 in a million over a lifetime, and are extremely conservative given the current lifetime cancer risk in the population of over 1 in 4 (http://seer.cancer.gov/statfacts/html.all.html).  The proposals in this document apply to all clinical routes of administration and to compounds at all stages of clinical development.  It is important to note that certain types of products, such as those for life-threatening indications for which there are no safer alternatives, allow for special considerations using adaptations of the principles outlined in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzrrxAZj7F1Ubxh97K6Vt6fW6udTcc2eZE0qse_AOXsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287osFeqtw%253D%253D&md5=198b45bde3ed1df54be3595618311c22</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.yrtph.2005.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yrtph.2005.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DL.%26aulast%3DMauthe%26aufirst%3DR.%2BJ.%26aulast%3DRiley%26aufirst%3DC.%2BM.%26aulast%3DAndino%26aufirst%3DM.%2BM.%26aulast%3DDe%2BAntonis%26aufirst%3DD.%26aulast%3DBeels%26aufirst%3DC.%26aulast%3DDeGeorge%26aufirst%3DJ.%26aulast%3DDe%2BKnaep%26aufirst%3DA.%2BG.%2BM.%26aulast%3DEllison%26aufirst%3DD.%26aulast%3DFagerland%26aufirst%3DJ.%2BA.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DFritschel%26aufirst%3DB.%26aulast%3DGalloway%26aufirst%3DS.%26aulast%3DHarpur%26aufirst%3DE.%26aulast%3DHumfrey%26aufirst%3DC.%2BD.%2BN.%26aulast%3DJacks%26aufirst%3DA.%2BS.%26aulast%3DJagota%26aufirst%3DN.%26aulast%3DMackinnon%26aufirst%3DJ.%26aulast%3DMohan%26aufirst%3DG.%26aulast%3DNess%26aufirst%3DD.%2BK.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DVudathala%26aufirst%3DG.%26aulast%3DYotti%26aufirst%3DL.%26atitle%3DA%2520rational%2520for%2520determining%252C%2520testing%252C%2520and%2520controlling%2520specific%2520impurities%2520in%2520pharmaceuticals%2520that%2520possess%2520potential%2520for%2520genotoxicity%26jtitle%3DRegul.%2520Toxicol.%2520Pharmacol.%26date%3D2006%26volume%3D44%26spage%3D198%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Broadhurst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G. J.</span><span> </span><span class="NLM_article-title">Tetracycline studies. Part 5. New syntheses of anthracenes and anthraquinones through benzophenone carbanions</span> <span class="citation_source-journal">J. Chem. Soc., Perkin 1 Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_fpage">2502</span><span class="NLM_x">–</span> <span class="NLM_lpage">2512</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm501532z&amp;key=10.1039%2Fp19770002502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm501532z&amp;key=1%3ACAS%3A528%3ADyaE1cXhtlKgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&pages=2502-2512&author=M.+J.+Broadhurstauthor=C.+H.+Hassallauthor=G.+J.+Thomas&title=Tetracycline+studies.+Part+5.+New+syntheses+of+anthracenes+and+anthraquinones+through+benzophenone+carbanions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tetracycline studies.  Part 5.  New syntheses of anthracenes and anthraquinones through benzophenone carbanions</span></div><div class="casAuthors">Broadhurst, Michael J.; Hassall, Cedric H.; Thomas, Gareth J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1:  Organic and Bio-Organic Chemistry (1972-1999)</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2502-12</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    </div><div class="casAbstract">The title syntheses are of wide applicability and gave good yields of products.  E.g., the benzophenone I (R = CN) with Me3COK in DMF at 90° for 1 h gave 95% anthrol II (R = Me, R1 = PhCH2, R2 = R4 = OMe, R3 = CO2Me) which with H2O2 and NaOH gave 96% anthraquinone III.  I (R = CO2Me) with Me3COK in DMF followed by H2O2-NaOH treatment gave 41% III.  Regiospecificity of cyclization was achieved by preferential displacement of Cl-.  E.g., 2-(2,4-dichlorobenzoyl)-3,5-dimethoxyphenylacetonitrile with Me3COK in DMF gave 46% II (R = R2 = R3 = H, R1 = Me, R4 = Cl).  In some circumstances 2-cyanomethylbenzophenones with (F3CCO)2O gave isoquinolin-3-one derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps0Di-H8gl_LVg90H21EOLACvtfcHk0lg4vVT4LayJjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXhtlKgt74%253D&md5=33d31545d472a951b9f74d9180760a2b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1039%2Fp19770002502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp19770002502%26sid%3Dliteratum%253Aachs%26aulast%3DBroadhurst%26aufirst%3DM.%2BJ.%26aulast%3DHassall%26aufirst%3DC.%2BH.%26aulast%3DThomas%26aufirst%3DG.%2BJ.%26atitle%3DTetracycline%2520studies.%2520Part%25205.%2520New%2520syntheses%2520of%2520anthracenes%2520and%2520anthraquinones%2520through%2520benzophenone%2520carbanions%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%25201%2520Trans.%26date%3D1977%26spage%3D2502%26epage%3D2512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i36"><a href="/doi/suppl/10.1021/jm501532z">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_82258"></div></div></div></div></div><hr /></hr><p class="last">Mass spectral and <sup>1</sup>H NMR data for building blocks, mass spectral and HPLC homogeneity data in table format, and a copy of the <sup>1</sup>H NMR for all inhibitors. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501532z/suppl_file/jm501532z_si_001.pdf">jm501532z_si_001.pdf (573.49 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501532z&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm501532z" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501532z" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                981KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679995e179e13dac","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
